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ABSTRACT 
 
This study uses in vivo and ex vivo imaging to explore the hypothesis that 
galectin-3 (Gal-3) acts as a positive regulator of leukocyte recruitment to 
the inflamed microcirculation.  In addition to this, due to its localisation 
both within and outside the cell, the effect of exogenous as well as the 
role of endogenous Gal-3 was investigated.  Leukocyte recruitment in the 
cremasteric microcirculation of wild-type (C57BL/6), Gal-3-/- and 
CX3CR1gfp/+ mice was assessed by intravital microscopy following intra-
scrotal injection of PBS, IL-1β, TNF-α or Gal-3 and intravenous 
administration of anti-Ly6G to label neutrophils.  Concurrently, these 
responses were investigated further with the use of the parallel plate flow 
chamber assay, confocal microscopy, flow cytometry, PCR analysis and 
proteome profile array.   
 
Treatment with IL-1β and TNF-α significantly reduced leukocyte rolling 
velocities in WT mice, an effect that was absent in Gal-3-/- mice.  These 
observations were repeated in the flow chamber where Gal-3-/- leukocytes 
did not capture to E-selectin and initiate downstream changes in their 
activation state and cell morphology.  Flow cytometric analysis showed 
that Gal-3-/- neutrophils express reduced PSGL-1 in response to TNFα 
and that basally both neutrophils and monocytes display reduced HPA 
and PNA lectin binding – suggesting that the Gal-3-/- leukocytes have an 
altered glycophenotype.  Furthermore, Gal-3-/- neutrophils express 
reduced CD11b basally and after TNFα treatment, though both Gal-3-/- 
neutrophils and monocytes express comparable levels of L-selectin.  
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Finally, Gal-3-/- endothelial cells express reduced ICAM-1 basally and 
after TNFα or IL-1β treatment, in addition to expressing reduced E-
selectin after IL-1β treatment only.  Since these cell adhesion molecules 
are involved in slow rolling, their reduced expression in Gal-3-/- animals 
may provide the answer behind reduced slow rolling.  In addition, a 
significant reduction in cell emigration was observed in the Gal-3-/- mice 
treated with IL-1β when compared to their wild type counterparts, which 
could be due to impaired expression of cell adhesion molecules and an 
altered cell surface glycoproteome in these animals. 
 
Administration of recombinant Gal-3 to WT mice resulted in a dose-
dependent reduction in rolling velocity associated with increased numbers 
of adherent and emigrated leukocytes, approximately 50% of which were 
Ly6G-positive neutrophils.  Administration of Gal-3 to CX3CR1gfp/+ mice 
confirmed that approximately equal numbers of monocytes are also 
recruited in response to this lectin.  After 4 h treatment with the lectin the 
cremaster contained increased mRNA for IL-1β, TNFα, KC, MCP-1 and 
IL-6; increased protein expression of these mediators with the exception 
of IL-1β, was confirmed by proteome profile array alongside IFNγ, MIP-2 
and MIP-1α.  The recombinant lectin was not acting directly on the 
leukocytes, which was confirmed in the flow chamber by treating Gal-3-/- 
leukocytes with recombinant Gal-3 and wild type plasma, by flow 
cytometric analysis of CD11a/b/c, CD44, PSGL-1 and L-selectin 
expression after treatment, and by intravenous administration of the lectin 
during intravital microscopy.  Finally, endothelial cells treated in vitro with 
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Gal-3 did not increase ICAM-1 or E-selectin expression however, 
treatment in vivo followed by confocal analysis indicated possible 
increases in PECAM-1, VCAM-1 and E-selectin expression. 
 
These data suggest the mechanisms mediating leukocyte rolling are 
impaired in Gal-3 null-/- mice and support a role for Gal-3 as a positive 
regulator of neutrophil and monocyte trafficking. In conclusion, this study 
unveils novel biology for exogenous and endogenous Gal-3 in controlling 
vascular inflammation. 
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1.1 Galectin-3 is a unique member of the galectin 
superfamily 
Galectin-3 (Gal-3) is a member of the highly conserved β-galactoside-
binding family of animal lectins, which are differentially expressed in a 
wide range of cells including many immune cells (Cooper et al., 2012).  
The group comprises 15 lectins characterized by large carbohydrate-
recognition domains (CRD) in their C-terminals which may be folded into 
five or six β-pleated sheets and bind their ligands in the absence of 
divalent cations (Dhirapong et al., 2009). The family can be further 
subdivided according to the tertiary structure of their CRD (Figure 1.1).  
 
 
Figure 1.1 The Galectin family.   
The galectin family of β-galactoside-binding proteins display distinct 
tertiary and quaternary structures by which they can be divided into 
three sub-groups, as shown.  The unique structure of Gal-3 enables its 
self-oligomerisation upon ligand binding. 
 
Prototype 
Gal-1, 2, 5, 7, 10, 11, 
13, 14 & 15 
Tandem repeat-type 
Gal-4, 6, 8, 9 & 12 
             Hetero-
oligomerisation 
 
Chimera-type 
Gal-3 
N
C 
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The prototype galectins Galectin-1, -2, -5, -7, -10, -11, -13, -14 and -15 all 
have one CRD that can exist as a single lectin or as a dimer.  The 
tandem repeat-type galectins Galectin-4, -6, -8, -9 and -12 all display two 
CRDs in a single polypeptide chain.  Gal-3 is the first lectin to be labelled 
as a chimeric molecule as it is known to contain one CRD of two anti-
parallel β-sheets, one 5-stranded and the other 6-stranded – this one 
containing the amino acid side chains which form the sugar binding site.  
Crucially, this is joined to a relatively flexible non-lectin extended N-
terminal made up of proline-, tyrosine- and glycine-rich motifs (de Boer et 
al., 2010).  The Lgals3 gene is located on chromosome 14 and is formed 
by 6 exons and 5 introns totalling 17 kilobases; exons IV-VI code for the 
135 amino acid C-terminus while exon III and part of exon II code for the 
100-150 amino acid N-terminus (Argüeso and Panjwani, 2011).  This 
structure, unique among the galectins, is thought to contribute to many of 
the singular properties of Gal-3.   
 
Each galectin is able to bind the N-acetylactosamine (LacNAc) 
disaccharide units found both terminally and internally in N- and O-
glycans on glycoreceptors for the lectins, these are most commonly 
glycoproteins but also include glycolipids (Di Lella et al., 2011).  
Specifically, Gal-3 binds glycoproteins that have been post-translationally 
modified by the glycosyltransferase Mgat5 (β1,6-N-acetylglucosaminyl 
transferase 5) which is responsible for the addition of β1,6 branched N-
acetlyglucosamine to the α-linked mannose of biantennary N-linked 
oligosaccharides (Figure 1.2).  Gal-3 has also been identified as a 
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receptor for advanced glycation end products (AGE), which are produced 
when reducing sugars react with proteins to form highly reactive 
glycoproteins that have been implicated in diabetes and cardiovascular 
diseases as well as normal process such as chemotaxis and cytokine 
release from activated cells (Vlassara et al., 1995).   
 
 
Figure 1.2 Gal-3 binding preference.   
Gal-3 binds terminal or internal N-glycans produced by post-translational 
modification with β1,6 N-acetylglucosaminyltransferase V (Mgat5). 
 
 
The prototype, tandem repeat-type and chimera-type galectins are, 
respectively, able to homodimerise, heterodimerise or hetero-oligomerise 
in the presence of multivalent ligands. When acting extracellularly, 
galectin-glycan interactions result in large cell surface lattices distinct for 
each member, thus initiating divergent functions.  Specifically, Gal-3 CRD 
binding to glycan ligands results in conformational changes in the 
backbone protein loops of the N-terminal that enables the molecule to 
oligomerize and form heterogeneous and disorganised lattices, displaying 
positive cooperativity of this binding.  In this way, Gal-3 is able to bind 
glycans at the plasma membrane and through self-assembly results in 
the cross-linking of these oligosaccharides on the cell surface, initiating 
intracellular effector signalling pathways (Henderson and Sethi, 2009). 
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Figure 1. Gal-3 binds N-linked glycans produced by post-translational modification 
with !1,6 N-acetylglucosaminyltransf ras  V (Mgat5). 
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The approximately 30kDa Gal-3 can also exert its effects intracellularly 
where it oligomerizes; the resulting large aggregates being able to exert 
many different effects on cellular pathways.  Indeed, it is known to bind a 
number of proteins involved in intracellular signalling including Bcl-2, a 
protein important for programmed cell death with which Gal-3 shares an 
NWGR amino acid sequence (Haudek et al., 2010). Early studies found 
that the lectin is itself phosphorylated at Ser6 and Ser12 on the N-terminus 
by kinases including casein kinase I and that this resulted in reduced 
ligand binding, suggesting that the ratio between the two forms would 
regulate its function, a similar mechanism to that proposed for the 
selectins (Mazurek et al., 2000).  More recently, it has been found that 
though both forms can be found in the nucleus, only the phosphorylated 
lectin is detected in the cytosol.  Indeed, Gal-3 can carry out nuclear 
splicing of pre-mRNA along with Galectin-1, a process which evidently 
would have far-reaching effects inside the cell (Liu et al., 2002). 
 
Gal-3 is expressed in the majority of human and murine immune cells, in 
both species it is predominantly produced by macrophages (Forsman et 
al., 2008).  Gal-3 belongs to a small group of proteins that can be 
secreted in the absence of a classical signal sequence, possibly via 
interaction with extracellular matrix proteins; thus, it is localised primarily 
in the cytoplasm but also the nucleus and, significantly for this thesis, in 
the extracellular compartment (de Boer et al., 2010).  Since it was first 
investigated in the 1980s Gal-3 can influence many cellular processes 
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that have direct effects on the continuation and resolution of the 
inflammatory response. 
 
Since its characterization, Gal-3 has been implicated in a diverse group of 
human pathologies, many of which have been replicated in murine 
models of disease (Cooper et al., 2012).  In healthy adults, levels of 
circulating Gal-3 average at ~7ng/mL and this is increased by 2-3 fold in 
infectious disease such as bacterial sepsis, viral lower respiratory tract 
infections and candidaemia (Ten Oever et al., 2013).  Its expression was 
previously found to be upregulated in certain types of lymphomas while 
downregulated in breast, colon and ovarian carcinomas; furthermore, 
levels of circulating Gal-3 are again increased in metastatic disease 
(Sano et al., 2000, Iurisci et al., 2000).  In addition to this, it is up-
regulated in the foam cells of atherosclerotic lesions (Nachtigal et al., 
1998).  In a murine model of pneumonia, Gal-3 accumulated in the 
alveolar space of S. pneumoniae-infected lungs, this was closely 
correlated with the onset of neutrophils to the area (Sato et al., 2002).  
Additionally, Gal-3 has been localized to sites of joint destruction in the 
synovial tissue of rheumatoid arthritis (RA) patients and furthermore, was 
found to be increased in these tissues when compared to those from 
healthy controls or osteoarthritis (OA) patients (Ohshima et al., 2003).  
Gal-3 has also been shown to act similarly in the CNS, where it was 
upregulated following experimental stroke and this correlated closely with 
ischaemia (Yan et al., 2009).  These disease states, particularly RA, 
stroke and S. pneumoniae infection, all involve large inflammatory 
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responses characterised by leukocyte infiltration to the inflamed area.  
Thus, it is possible that Gal-3 is exerting its effects by mediating this 
leukocyte recruitment, a process imperative to the onset and ultimately, 
conclusion, of acute and chronic inflammatory disorders.   
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1.2 The leukocyte recruitment cascade 
Leukocytes are fundamental to both the acute and chronic phases of the 
immune response. The large group of haematopoietic stem cell-derived 
immune cells can be divided into two groups based on their morphology – 
granulocytes such as neutrophils, basophils, eosinophils and mast cells 
as well as agranulocytes such as lymphocytes, monocytes and 
macrophages.  Regardless of their specific function, an important 
hallmark of all leukocytes is their ability to migrate quickly to the area of 
inflammation.  The basic mechanisms underlying leukocyte recruitment 
have been extensively studied both in vivo and in vitro; from this a model 
of cell movement across the endothelial cell wall has been formed (Figure 
1.3).  Briefly, recruitment in post capillary venules involves five stages – 
initial capture and rolling, activation, firm adhesion, crawling and finally 
transmigration (Petri et al., 2008, Ley et al., 2007).   
 
1.2.1 Capture and rolling 
The initial tethering, rolling and subsequent slow rolling of leukocytes is 
mediated primarily by selectins, which are Ca2+-dependent type-I 
transmembrane glycoproteins.  E- and P- selectin are found on the 
vascular endothelium and L-selectin is found on the surface of many 
leukocytes; all bind P-selectin Glycoprotein-1 (PSGL1) and other 
glycosylated cell surface ligands, many of which carry the tetrasaccharide 
sialyl Lewis X (sLex) (Sperandio et al., 2009).  It was originally shown by 
immunogold electron microscopy that PSGL-1 is localised to the tips of 
microvilli on quiescent neutrophils, monocytes, eosinophils, basophils and 
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lymphocytes and is not stored intracellularly, allowing for instantaneous 
association between the leukocytes and vascular endothelium (Bruehl et 
al., 1997).  Additional E-selectin ligands include E-selectin ligand-1 
(ESL1) and the hyaluronan receptor, CD44.  It is possible that E-selectin 
is more important in humans whereas P-selectin is more predominant in 
murine tissues (Pan et al., 1998).   
 
L-selectin is constitutively expressed on neutrophils, monocytes and 
lymphocytes; following cell activation it is rapidly shed from the cell 
surface to concentrated clusters on the microvilli.  It is a comparatively 
short molecule enabling optimal cell interactions with the endothelia at the 
initial tethering and rolling stages (rolling velocity >100µm/s) (Stein et al., 
1999). L-selectin also enables secondary leukocyte capture, whereby 
leukocytes can capture other leukocytes before further strengthening of 
interactions with the endothelia on E- and P-selectin (Ley et al., 2007).   
 
P-selectin is constitutively expressed in Weibel-Palade bodies of the 
endothelia, which, when stimulated by many inflammatory mediators fuse 
with the plasma membrane within minutes; thus P-selectin is also 
important for initial tethering and rolling.  P-selectin clustering on the 
endothelia via clathrin-coated pits increases the strength of selectin 
binding to neutrophils in vitro (Setiadi and McEver, 2003).  Studies in P-
selectin-/- mice have shown that P-selectin mediates rolling at velocities of 
approximately 40µm/s in response to cytokine-induced inflammation as 
well as surgery-induced trauma (Sundd et al., 2011).  
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E-selectin is not stored intracellularly, rather it is newly synthesised upon 
activation of the endothelial cells and has been shown to be upregulated 
in as little as 2h following cytokine treatment (Jung and Ley, 1997).  E-
selectin is predominantly responsible for slow rolling on the endothelia; in 
E-selectin-/- mice neutrophil slow rolling (<5µm/s) in response to TNFα 
was absent (Sundd et al., 2011).  The dramatic decrease in rolling 
velocity on E-selectin has been partly attributed to an association with the 
β2-integrins (Kunkel et al., 2000). It is thought that upon binding of E-
selectin to its ligand PSGL-1, the integrin LFA-1 becomes partially 
activated in a Syk-dependent manner allowing slow rolling, but not arrest 
on ICAM-1 (Zarbock et al., 2007).  This is reviewed in more detail in 
section 1.2.2.  
 
The selectins are clearly an important group of molecules for leukocyte 
recruitment, however studies have shown that there may be distinct 
routes of recruitment which exclude these molecules, such as α4–
integrin-induced rolling and molecules which may be able to replace 
selectins such as α4–integrin-like CD44 and vascular adhesion protein-1 
(VAP-1) (Petri et al., 2008). 
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1.2.2 Activation and firm adhesion 
Leukocyte activation and firm adhesion involves the integrin family of 
transmembrane heterodimers formed from one of 18 α subunits and one 
of 8 β subunits so far identified and which may exist in one of three 
conformational states classified according to the affinity with which they 
bind their ligands.  These are the low-affinity bent state, the intermediate-
affinity state where the integrin is extended however the headpiece and 
thus binding site is closed and finally the high-affinity open headpiece 
extended formation (Hogg et al., 2011).  Once in close contact with the 
endothelium the leukocytes become activated and this initiates integrin-
dependent pathways through inside-out signalling, which mediate firm 
adhesion via a conformational change of the integrin that allows firm 
binding with their leukocyte ligands.  It is thought that the α4–integrins 
such as very late antigen-4 (VLA-4) and the more prominent β2-integrins 
such as lymphocyte function associated antigen-1 (LFA-1) and 
macrophage-1 antigen (Mac-1) can be fully activated by shear flow in the 
vessel after E-selectin inside-out signalling, facilitating cell arrest on the 
vessel wall (Green et al., 2004).   
 
Initial integrin activation commonly occurs through the action of 
chemokines presented by endothelial cells binding GPCRs on the 
leukocyte cell surface.  In neutrophils, these Gαi2-coupled receptors most 
probably result in PLC-β activation, intracellular Ca2+ fluctuations and 
subsequent activation of the guanine nucleotide exchange factor (GEF) 
CalDAG-GEFI and its target Rap1.  In comparison, further investigation 
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since the Zarbock et al. (2007) findings have reported that neutrophil 
rolling on both E-and P-selectin can initiate the inside-out integrin 
pathways that cause LFA-1 to enter the extended but not high-affinity 
conformation, in the absence of chemokine signalling.  This was 
dependent on PSGL-1 binding and syk activation via the src family 
tyrosine kinase FGR, which in turn phosphorylated the immunoreceptor 
tyrosine-based activation motif (ITAM)-containing molecules DAP-12 and 
FcRγ before recruiting syk itself (Kuwano et al., 2010).  This 
complements work carried out using co-coated chamber slides in the in 
vitro flow assay showing that neutrophil engagement with E-selectin 
activates β2-integrin binding to ICAM-1, which was blocked by 
neutralising antibodies against E- and L-selectin, PSGL-1 or inhibitors of 
p38 mitogen-activated protein kinase (MAPK) (Simon et al., 2000).  
Further, cross-linking of E-selectin on human umbilical vein endothelial 
cells (HUVEC) resulted in MAPK/ERK kinase (MEK)-dependent MAPK 
activation, which was brought about by interaction with Ras and Raf-1 to 
upregulate the pro-inflammatory early response gene c-fos (Hu et al., 
2000).   
 
There are differences in the two activation routes described; selectin-
dependent neutrophil activation is much slower than activation induced by 
chemokine signalling, which is almost instantaneous.  Furthermore, it is 
thought the added force of the shear flow in vessels enables chemokine-
mediated activation to cause the high affinity, open headpiece 
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conformation of the integrin, suggesting that further layers of regulation 
occur in vivo (Kuwano et al., 2010).   
 
Once firm adhesion is fully effected, ICAM-1 dimers preferentially bind 
these LFA-1 and MAC-1 integrin ligands and through Src-dependent 
phosphorylation of the actin cytoskeleton the dimers form a concentrated 
cluster on the endothelial cell under the leukocyte which continues to 
surround the cell as it transmigrates through the vessel wall (Yang et al., 
2006).  VCAM-1 preferentially binds VLA-4 on monocytes and 
lymphocytes; clustering of this adhesion molecule in the later stages of 
the recruitment cascade has also been described.  This clustering of 
ICAM-1 and VCAM-1 is thought to aid the later stage of transmigration by 
leading to increases in cytosolic free Ca2+ and the subsequent loosening 
of the endothelial tight junctions via VE-cadherin phosphorylation.  ICAM-
2 is constitutively expressed on endothelial cells and preferentially binds 
β2-integrins, some studies report a functional role for ICAM-2 in neutrophil 
adhesion though its real relevance is still unclear and overall modest 
(Muller, 2011).  Finally, activation also induces neutrophil surface 
relocation of the selectin ligand PSGL-1 from the microvilli to the newly-
formed uropod, perhaps allowing for smoother transendothelial migration 
by disengaging bonds to the surface of the endothelial cell (Bruehl et al., 
1997). 
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Figure 1.3 The leukocyte recruitment cascade.  
Many leukocyte and endothelial cell molecules work in concert to coordinate 
the leukocyte recruitment cascade in a sequential manner.  The distinct stages 
include initial tethering, rolling, activation, slow rolling, adhesion, crawling and 
finally para- or transcellular transmigration.  PSGL-1, P-selectin glycoprotein 
ligand-1; ESL1, E-selectin ligand 1; CAM, cell adhesion molecule; VAP-1, 
vascular adhesion protein-1; LFA1, lymphocyte function-associated antigen-1; 
Mac-1, macrophage-1 antigen; VLA4, very late antigen-4; ICAM, intracellular 
CAM; VCAM, vascular CAM; MADCAM1; mucosal vascular addressin CAM-1, 
PI3K, phosphoinositide 3-kinase; Jam, junctional adhesion molecule; ESAM, 
endothelial cell-selective adhesion molecule.   
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1.2.3 Crawling and Transmigration 
The process of crawling is thought to aid leukocyte emigration as the cells 
search out endothelial cell junctions and appropriate places to 
transmigrate (Wojciechowski and Sarelius, 2005).  It was first identified as 
a critical step in the cascade by visualising monocyte transmigration 
through endothelial cells in vitro (Schenkel et al., 2004). Leukocyte 
crawling is also integrin-dependent, with Mac-1 having a dominant role.  
In vivo wild type neutrophils migrated to PECAM-1-stained junctions but 
neutrophils lacking Mac-1 failed to do so. In addition, inhibition of 
neutrophil crawling via Mac-1 antibody caused leukocytes to migrate at 
the point of their adherence resulting in a higher proportion of 
transcellular as opposed to paracellular migration of these cells 
(Phillipson et al., 2006).   
 
Though it has been shown that leukocyte subtypes behave differently 
under different conditions, all subtypes can migrate across the endothelia 
both transcellularly and paracellularly.  For example, neutrophils often 
emigrate at tricellular points of the endothelial barrier whereas monocytes 
often migrate at endothelial cell tight junctions and there is mounting 
evidence that lymphocytes prefer the transcellular route (Burns et al., 
2000, Carman and Springer, 2004).  Several endothelial cell junctional 
molecules are involved primarily in this stage of recruitment, these 
include platelet endothelial cell adhesion molecule -1 (PECAM-1), ICAM-
2, junctional cell adhesion molecules A-C (JAM-A/B/C), CD99 (also 
known as MIC2), endothelial cell-selective molecule (ESAM) and 
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vascular-endothelial-cadherin (VE-cadherin).  PECAM-1, CD99 and JAM-
A on the endothelia bind in a homophilic manner to their counterparts on 
transmigrating leukocytes and neighbouring endothelial cells; JAM-B and 
JAM-C bind VLA-4 and Mac-1, respectively; ICAM-2 binds LFA-1 and 
Mac-1 and ESAM binds unidentified ligands on leukocytes (Ley et al., 
2007).   
 
As described above, firm adhesion of the leukocyte involves the 
clustering of ICAM-1 and VCAM-1 at the endothelial cell membrane and 
this step initiates further stages, which aid paracellular transmigration by 
weakening the endothelial cell tight junctions. VCAM-1 multimerisation 
leads to increases in cytosolic free Ca2+, activation of Rac-1, production 
of reactive oxygen species and consequent protein kinase Cα activation, 
which in turn leads to the phosphorylation of VE-cadherin and its 
subsequent dissociation from the actin cytoskeleton (Muller, 2011).  
ICAM-1 clustering also increases intracellular Ca2+ ion concentration as 
well as initiating p38 MAPK pathways, which result in activation of RhoA.  
The increase in cytosolic Ca2+ brought about by ICAM-1 and VCAM-1 
clustering as well as the activation of RhoA signalling collectively 
activates myosin light chain kinase (MLCK) and consequently leads to 
endothelial cell contraction.  The leukocyte is then guided through the 
weakened tight junction between endothelial cells by the junctional 
molecules present on the leukocyte and at the endothelial border.  It is 
thought that the endothelial cell is able to direct a pool of molecules to aid 
this process; for example, VE-cadherin is directed away from the junction 
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whereas PECAM-1 and JAM-A migrate towards it (Ley et al., 2007).  
Specifically, Mamdouh et al. showed that intracellular PECAM-1 is 
targeted and recycled to a pool of molecules connected to the endothelial 
cell surface during transmigration and later termed the lateral border 
recycling compartment (LRBC) (Mamdouh et al., 2003, Mamdouh et al., 
2008). 
 
The molecules involved in this stage vary according to the type of 
stimulus that is applied to the inflamed zone, and whether it 
predominantly activates the endothelia or the leukocytes themselves.  
Stimuli known to activate the endothelial cells include 
ischaemia/reperfusion injury as well as the cytokine IL-1β; neutrophil 
transmigration elicited by the latter stimuli was shown to require ICAM-2, 
JAM-A then PECAM-1 in distinct but sequential steps (Woodfin et al., 
2009).  These junctional molecules were found not to be necessary for 
transmigration elicited by TNFα, LTB4 or N-formyl-Met-Leu-Phe (fMLF) – 
three stimuli known to activate leukocytes directly.  The same study 
reported that following TNFα stimulation, antibody blockade of Mac-1 and 
JAM-C reduced leukocyte transmigration; this was in accordance with 
earlier studies describing a role for JAM-C in monocyte and neutrophil 
transmigration (Bradfield et al., 2007, Chavakis et al., 2004). 
 
Transcellular migration is known to occur in the CNS and more commonly 
in in vitro models, it was first described convincingly in vivo using a 
guinea pig model of skin inflammation (Feng et al., 1998).  Clustering of 
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ICAM-1 is thought to play a role in initiating transcellular migration and 
overexpression of this molecule was shown to increase migration via this 
pathway (Yang et al., 2005).  In order for a pathway to form in the 
endothelial cells, it is reported that ICAM-1 ligation leads via F-actin 
interactions to the transport of caveolin-1 to the cell membrane and 
further stabilisation of channels by vimentin (Ley et al., 2007).  In addition 
to this, Muller suggested that ICAM-1 clustering may lead to recruitment 
of the LBRC, which is essential for transcellular migration (Muller, 2011).  
By this mechanism, the junctional molecules present throughout 
paracellular migration also play a part in transcellular migration, as they 
are contained within the LBRC.  The junctional molecules CD99, PECAM-
1 and JAM-A surround neutrophils and monocytes transmigrating 
transcellularly, though studies using blocking antibodies against CD99 
and PECAM-1 confirmed that only these two molecules were essential for 
leukocyte transcellular transmigration (Mamdouh et al., 2009).  
 
Many factors can alter the mode of leukocyte recruitment; for example, 
the tissue localisation, the type of stimulus or how long the endothelium 
has been activated for, as well as what leukocyte subtype is 
predominantly being recruited.  Furthermore, these factors may alter the 
catalogue of molecules that the cells are using to migrate to the site of 
injury and much work has shown that these may differ from the classical 
selectin and integrin  ligands that have been so well characterised (Kubes 
and Kerfoot, 2001, Sato et al., 2002, Li et al., 2006, Hogg and Doerschuk, 
1995, Mizgerd et al., 1997).  Investigating the roles of these factors in 
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leukocyte recruitment may have many implications for inflammatory 
diseases such as RA and stroke where this process plays a large part.  In 
order to establish whether Gal-3 may be an alternative molecule involved 
in leukocyte recruitment, taking into account its relevance in a wide 
variety of pathologies in addition to its intra- and extracellular localisation, 
it is important to examine both exogenous effects and endogenous roles 
on leukocyte subsets individually. 
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1.3 Galectin-3 roles and effects on Neutrophils 
Neutrophils are integral cells of the innate immune system and constitute 
the first line of defence against invading pathogens.  Gal-3 is expressed 
in human neutrophils and at much lower levels in murine neutrophils 
though both species express Gal-3 surface ligands such as CD66 (Sato 
et al., 2002, Farnworth et al., 2008).  Many in vivo and in vitro studies 
carried out in human as well as in murine systems indicate a role for Gal-
3 in the recruitment of neutrophils to the inflamed zone.  Sano et al. 
reported that Gal-3 acts as a chemoattractant for human neutrophils in 
vitro and that Gal-3 induced their recruitment to a mouse air-pouch model 
(Sano et al., 2000).  Studies have also examined the role of Gal-3 in 
murine models of Streptococcal pneumoniae lung infection, where 
neutrophil extravasation in response to the pathogen is predominantly β2-
integrin-independent (Mizgerd et al., 1999).  This is in contrast to 
Escherichia coli-induced alveolar inflammation, where tight adhesion and 
subsequent emigration of the neutrophils through the vascular 
endothelium is reduced by β2-integrin antibody blockade (Hogg and 
Doerschuk, 1995).  Accumulation of Gal-3 in the lungs correlated with 
neutrophil emigration to the alveoli during infection and low levels of Gal-
3 were bound to the neutrophil cell surface (Sato et al., 2002).  Farnworth 
et al. demonstrated that Gal-3-/- mice developed more severe lung injury 
and reduced neutrophil recruitment, which was restored by administration 
of exogenous Gal-3 (Farnworth et al., 2008).  Nieminen et al. found that 
there was a reduction in the number of neutrophils recruited to the 
alveolar space of Gal-3-/- mice at 24h after infection; they reported no 
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effect on mice infected with E.Coli, suggesting that Gal-3 facilitates β2-
integrin-independent migration of neutrophils to the infected alveoli during 
lung inflammation (Nieminen et al., 2008).  
 
Another study indicating a stimulus-specific role for Gal-3 found that 
endogenous Gal-3 was required for acute neutrophil recruitment to 
Leishmania major-infected murine air pouches in those mice infected with 
the LV39 strain but not the Friedlin strain.  This was without any defects 
in macrophage, monocyte, lymphocyte or eosinophil recruitment and not 
due to any differences in cytokine production or neutrophil mobility and 
capacity to phagocytose.  Furthermore, Gal-3 binds the L.major glycan 
epitope (Galβ1-3)n and is then cleaved; interestingly Friedlin strain does 
not contain high levels of this epitope, suggesting complex regulation via 
different routes for Gal-3 roles (Bhaumik et al., 2013).  Indeed, the study 
drew two conclusions; firstly that Gal-3 was released and accumulated in 
exudates in response to L.major bacterial challenge.  Secondly, since it 
could also initiate neutrophil recruitment when injected alone to murine air 
pouches, the authors suggested that Gal-3 was acting as a damage-
associated molecular pattern (DAMP) molecule, which interacts directly 
with the neutrophils.  This is in addition to recent research suggesting that 
along with other galectins, Gal-3 is starting to be classified as a pattern 
recognition receptor itself (Cerliani et al., 2011). 
 
Murine models of sterile peritonitis have also been employed to 
investigate exogenous and endogenous Gal-3 effects on leukocyte, 
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specifically neutrophil, trafficking.  Thioglycollate broth elicits peak 
leukocyte recruitment at 6h, this was unchanged in Gal-3-/- mice; 
however, these animals displayed reduced neutrophil recruitment at 3, 6 
and 9 h post-treatment when compared to wild type counterparts (Alves 
et al., 2013).  Another study which did not look at these early time-points 
found Gal-3-/- mice had reduced peritoneal granulocytes after 4 days and 
furthered this by confirming that in this setting, the mutant cells had a 
normal rate of apoptosis and macrophage phagocytosis suggesting that 
defects in recruitment are singularly down to an inability to traffic properly 
(Colnot et al., 1998).  In contrast, peritoneal treatment with exogenous 
recombinant Gal-3 (rGal-3) did not alter neutrophil influx in a carrageenan 
model of rat peritonitis despite levels of Gal-3 being increased in 
peritoneal lavage fluid and extravasated neutrophils at 4 h post-treatment 
in wild type animals (Gil et al., 2006).  In accordance with this, Mgat5-/- 
mice, which display reduced Gal-3 ligands on the cell surface, had 
reduced leukocyte extravasation to the peritoneal cavity after treatment 
with thioglycollate broth, suggesting that it is extracellular Gal-3 that 
affects trafficking directly.  The authors suggested that Gal-3 cross-linked 
Mgat5-modified N-glycans on cytokine receptors at the cell surface, and 
obstructed their depletion by constitutive endocytosis, for example the 
TGFβ receptor (Partridge et al., 2004).  Hsu et al. (2000) have 
investigated this further and observed that thioglycollate broth-elicited 
peritoneal inflammatory cells from Gal-3-/- mice had much reduced NFκB 
activation.  In contrast to earlier studies however, these authors also saw 
increased levels of apoptosis and altered cell morphology in macrophage 
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cultures of Gal-3-/- cells compared to wild type counterparts (Hsu et al., 
2000).   
 
Human neutrophils have been investigated under static conditions in 
vitro; adhesion to an endothelial monolayer was increased 5-fold in the 
presence of exogenous Gal-3 (Sato et al., 2002).  Furthermore, Gal-3 
promotes human neutrophil adherence to the extracellular matrix proteins 
laminin and at higher concentrations, fibronectin.  This effect is 
dependent on the carbohydrate recognition domain and amino terminal of 
Gal-3 as well as being temperature and Ca2+/Mg2+-dependent, 
suggesting that Gal-3 oligomerizes at the cell surface (Kuwabara and Liu, 
1996).  Taken together, these data indicate that Gal-3 may act as a 
soluble adhesion molecule for neutrophils. 
 
Gal-3 has additional effects on neutrophils that may be central to its 
inflammatory role.  There has been some debate over direct Gal-3 effects 
on neutrophils.  Initial studies reported that it was able to induce an 
oxidative burst in exudated hence primed neutrophils but not in peripheral 
blood neutrophils.  Neutrophil priming occurs in vivo during migration and 
in vitro can be induced by pre-incubation with, amongst others, LPS, IL-8 
(low concentration) or cytochalasin B.  It occurs in degrees and via 
granule mobilisation, intracellular Ca2+ fluctuations and increased 
phosphorylation activity, to enable neutrophils to rapidly respond once 
they have reached their target site (Almkvist et al., 2001).  Cytochalasin B 
was used to show an increase in Gal-3-mediated oxidative burst and 
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reactive oxygen species (ROS) production when compared to unprimed 
cells (Yamaoka et al., 1995).  Karlsson et al. furthered these studies by 
examining differences in NADPH-oxidase activity in peripheral or human 
skin blister neutrophils, which responded much more to Gal-3.  They also 
distinguished two signals in the cell response to Gal-3 – extracellular 
release of ROS attributed to plasma membrane NADPH-oxidase 
activated by Gal-3 receptors in the gelatinase and secretory granules, as 
well as intracellular ROS production attributed to Gal-3 receptors 
activating NADPH-oxidase in the specific granule membrane (Karlsson et 
al., 1998).  In contrast to this, more recent studies looking at different 
markers of activation have shown Gal-3 can indeed activate naïve as well 
as primed neutrophils, causing L-selectin shedding within 5 min and IL-8 
release after 30 min in these cells; in both cases CRD binding and N-
terminal oligomerization was required.  Furthermore, the study showed 
that Gal-3 was cleaved by the serine protease neutrophil elastase in 
primed cells upon its CRD binding and suggested that this regulation of 
Gal-3 activity was coupled to its internalisation (Nieminen et al., 2005).  
Particularly relevant to neutrophil recruitment, Farnworth et al. 
demonstrated that 30 min treatment with recombinant Gal-3 also caused 
L-selectin shedding on human neutrophils as well as CD11b upregulation 
on both human and mouse neutrophils (Farnworth et al., 2008).   
 
Human recombinant Gal-3 increased the phagocytic capacity of isolated 
human neutrophils; this response was dependent on p38 MAPK 
phosphorylation and disruption of this pathway abrogated these effects 
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(Fernández et al., 2005).  Finally, there is work indicating a role in 
neutrophil apoptosis – some studies show that Gal-3 is protective, most 
likely due to intracellular mechanisms of action whereas when acting 
extracellularly it may induce apoptosis (Farnworth et al., 2008, Fernández 
et al., 2005). In the case of human neutrophils, Gal-3 is able to induce 
phosphatidylserine (PS) exposure in the absence of cell death and it was 
suggested that Gal-3 would act as an immunomodulatory molecule via 
this function (Stowell et al., 2008). 
 
1.4 Gal-3 roles and effects on Monocytes and 
Macrophages 
Monocytes and macrophages are vital members of the innate immune 
system, monocytes arrive at the site of injury quickly before differentiating 
into macrophages, which can engulf invading pathogens and cell debris.  
Despite this, much less is known about Gal-3 roles and effects in these 
cells.  Gal-3 is expressed in both cell types and monocyte differentiation 
into macrophages as well as stimulation with IL-4 results in increased 
expression of the lectin (van Stijn et al., 2009).  It has also been found in 
both peritoneal and alveolar murine macrophages and can be released 
from the latter without compromising plasma membrane integrity.  The 
same study found that S. pneumoniae infection increased the expression 
of Gal-3 in alveolar macrophages as well as stimulating its release from 
these cells (Sato et al., 2002).   
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There is also evidence that supports the view that Gal-3 may affect 
recruitment of monocytes and macrophages.  The lectin can act as a 
chemoattractant for human monocytes where it is chemokinetic at low 
concentrations (10-100nM) and chemotactic at higher concentrations 
(~1µM).  This biological property did not occur via any known 
chemoattractant receptors; it was coupled to an increase in intracellular 
Ca2+ in addition to being Pertussis toxin-sensitive, suggesting a role for 
G-inhibitory protein coupled receptors in some Gal-3 actions.  Similarly, 
Gal-3 induces macrophage chemoattraction and is one of few 
chemokines that have been shown to do so.  Its chemoattractant 
properties have been confirmed in vivo with increased numbers of 
monocytes recruited to mouse air-pouches in response to Gal-3 (Sano et 
al., 2000).   
 
In actions separate to those affecting chemoattraction, exogenous 
application of Gal-3 triggered human macrophages and peripheral blood 
monocytes to produce superoxide (Liu et al., 1995).  It also affected 
macrophage phagocytosis, possibly due to its localisation in the 
phagosome, where it could interact with binding partners including Alix 
(Chen et al., 2005).  In human cells exogenous Gal-3 increased the 
proportion of macrophages that engulfed apoptotic neutrophils, as well as 
the number engulfed by each cell; the authors proposed that Gal-3 acted 
as an opsonin between the macrophage and the apoptotic cell (Karlsson 
et al., 2009).  These observations are repeated in murine models where 
Gal-3-/- macrophages displayed impaired phagocytic capacity of apoptotic 
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neutrophils (Farnworth et al., 2008).  Recent work established that Gal-3 
acts as an ‘eat-me’ ligand for macrophages by binding to the 
phagocytosis receptor mer receptor tyrosine kinase (MerTK) and leading 
to its autophosphorylation (Caberoy et al., 2012).   
 
Gal-3 can also regulate the differentiation of macrophages into alternative 
lineages, which have been associated with various pathologies including 
fibrotic diseases, asthma, and atherosclerosis (MacKinnon et al., 2013). 
Classical M1 macrophages are produced by IFNγ/LPS stimulation and 
release higher levels of IL-12 than IL-10, whereas alternatively activated 
M2 macrophages are typically brought about by IL-4/IL-13 stimulation and 
release low levels of both cytokines.  Cytotoxic and pro-inflammatory M1 
macrophages effect the initial inflammatory response to injury whereas 
the M2 cells drive the resolution of inflammation by promoting tissue 
repair.  Gal-3-/- bone marrow-derived macrophages (BMDM) displayed no 
defect in IFNγ/LPS –induced TNFα and IL-6 production.  However, Gal-3-
/- BMDMs treated with IL-4/IL-13 showed much reduced arginase-1 
activity when compared to their wild type counterparts, suggesting the 
cells were not able to enter the M2 state; these results were replicated in 
in vivo-derived peritoneal macrophages.  Furthermore, IL-10-induced 
deactivation of BMDMs was measured in inhibition of LPS-induced TNFα 
release and was unchanged between the two genotypes.  Additionally, 
M2 BMDMs were found to release Gal-3; co-incubation with a Gal-3 CRD 
inhibitor or an inhibitor of the macrophage-binding partner for Gal-3, 
CD98, blocked this IL-4-mediated arginase-1 activation.  CD98 is known 
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to constitutively associate with the β1 integrins and through this 
association results in focal adhesion kinase (FAK) and phoshoinositide-3 
kinase (PI3K) activation.  Upon further investigation, alternative activation 
of THP-1 differentiated macrophages was driven by Gal-3 binding to 
CD98 resulting in subsequent PI3K activation and a Gal-3 feedback loop 
(MacKinnon et al., 2008).  Research from the same group found that Gal-
3 has significant roles in the pathogenesis of atherosclerosis and that 
deletion of this lectin is associated with reduced M2 macrophages in the 
plaque, which had previously been linked to increased atherosclerosis 
susceptibility (Waldo et al., 2008, MacKinnon et al., 2013).   
 
1.5 Gal-3 roles and effects on secretory leukocytes 
Gal-3 is expressed and secreted in both human and murine mast cells, 
where it was specifically localised to the secretory vesicles by electron 
microscopy (Craig et al., 1995, Frigeri and Liu, 1992).  Murine mast cells 
null for Gal-3 exhibited lower levels of degranulation and decreased 
production of cytokines in response to IgE cross-linking on the cell 
surface, which are both vital processes of these cells (Chen et al., 2006).  
In addition, exogenous Gal-3 induces mediator release from these cells, 
which is thought to occur by the cross-linking of IgE and its receptor 
FcεRI on the cell surface (Frigeri et al., 1993). 
 
Gal-3 has been localized to the secretory vesicles of human basophils 
though its effects on these important secretory cells are less well 
characterised (Craig et al., 1995).  In contrast, Gal-3 roles in eosinophils 
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where it is expressed both intra- and extracellularly have been 
investigated, especially in models of allergic airway inflammation and the 
murine air pouch model where Gal-3 increased the number of eosinophils 
that migrated to the site of inflammation (Truong et al., 1993, Sano et al., 
2000).  Gal-3 expression is increased in murine lungs with allergic 
asthma and Gal-3-/- mice display reduced lung and airway eosinophilia in 
response to acute and chronic allergen (Ovalbumin) challenge, 
respectively (Ge et al., 2010).  Further investigation showed endogenous 
Gal-3 is required for rolling of bone marrow-derived eosinophils on 
VCAM-1 and showed a trend to be required for stable adhesion on ICAM-
1 under conditions of flow.  This was in addition to its requirement for 
subsequent activation-induced morphological changes such as cell 
spreading and protrusion formation as well as intracellular Gal-3 being 
vital for eosinophil migration to eotaxin-1 in transwells (Ge et al., 2013).  
These findings could be split into extracellular versus intracellular roles 
for the lectin.  Extracellular Gal-3 enables clustering of the eosinophil 
stable adhesion receptor αM in lipid rafts by cross-linking CD66b, with 
which it is constitutively associated on the cell surface (Yoon et al., 2007).  
Additionally, Rao et al. (2007) found extracellular Gal-3 could bind 
glycoprotein receptors including integrin α4β1 and support eosinophil 
rolling and adhesion under flow by interacting with VCAM-1 (Rao et al., 
2007b).  Not much is known in terms of Gal-3 binding to extracellular 
glycans and initiating signalling pathways inside the cell; however, a 
study in mammary epithelial tumour cells showed exogenous Gal-3 
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increased PI3K and FAK activation as well as F-actin turnover, which are 
all required for eosinophil trafficking (Lagana et al., 2006).   
 
Conversely, intracellular Gal-3 could regulate eosinophil adhesion 
molecule expression.  This has been shown for the intracellular trafficking 
of epidermal growth factor receptor; in association with Alix, endogenous 
Gal-3 enables correct trafficking of the protein to the cell surface thus 
promoting keratinocyte migration (Liu et al., 2012).  Indeed, eosinophil 
migration to eotaxin-1 was dependent on intracellular Gal-3 and this may 
be due to direct regulation of kinases, though this has so far only been 
investigated in pancreatic tumour cells where Gal-3 activated Ras with 
downstream extracellular signal-related kinase (ERK) resulting in 
increased cell invasion (Song et al., 2012).  These data highlight the 
pleiotropic cell and injury type-specific roles of Gal-3 and suggest that 
Gal-3 may mediate recruitment of some of the less prominent leukocytes 
thus impacting much more on the inflammatory response by changing 
numbers of lowly expressed cells.   
 
1.6 Gal-3 roles and effects on the adaptive immune 
response 
Gal-3 is expressed in both human and murine dendritic cells, which act as 
the antigen-presenting cells of the innate immune system, by transferring 
information to the adaptive immune system.  In a role which would have 
great effects on immune responses, Gal-3 is thought to suppress Th1 
responses by reducing the levels of IL-12 released from Dendritic cells in 
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response to microbial challenge by Toxoplasma gondii (Bernardes et al., 
2006).  In terms of leukocyte recruitment, intracellular Gal-3 can increase 
the migratory profile of dendritic cells while accumulating in lipid rafts 
(Hsu et al., 2009b).  Additionally, extracellular Gal-3 increased their 
adhesion to the endothelia, a property that correlated with the higher 
number of glycans on the surface of mature dendritic cells (Vray et al., 
2004).   
 
Gal-3 is lowly expressed in resting CD4 and CD8 positive T-cells, though 
is constitutively present in regulatory and memory T-cells and can be 
induced, for example, by T-cell receptor (TCR) ligation (Hsu et al., 
2009a).  The lectin is able to regulate T-cell activation and functions to 
maintain homeostasis, specifically by binding and self-oligomerising on N-
glycans of the TCR thus restricting its lateral mobility and subsequent 
signal transduction (Demetriou et al., 2001).  In terms of lymphocyte 
migration, Gal-3 did not increase their trafficking to murine air pouches 
and did not behave as a chemoattractant for these cells in vitro (Sano et 
al., 2000).  However, it has been documented that Gal-3 promotes Th17 
cell responses, especially in experimental autoimmune encephalomyelitis 
(EAE) models; Gal-3-/- mice displayed reduced demyelination and 
macrophage infiltration compared to wild type animals and in vitro Gal-3 
was associated with increased IL-17 and IFNγ synthesis and reduced IL-
10 production (Jiang et al., 2009).  In a separate model investigating BSA 
antigen–induced arthritis, Gal-3-/- mice had significantly less joint erosion 
and cartilage damage; this was coupled to decreased IL-17-producing T-
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cells in the spleen and reduced levels of sera TNFα and IL-6 in these 
animals compared to wild type controls (Forsman et al., 2011).  The study 
also observed a partial phenotype recovery after administration of 
exogenous Gal-3, since this would predominantly affect the extracellular 
compartment it is likely that Gal-3 roles in arthritis involve the extracellular 
volume of this lectin.   
 
Much research has been directed towards examining the effects of Gal-3 
on lymphocyte proliferation and apoptosis as it is expressed in both T- 
and B-cells.  Human leukaemia T-cells overexpressing Gal-3 display 
higher growth rates and resistance to apoptosis (Yang et al., 1996).  In 
contrast, secreted extracellular Gal-3 signals T-cell apoptosis in murine 
and human cell lines; this was dependent on pre-existing cytoplasmic 
concentration of the lectin and the study proposed that CD7 and CD29 
mediated this effect via cytochrome c and caspase-3 but not caspase-8 
(Fukumori et al., 2003). Upon further investigation in T cells it has been 
found that intracellular Gal-3 is protective whereas actions of extracellular 
Gal-3 promote apoptosis in these cells (Nakahara et al., 2005).  In B-
cells, expression was increased in human B-cell lymphomas and in Gal-3-
/- mice B-cells exhibited enhanced apoptosis (Acosta-Rodríguez et al., 
2004, Hoyer et al., 2004).  These data support the view that intracellular 
Gal-3 is protective and it is now thought that this is due to engaging 
intracellular apoptosis regulation pathways or by affecting mitochondrial 
homeostasis (Liu et al., 2002, Matarrese et al., 2000).  In contrast, 
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extracellular Gal-3 induces apoptosis though the specific receptors and 
pathways involved have not been fully characterised.  
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1.7 Gal-3 roles and effects on endothelial cells 
Gal-3 is expressed in endothelial cells and is localized predominantly at 
the cell membrane, along with surface ligands for the lectin (Sato et al., 
2002).  In HUVEC cells mRNA content confirmed Gal-3 expression, 
which was found to be almost exclusively present at the plasma 
membrane by flow cytometry.  Immunohistochemical studies showed 
absence of Gal-3 expression in human liver endothelial cells whereas 
vessels of the kidney and placenta indicated low expression of the lectin.  
Gal-3 expression was unaltered after culture with 20% human serum 
though it has been reported that endothelial cells increase their 
expression on contact with tumour cells expressing specific 
carbohydrates on their surface (Thijssen et al., 2008).  Gal-3 is 
proteolytically cleaved by matrix metalloproteinase-2 and this 27kDa 
fragment binds HUVEC with 20-fold higher affinity than the full-length 
30kDa protein (Shekhar et al., 2004).  In an in vivo model, upon S. 
pneumoniae infection murine alveolar vascular endothelial cells were 
thought to be among those increasing their Gal-3 expression (Sato et al., 
2002) suggesting a role in leukocyte recruitment via the endothelia itself, 
which complements those which occur on the circulating leukocytes.   
 
A recent paper examined whether Gal-3 could internalise to HUVEC and 
if so by which pathway; indeed, it was found that the lectin was 
endocytosed and then trafficked through one of two pathways.  Gal-3 
enters the cell upon ligand binding and reaches the early/recycling 
endosomes from where it is either recycled for exocytosis or targeted into 
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late endosomes or lysosomes (Gao et al., 2012).  The authors suggest 
that these two pathways may be mediated by different receptors on the 
endothelial cell surface, which is in line with previous studies showing that 
HUVEC display high and low-affinity Gal-3 ligands (Nangia-Makker et al., 
2000).  These ligands were not identified and so far only a few others 
have been described, these include the main candidate integrin αvβ3, 
integrin α3β1, CD13 and VEGF-R2 (Markowska et al., 2010, Fukushi et 
al., 2004, Yang et al., 2007, Markowska et al., 2011). 
 
Studies investigating the role of Gal-3 in angiogenesis have reported that 
soluble recombinant Gal-3 stimulates this process in vitro and in vivo, and 
that this may be due to its ability to induce locomotion of endothelial cells 
thus aiding the initial tube forming phase.  This effect required the CRD of 
Gal-3, which bound at least two cell surface receptors on the endothelial 
cells before they significantly upregulated expression of integrin αvβ3. 
Gal-3 can also modulate VEGF-mediated signalling through these 
integrins (Nangia-Makker et al., 2000, Markowska et al., 2010).  Further 
investigation into vascular endothelial growth factor receptor-2 (VEGF-
R2) induced angiogenesis showed that Gal-3 bound Mgat5-modified N-
glycans on endothelial cell surface VEGF-R2, initiating its 
phosphorylation and retention at the membrane and promoting its pro-
angiogenic function (Markowska et al., 2011).   
 
Gal-3 has also been implicated in ischaemic injury repair.  In the rat brain 
administration of Gal-3 neutralising antibodies diminished ischaemia-
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induced angiogenesis and in vitro exogenous Gal-3 was shown to dose-
dependently stimulate the proliferation of endothelial cells (Yan et al., 
2009).  Exogenous Gal-3 increased the number of angiogenic structures 
formed in a microglia-HUVEC co-culture model and this was associated 
with increased VEGF expression by BV2 microglial cells.  The same 
study found extracellular Gal-3 increased the migratory profile of BV2 
cells in scratch assays and Boyden-matrigel chambers.  These effects 
were dependent on the serine/threonine kinase integrin-linked kinase 
(ILK), which acts via MAPK/ERK1/2 and PI3K/Akt pathways resulting in 
increased VEGF expression and subsequently, increased endothelial 
proliferation and migration (Wesley et al., 2013).   
1.8 Possible mechanisms of Gal-3 action on leukocyte 
recruitment 
There are many possible mechanisms of action of Gal-3 on inflammatory 
processes, especially leukocyte recruitment and it is probable that these 
operate in concert to exert its effects.  One area of speculation is that of 
identifying Gal-3 ligands; studies using isolated human neutrophils and 
the HL-60 promyelocyte cell line have identified the CD66 proteins 
CD66a and CD66b as the major receptor candidates (Feuk-Lagerstedt et 
al., 1999).  It was previously shown in neutrophils that receptors for Gal-3 
must be mobilized to the cell surface from specific and gelatinase 
intracellular granules (Karlsson et al., 1998).  Neutrophil granules were 
subsequently analysed by affinity chromatography and from this the 
CD66 proteins were identified as able to bind Gal-3.  In addition to this, 
the subcellular localization of CD66 proteins are consistent with the 
proposed Gal-3 receptor distribution, as they are found in specific and 
gelatinase granules and are less well concentrated in the secretory 
vesicles or at the plasma membrane of unprimed cells (Feuk-Lagerstedt 
et al., 1999).  It has since been reported that Gal-3 responsiveness is 
markedly increased upon gelatinase granule mobilisation; for example 
after LPS priming, which does not mobilise the specific granules, 
suggesting that it is these granules that store most Gal-3 binding partners 
(Almkvist et al., 2001).  
 
The effects of binding to CD66 proteins have recently been under 
investigation.  It was found that cross-linking of CD66b on peripheral 
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blood neutrophils mediates the release of IL-8 from intracellular stores 
(Schröder et al., 2006).  IL-8 is known to be the major chemotactic factor 
for neutrophils, which suggests a mechanism for Gal-3 effects on 
neutrophil migration.  Furthermore, the binding of both CD66a and CD66b 
can result in intracellular oxidative burst upon their cross-linking on the 
cell surface, a property that is often associated with Gal-3 binding 
(Jantscheff et al., 1996, Lund-Johansen et al., 1993).  Finally, the cross-
linking of antibodies binding to CD66b on neutrophils resulted in their 
increased adhesion to endothelial cells, a finding which may underlie the 
effects of Gal-3 on leukocyte recruitment (Skubitz et al., 1996).  Further 
information on these molecules would provide interesting data for 
possible intracellular pathways of Gal-3, especially as signalling through 
CD66a and CD66b is known to differ. 
 
Though Gal-3 may utilize many different pathways within leukocytes, it 
has been shown that in granulocytes, Gal-3-induced degranulation, 
phagocytosis and apoptotic rate is dependent on the p38 MAPK pathway 
(Fernández et al., 2005).  This was demonstrated by p38 MAPK 
inhibition, which abrogated the effects of human recombinant Gal-3 as 
well as by analysis of p38 phosphorylation after incubation with human 
recombinant Gal-3.  Interestingly, the major intracellular pathways of the 
MAPK family, ERK1/2, were unaffected by Gal-3.  Additionally, it is 
possible that Gal-3 regulates levels of c-jun N-terminal kinase (JNK), 
another member of the MAPK family, which is an important regulator of 
apoptosis.  However, JNK levels were found to differ only in mast cells of 
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Gal-3-/- mice, signalling that this is not a universal mechanism of action of 
the molecule (Liu et al., 2002).  These data signal that Gal-3 may initiate 
some members of the MAPK family, which are known to respond to pro-
inflammatory cytokines and alter gene expression, proliferation and 
apoptosis; though more information is needed to confirm specifically the 
pathways involved. 
 
Gal-3 is one of a small number of molecules that have been proposed to 
act as soluble cell-cell and cell-cell matrix adhesion proteins and thus 
may have direct effects on leukocyte recruitment through this process.  
Sato et al. noted that the lectin mediates neutrophil adhesion to 
endothelia and that this is dependent on its self-oligomerization via its N-
terminal domain; in addition, they noted that this effect was not due to the 
activation of any other adhesion molecule (Sato et al., 2002).  Gal-3 
oligomerization on the cell surface and the resultant receptor clustering 
has previously been linked to cell activation; it is now thought that this 
process can also lead to adhesion.  Imaging studies have shown that 
Gal-3 clusters are concentrated at tricellular corners of the endothelium 
and adherent neutrophils, points of the vascular cell wall at which 
neutrophils are known to preferentially transmigrate (Nieminen et al., 
2007), as discussed above.  Similar observations have been found 
between eosinophils and breast carcinoma cells (Rao et al., 2007b).  This 
mechanism of cross-linking has also been suggested for Gal-3 
interactions with neutrophils and the extracellular cell matrix protein, 
laminin, where FITC-labelled Gal-3 was shown to aggregate on the 
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neutrophil cell surface (Kuwabara and Liu, 1996).  Furthermore, binding 
studies suggest that Gal-3 mediates tight cell adhesion similar to that 
caused by the binding of β2-integrins to their ligand ICAM-1 (Barboni et 
al., 1999).  This is interesting as Gal-3 has been reported to have no 
effect on leukocyte recruitment in models where β2-integrin-dependent 
migration is initiated, such as in E. Coli infection in the lungs and 
suggests that Gal-3 may be as important as the β2-integrins in an 
equivalent role in another pathway.  Thus, Gal-3 is involved in β2-integrin-
independent leukocyte migration by directly cross-linking leukocytes, 
endothelia and the extracellular matrix at specific points on the plasma 
membrane.   
 
Previous work has also started to characterise the way in which Gal-3 
may act as a chemoattractant for neutrophils, eosinophils, monocytes and 
macrophages.  Work by Sano et al. established that Gal-3 most likely 
activates PTX-sensitive G-protein coupled receptors (GPCRs), 
suggesting that there is more than one type of receptor for Gal-3 and that 
they may be role- and cell type-specific.  It is known that many 
chemoattractants and chemokines exert their effects via GPCRs and 
result in Ca2+ influx.  However, there was no cross-reactivity between 
Gal-3 and other previously characterised chemokine receptors, 
suggesting that Gal-3 utilises an entirely new pathway.  In addition to this, 
it was suggested that Gal-3 might activate different sets of receptors 
depending on its cell concentration as PTX inhibition varied in a Gal-3 
concentration-dependent manner (Sano et al., 2000).  Though this area 
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has been less well characterised, it will be important to establish the 
receptors involved in the lectin’s role as a novel chemokine, as utilising 
this effect pharmacologically could prove to be very useful in modulating 
the inflammatory response. 
 
These studies provide many answers to the question of Gal-3 
mechanisms of action inside the cell; however, they undoubtedly raise 
many more questions that must be addressed.  The prospect that Gal-3 
receptors and the corresponding intracellular pathways may differ as a 
result of cell type, Gal-3 concentration and the effect exerted on the cell is 
an exciting one, as it suggests Gal-3 is a multi-faceted molecule which 
may be involved in many aspects of the immune response.  
 
 
Gal-3 roles in leukocyte recruitment have been studied in in vivo models 
of inflammation, albeit using different tissues and inflammatory stimuli; 
the findings presented here are in keeping with published results, which 
are summarised in Table 1.1.  Many investigations report reduced 
leukocyte infiltration of the affected tissue in Gal-3-/- mice; lower numbers 
of lymphocytes and eosinophils were recruited to OVA-challenged 
airways (Ge et al., 2010), there was reduced monocyte, macrophage and 
neutrophil recruitment to the CNS in a model of EAE (Jiang et al., 2009) 
and despite slightly conflicting reports using a thioglycollate broth model 
of peritonitis, two studies found reduced infiltration of neutrophils at either 
day 1 or 4 after insult (Hsu et al., 2000, Colnot et al., 1998).  Farnworth et 
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al. found that Gal-3-/- mice exhibited more severe lung injury associated 
with reduced neutrophil recruitment at 15 h after S. pneumoniae infection, 
which is β2-integrin-independent (Farnworth et al., 2008).  This reduction 
in extravasated neutrophils at 12-24 h was also reported by Nieminen et 
al., who found that recruitment was unaffected in β2-integrin-dependent E. 
Coli-driven lung infection in Gal-3-/- animals (Nieminen et al., 2008).  This 
is in slight contrast to the reduction in rolling velocity in Gal-3-/- mice 
presented here as slow rolling in TNFα-treated cremaster venules is 
dependent on β2-integrins; since leukocyte velocities in CD18-/- mice 
treated with TNFα were approximately 3-fold higher than those in wild 
type mice (Jung et al., 1998).  However, as these findings have been 
reported when investigating different vascular beds and responses to 
varied stimuli, they would involve different phenotypes such as adhesion 
molecule profiles and ultimately, distinct outcomes (Rao et al., 2007a).  
Indeed, taken together these investigations further suggest that Gal-3 is a 
multi-faceted molecule capable of interacting with and acting via different 
receptors in different cells and tissues.    
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1.9 Hypothesis and aims of this PhD studentship 
As previously described with respect to different cell types, the 
involvement of Gal-3 in leukocyte trafficking during inflammation has 
been investigated using diverse in vivo models, which are summarised in 
Table 1.1.  Reduced leukocyte infiltration to the area of insult was noted 
in models of S. pneumoniae infection (Farnworth et al., 2008), allergic 
airway inflammation (Ge et al., 2010), EAE (Jiang et al., 2009) and sterile 
peritonitis (Hsu et al., 2000, Colnot et al., 1998).  This is in addition to 
work showing that treatment with the recombinant lectin increased 
neutrophil, monocyte and eosinophil but not lymphocyte recruitment to 
the murine air pouch, a useful in vivo model for looking at end-point cell 
numbers (Sano et al., 2000).  In spite of what is already known, so far 
Gal-3 roles and effects on specific aspects of the leukocyte recruitment 
cascade in vivo and in real time have not been reported.  
 
Thus the overarching hypothesis for this thesis is that Gal-3 is a positive 
regulator of leukocyte, in particular neutrophil and monocyte recruitment 
in vivo.  In addition to investigating this and due to its localisation both 
within and outside the cell, both endogenous Gal-3 roles in leukocyte 
recruitment as well as exogenous Gal-3 effects on this inflammatory 
process were examined.   
 
1.9.1 Aims  
There are three separate aims of this studentship, these are: 
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1. Study the leukocyte and endothelium interactive events in post-
capillary venules of Gal-3-/- mice. 
 
The use of intravital microscopy to visualize in real time the vascular 
system and in particular, leukocyte recruitment will provide detailed 
information on this process. It will be important to first characterise 
responses of the leukocyte subsets to various inflammatory stimuli in wild 
type mice, before examining the same response in those that are null for 
Gal-3.  This will be carried out using a fixed-time protocol where sham, IL-
1β or TNF-α intrascrotal injections will be given 2 or 4h before IVM.  
Parameters such as leukocyte rolling velocity, rolling flux as well as the 
number of adherent and emigrated cells will be measured.   
 
Concurrently, it will be important to confirm the genotype of the mice from 
the Gal-3-/- colony on a regular basis.  Samples will undergo DNA 
extraction, PCR and subsequent gel analysis to confirm that they are null 
for Gal-3.  
 
2. To determine the pharmacological effects of Gal-3. 
 
The effect of exogenous Gal-3 can then be investigated by examining the 
pharmacological effects of Gal-3 itself; in the first case recombinant Gal-3 
will be administered intrascrotally to examine its possible positive effects 
on recruitment.  Any responses to the lectin can then be further 
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characterised in vitro with the use of flow cytometry, real-time PCR and 
the parallel plate flow chamber assay. 
 
3. To pinpoint any effects of exogenous Gal-3 or defects caused by 
the lack of endogenous Gal-3 in relation to leukocyte sub-type. 
 
Traditional bright-field microscopy methods cannot provide accurate 
information on the specific leukocyte subsets that may migrate in different 
environments; depending on previous results, the use of fluorescent dyes 
with intravital or static microscopy will enable Gal-3 roles and effects to 
be investigated further.  
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Chapter 2: Materials and 
Methods 
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2.1 Animals  
Breeding founders for the Gal-3-/- mouse colony were obtained from the 
Consortium for Functional Glycomics on a C57BL/6 background and a 
colony was established at Charles River UK.  Male mice bearing green 
fluorescent protein (GFP) under their CX3CR1 promoter were kindly 
donated by Prof. S. Nourshargh (QMUL, London).  In all experiments age 
and sex-matched controls [wild type (WT) C57BL/6] were also purchased 
from Charles River UK.  All animals were fed standard laboratory chow 
and water ad libitim and were housed in a 12h light-dark cycle under 
specific pathogen-free conditions.  All experiments were performed with 
mice (20-28g), strictly following UK Home Office regulations (Guidance 
on the Operation of Animals, Scientific Procedures Act, 1986). 
 
2.2 Intravital microscopy of the murine cremaster muscle 
2.2.1 Exteriorisation of the murine cremaster muscle 
Intravital microscopy (IVM) of the cremaster muscle was used to visualise 
leukocyte recruitment in real time. Male mice from wild type C57BL/6, 
monocyte GFP or Gal-3-/- strains were anaesthetised using a mixture of 
xylazine (7.5 mg/kg; Rompun) and ketamine (150 mg/kg; Narketan) made 
up in sterile dH2O and mixed before intraperitoneal (i.p.) injection.  Once 
anaesthetised, the mice were placed onto the viewing stage, which 
comprised a raised Perspex cylinder covered with a permanently 
attached glass coverslip.  The raised cylinder also served as a small 
reservoir for warm bicarbonate buffered solution (BBS: 132nM sodium 
chloride (Sigma), 5mM Potassium Chloride (Sigma), 2mM Calcium 
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Chloride (AnalaR), 1mM Magnesium Sulphate (Sigma) and 20mM 
Sodium Hydrogen Carbonate (AnalaR), pH 7.4) to prevent the tissue from 
drying out, excess buffer was then drained away by attachment of the 
stage to vacuum suction.  The BBS was used to wet the tissue 
throughout surgery and consequently was held at 37°C.  Throughout the 
surgery, extreme care was taken to avoid agitating the cremaster muscle 
by touching the underlying tissue with any of the instruments used. 
 
The skin and fascia covering the ventral aspect of the right scrotum was 
removed, exposing an area extending from the inguinal fold and to the 
distal end of the scrotum.  Any remaining fascia was separated from the 
cremaster muscle using forceps and vannas scissors.  Once the 
cremaster was cleared of fatty deposits the mouse was moved into 
position on a heat pack with the cremaster resting on the glass coverslip 
of the viewing stage (Figure 2.1A).  A suture (BV1; Ethicon) was threaded 
through the distal point of the cremaster sack to secure and slightly 
extend the tissue.  A cauteriser was used to score a line down the centre 
of the cremaster and also two lengths at the top edge of the muscle, 
forming a T-section (Figure 2.1B).  Vannas scissors were then used to cut 
over the T-section and the cremaster was spread flat over the glass 
coverslip, four hooks were used to secure the cremaster in place (Figure 
2.1C).  The cauteriser was used to separate the vessel connecting the 
cremaster and the testicle, which was then separated from the cremaster 
using vannas scissors and secured out of the way of the viewing area 
(Figure 2.1D).  The viewing stage was then moved to one of two 
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microscope set-ups with water immersion lenses to allow for continuous 
superfusion with BBS.  Immediately before recording, the mice underwent 
a 30min stabilisation period which is critical for reducing the impact of the 
surgery itself on the leukocyte recruitment seen; for example, surgery 
quickly increases P-selectin expression thus affecting initial fast rolling of 
the leukocytes (Ley et al., 1995).  
 
Brightfield recordings were carried out using a Zeiss Axioskop FS 
microscope with a x40 objective (Carl Zeiss Ltd) which was illuminated 
with a 12V, 100W halogen light source.  An Optical Doppler Velocimeter 
(Microvascular Research Institute, Teas A&M University) was used to 
measure centerline red blood cell velocity and a video time-date 
generator (FOR-A company Ltd) sealed the date and stopwatch function 
onto the recordings.  Fluorescence microscopy was carried out using an 
Olympus BX61W1 microscope with a x40 water immersion objective (Carl 
Zeiss Ltd.) connected to an Olympus BXUCB lamp, Uniblitz VCMD1 
shutter driver and DG4-700 shutter instrument.  The setup also used an 
Optical Doppler Velocimeter and a Hamamatsu C9300 digital camera 
with a Videoscope VS4-1845 image intensifier attached.  All videos were 
captured using Slidebook 5.0 software from Intelligent Imaging TTL. 
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Figure 2.1 Preparation of the murine cremaster muscle for intravital 
microscopy 
A) The skin and fascia covering the ventral aspect of the right scrotum is 
removed and the cremaster cleared of fatty deposits before the mouse is 
moved into position with the cremaster resting on the glass coverslip of 
the viewing stage and supported by a heat pack.  B)  A suture is threaded 
through the distal point of the cremaster sack and secured to slightly 
extend the tissue.  The cauteriser is used to score a T-section down the 
centre of the cremaster (dotted line).  C) The T-section is cut and the 
cremaster spread flat over the glass coverslip, four hooks are used to 
secure the cremaster in place.  D) The testicle is then separated from the 
cremaster and secured out of the way of the viewing area. 
 
 
  
A B 
C D 
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Post-capillary venules with a diameter of 20-40µm, an adequate 
centerline velocity (≥500S-1) and no branches within 100µm either side of 
the segment to be analysed were chosen.  Vessel segments of 100µm in 
3-5 vessels per mouse and of 3-5 mice per group were recorded for 
offline analysis. The analysis parameters are shown in Figure 2.2.  
Rolling flux was recorded as the number of leukocytes rolling past a 
specific point, averaged over 5 min.  Rolling velocity was determined from 
the time taken for the leukocytes to travel 100µm.  Adherent cells were 
those that were stationary on the vessel wall for more than 30 sec.  
Transmigrated cells were those found in the tissue 50µm by 100µm on 
either side of the vessel.  
 
 
Figure 2.2 Analysis parameters of intravital microscopy 
 
 
2.2.2 Cytokine-induced inflammation 
To assess inflammation in the cremaster muscle, mice were-treated with 
an intrascrotal (i.s.) injection of PBS (sham), IL-1β (30ng), murine TNF-α 
(300ng; Gibco) and/or Gal-3 (200-1000ng) in a final volume of 400µl.  
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The injection was carried out 2 or 4h before the vessel was recorded, 
allowing time for the 30min stabilization period after the surgery had been 
completed, as shown in Figure 2.3.  In order to perform the i.s. injection, 
mice were briefly anaesthetised with inhaled Isofluorane gas 
(approximately 5%: Baxter) and the scrotum gently extended to allow for 
a large injection site.   
 
In addition to the i.s. injection, some animals also underwent a tail-vein 
intravenous (i.v.) injection of fluorescent antibody, rat anti-mouse Ly-6G 
(clone 1A8, 2µg; BD Pharmingen) in 200µL saline.  This was 
administered approximately 15 min before the i.s. injection so that all 
circulating neutrophils were labelled before possible emigration into the 
cremaster muscle.  The mice were heated in an incubated chamber set to 
32°C until the tail vein was visible through the skin, typically for 10min, 
they were then transferred to a restrainer; the tail was exposed and 
pinched near the body to allow the tail vein to become prominent.  The 
needle was inserted with the bevel facing upwards and the antibody 
solution administered carefully before the animal was replaced to its 
cage.  Once recording, it was important to be careful not to expose the 
cremaster to excessive fluorescent excitation as the fluorophore faded 
quickly. 
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Figure 2.3 Protocol for analysis of inflammation in the cremaster 
muscle 
 
 
2.2.3 Intravenous administration of recombinant Gal-3 
To assess rGal-3 effects on circulating leukocytes prior to cremaster 
exteriorisation, the external jugular vein was exteriorised and cannulated 
with microtubing (Size 8.0) connected to a saline-filled syringe.  Briefly, 
the skin covering the left submaxillary gland was removed and the 
salivary gland dissected away to allow access to the vein.  The 
surrounding fascia was cleared and two sutures put in place, the upper 
suture was tied and an incision made before guiding the cannula into the 
vein and tying off the lower suture to hold it in place.  Once the mouse 
was on the stage and a baseline recording had been made, 150ng rGal-3 
or vehicle in 200µL saline was injected intravenously and subsequent 
recordings of cremaster post-capillary venules made at 10 min intervals 
for up to one hour.  
 
2.3 Ex vivo confocal imaging of the murine cremaster 
muscle 
Cremasters from CX3CR1gfp/+ mice treated intrascrotally for 4h with sham 
PBS or rGal-3 (1000ng, section 2.2.2) were exteriorised (section 2.5.1), 
spread flat onto wax sheets and then pinned in place using hooks made 
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from shortened 19.5G needles.  The cremasters were then dissected 
away from the mouse and placed into a 5mL bijou container of 4% PFA in 
PBS for 10 min on ice before being washed twice in the same volume of 
PBS.  Permeabilisation and blocking buffer was prepared as PBS 
containing 12.5% each of fetal bovine serum (FBS; Sigma) and normal 
goat serum (NGS; Sigma) and 0.5% Triton-X-100 (Sigma).  The 
cremasters were removed from the wax, gently blotted on tissue then 
transferred to a 1.5mL microcentrifuge tube containing 500µL 
permeabilisation and blocking buffer and were incubated on a rotating 
wheel for 2h at room temperature.  Primary antibodies against VE-
Cadherin (Alexa Fluor® 555 conjugated, 1µL; donated by Prof. 
Nourshargh, QMUL) and MRP14 (Alexa Fluor® 647 conjugated, 0.5µL; 
donated by Prof. Nourshargh, QMUL) were diluted into PBS containing 
5% each NGS and FBS; the cremasters were incubated in 200µL 
overnight at 4°C.  The cremasters were then washed three times in 1mL 
PBS for 30 min each time on a rotating wheel before longer storage in 
PBS at 4°C.  A coverslip was used to flatten the cremasters onto a 
microscopy slide and the vessels viewed using a Leica SP5 confocal 
microscope. 
 
In addition to the above protocol, cremasters from wild type C57BL/6 
mice treated intrascrotally for 4h with sham PBS, rGal-3 (1µg), rGal-3 
plus lactose (1µg plus 30mM) or rTNFα (300ng) were collected and 
blocked/permeabilsed as above.  The cremasters were then stained in 
TBS containing 1% FBS with either rat ant-mouse E-selectin (Clone 
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10E9.6, 5µg/mL; BD Pharmingen) or rat anti-mouse PECAM-1 (Clone 
MEC 13.3, 5µg/mL; BD Pharmingen) for 1h at room temperature followed 
by 3 brief washes in TBS-FBS.  The cremasters were then incubated with 
the secondary antibody Alexa Fluor® 488 Donkey Anti-Rat IgG (4µg/mL 
in TBS-FBS, Invitrogen) for 30 min at room temperature in the dark 
before another 3 washes as before.  The cremasters were subsequently 
stained again in TBS-FBS with either PE-conjugated rat anti-mouse 
ICAM-1 (clone YN1/1.7.4, 1µg/mL; eBioscience) or PE-conjugated PE-
conjugated rat anti-mouse VCAM-1 (429 (clone MVCAM.A), 1µg/mL; BD 
Pharmingen) for 30 min at room temperature in the dark before another 3 
washes as before.  Control cremasters were stained with secondary anti-
Rat IgG only or the isotype controls PE-conjugated IgG2a (clone eBR2a, 
1µg/mL; eBiosciences) or PE-conjugated IgG2b k (1µg/mL; eBioscience), 
alongside the test cremasters.  Finally, they were mounted on microscopy 
slides with 4',6-diamidino-2-phenylindole (DAPI) mounting medium 
(Vectasheild) and imaging using the Zeiss LSM 510 (Mark 4) Laser 
Scanning Confocal Microscope. 
 
2.4 Murine endothelial cell culture 
2.4.1 Immortalised murine cardiac endothelial cells (MCECs) 
MCECs (donated by Dr Egle Solito, QMUL, London) were cultured on 
tissue culture plasticware in Dulbecco’s modified Eagle’s medium 
(DMEM; Gibco) with 5% fetal calf serum (FCS; Sigma), penicillin 
(100U/mL; Sigma), streptomycin (100µg/mL; Sigma) and HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) buffer (10µM; Sigma).  
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Cells were stored in a humidified chamber with 5% CO2 at 37°C and 
passaged once they reached 95% confluence.   
 
2.4.2 Primary murine lung endothelial cells (MLECs) 
MLECs were isolated from the lungs of wild type or Gal-3-/- mice 
(Reynolds et al., 2004).  Tissue culture flasks and plates were coated with 
10mL 0.1% Gelatin in PBS containing bovine collagen (30µg/mL, 97% 
Type I 3% type III; Nutacon) and bovine plasma fibronectin (10µg/mL; 
Sigma) for a minimum of 2h at 37°C.  Care was taken to aspirate all 
remaining solution, as collagen solution is highly acidic.  MLEC media 
was prepared using equal parts low glucose DMEM and Ham’s F12 
(Gibco) before adding heparin (100µg/mL; Sigma), penicillin (100U/mL), 
streptomycin (100µg/mL) and L-Glutamine (2mM; Sigma) and filter 
sterilising using a 0.4µm disposable filter (Nalgene).  Finally, endothelial 
cell growth supplement (25µg; AbD Serotech) and 100mL FCS was 
added. Cells were stored in a humidified chamber with 5% CO2 at 37°C 
and passaged once they reached 95% confluence.   
 
2.4.3 MLEC isolation 
Lungs from three mice were collected for each genotype; mice were 
euthanised by cervical dislocation before being transferred to a sterile cell 
culture hood and sprayed with 70% EtOH (Sigma).  Being careful to avoid 
the peritoneal cavity, the lungs were excised and placed in Ham’s F12 
media (Gibco) on ice.  Connective tissue, fat and blood clots were 
removed from the lungs, which were briefly rinsed in 70% EtOH, followed 
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by MLEC media and then chopped into small pieces using two scalpel 
blades.  Tissue was further digested in 10mL 1mg/mL collagenase Type 
I-S for 2h at 37°C in a rocking waterbath.  The digest was diluted in 10mL 
MLEC media and passed through a 19.5G needle five times followed by a 
70µm cell-strainer (BD Falcon).  The cell suspension was centrifuged at 
3000 g for 5min and resuspended in 15mL MLEC media before transfer 
to pre-coated T75 flasks. 
 
Endothelial cells were first purified by removal of contaminating 
macrophages using magnetic Dynabeads (Dynal Biotech).  The flasks 
were removed from the incubator and the media replaced with fresh 
MLEC media before being stored at 4°C for 20min.  The MLEC media 
was replaced with primary antibody solution, purified rat anti-mouse 
CD16/32 (5µg/3mL; BD Biosciences) diluted in PBS and incubated at 4°C 
for 30min with occasional swirling to ensure even coating of the antibody.  
The antibody solution was removed and the cells washed gently with PBS 
before the secondary antibody-conjugated dynabeads were added.  
Flasks were incubated with PBS containing approximately 4x106 sheep 
anti-rat IgG magnetic dynabeads (10µL/3mL) for 30min at 4°C, with 
occasional swirling.  The solution was aspirated and the cells were 
washed three times with PBS before checking that the beads had 
attached to the macrophages.  Cells were trypsinised with 1x Trypsin 
(Sigma) and MLEC media was added to stop the reaction, the cell 
suspension was then transferred to a 15mL falcon and placed in a 
magnetic holder (Invitrogen).  The cells were allowed to attach to the side 
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of the falcon for 5min before the medium was carefully pipetted off and 
transferred to a new culture flask.  The cells were cultured until colonies 
of approximately 20 endothelial cells could be seen. 
 
The culture was then purified further by positive selection for the 
endothelial cells using ICAM-2/CD102 [Clone 3C4(mIC2/4); BD 
Pharmingen] as a cell marker.  The flasks were removed from the 
incubator and the media replaced with fresh MLEC media before being 
stored at 4°C for 20min.  The MLEC media was replaced with primary 
antibody solution, purified rat anti-mouse CD102 (10µg/3mL) diluted in 
PBS and incubated at 4°C for 30min with occasional swirling to ensure 
even coating of the antibody.  The antibody solution was removed and 
the cells washed gently with PBS before the secondary antibody-
conjugated dynabeads were added.  Flasks were incubated with PBS 
containing approximately 4x106 sheep anti-rat IgG magnetic dynabeads 
(10µL/3mL) for 30min at 4°C, with occasional swirling.  The cells were 
checked to ensure that the beads had attached to the endothelial cells 
before the bead solution was aspirated and the cells washed three times 
with PBS.  Cells were trypsinised with 1x Trypsin (Sigma) and MLEC 
media was added to stop the reaction: the cell suspension was then 
transferred to a 15mL falcon and placed in the magnetic holder.  The cells 
were allowed to attach to the side of the falcon for 5min before the 
medium was carefully pipetted off and discarded.  10mL MLEC media 
was used to resuspend the cells, which were then cultured until they 
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reached 50% confluence, at which point the positive sort was repeated to 
enhance the culture. 
 
2.5 Flow cytometric analysis of vascular endothelial cells 
Flow cytometry was used to analyse cellular expression of Gal-3 as well 
as various proteins of interest found intra- or extracellularly.  Flow 
cytometry is a valuable tool based on the principle that light will either be 
absorbed or scattered when it is directed at an object.  In this case, cell 
suspensions are aspirated through a narrow chamber, which allows for 
only one cell to pass through at any one time.  The cells are illuminated 
by lasers emitting light of varying wavelengths, which may excite 
fluorochromes present on the surface or within the cell.  These 
fluorochromes may be naturally occurring (autofluorescence) or attached 
to the cell by the addition of fluorochrome-labelled antibodies.  The 
subsequent light scatter is assessed from different angles of viewpoint; 
the forward scattered light (FSC) at small angles (0.5-5°) and the side 
scattered light (SSC) at larger angles (15-150°).  The FSC is a measure 
of the size of the cell or particle to pass through the light whilst the SSC is 
a measure of the internal granularity of the cell; in some cases these 
measurements alone are enough to distinguish between different cell 
types in the sample.  FSC and SSC can also be plotted against the 
amount of fluorescence emitted from the cells due to binding of one or 
more fluorochromes linked to cell surface or intracellular antigens, 
thousands of which are available today.  Antibodies conjugated to 
Phycoerythrin (PE) were analysed in the yellow FL2 channel, those 
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conjugated to fluorescein isothiocyanate (FITC) or Alexa Fluor® 488 were 
analysed in the green FL1 channel and those conjugated to 
Allophycocyanin (APC) were analysed in the red FL4 channel. 
 
2.5.1 Flow cytometry using HUVEC 
HUVEC were grown to confluence in gelatin-coated 6-well plates and 
were-treated with cytokines as described in section 2.1.2. Once ready for 
staining, the cells were detached using trypsin (Sigma) or Accutase 
solution (Millipore) and plated in a 96-well plate at a density of 
approximately 2x105 cells per well.  Cells were washed by centrifuging at 
350 g for 30sec followed by resuspension in PBS containing bovine 
serum albumin (0.02% PBS-BSA; Sigma).  Cells were then incubated 
with primary antibodies in the presence of human blocking IgG 
(16mg/mL) for 45min on ice in the dark.  Antibodies were used as follows:  
PE-conjugated rat anti-human Gal-3 (clone M3/83, 8µg/mL; 
eBiosciences), PE-conjugated rat anti-human IgG2a isotype control 
(clone eBR2a, 8µg/mL; eBiosciences), FITC-conjugated mouse anti-
human VCAM-1 (clone 1.G11B1, 2µg/mL; AbD Serotech), FITC-
conjugated mouse anti-human IgG1 (2µg/mL; AbD Serotech), PE-
conjugated rat anti-human ICAM-1 (clone HA58, 0.25µg/test; 
eBiosciences), PE-conjugated rat anti-human IgG1κ (0.25µg/test; 
eBiosciences). 
 
Cells were washed twice with PBS-BSA and those stained for cell surface 
antigens only were transferred to flow cytometry tubes.  Wells stained for 
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intracellular antigens were fixed using 1X fixation buffer (eBioscience) for 
20min in the dark at room temperature followed by addition of 1X 
permeabilisation buffer (eBioscience).  Cells were washed twice in 1X 
permeabilisation buffer before incubation with primary antibodies at the 
same concentration as for the cell surface stains.  The cells were washed 
twice more in permeabilisation buffer before a final wash in PBS-BSA and 
transfer to flow cytometry tubes.  The samples were fixed in 2% 
paraformaldehyde (w/v; Sigma) in PBS-BSA and stored until analysis 
using the FACSCalibur Flow Cytometer (BD Biosciences) and data 
acquisition using Cell Quest software (BD Biosciences).  Unstained and 
isotype control wells were used for calibration.  Fluorescence was 
expressed as median fluorescence intensity (MFI) units in the relevant 
fluorescence channel for each fluorochrome. 
 
2.5.2 Murine endothelial cell adhesion molecule expression  
WT and Gal-3-/- MLEC or MCEC cells were treated for 4 hours or 
overnight with PBS (sham), murine IL-1β (1-100ng/mL), murine TNF-α 
(10-200ng/mL; Gibco) or rGal-3 (200-1000ng/mL); supernatants were 
collected for analysis by ELISA and cells were detached using Accutase.  
Cells were plated into a 96-well plate at a density of approximately 2x105 
cells per well and were washed twice with PBS-BSA by centrifuging at 
350 g for 30sec before 10 min pre-incubation with murine Fc Block 
(0.5µg/mL; eBiosciences) on ice.  The following rat anti-mouse primary 
antibodies were added directly to the cells with Fc Block and incubated 
for 45min on ice in the dark: PE-conjugated Gal-3 (clone M3/83, 8µg/mL; 
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eBiosciences), PE-conjugated IgG2a isotype control (clone eBR2a, 
8µg/mL; eBiosciences), PE-conjugated PECAM-1 (CD31 clone MEC 
13.3, 4µg/mL; BD Pharmingen), PE-conjugated ICAM-1 (CD54 clone 
YN1/1.7.4, 2µg/mL; eBioscience), PE-conjugated IgG2bκ (2µg/mL; 
eBioscience), FITC-conjugated ICAM-2 (CD102 clone 3C4, 10µg/mL; BD 
Pharmingen), purified E-selectin (CD62E clone 10E9.6, 5µg/mL; BD 
Pharmingen).  Cells to be surface stained only were washed twice in 
PBS-BSA and either transferred to flow cytometry tubes in 2% PFA or 
incubated with secondary antibody FITC-conjugated F(ab’)2 rabbit anti-
rat IgG (1:200; AbD Serotech) for 30min on ice in the dark.  Those cells 
were washed twice more before transfer to flow cytometry tubes in 2% 
PFA.  Cells stained for intracellular antigens were fixed for 10 min at room 
temperature and permeabilised (eBioscience) before subsequent staining 
as for cell surface antigens, with the exception that antibodies and 
washes were carried out in 1x permeabilisation buffer.  Samples were 
analysed on the FACSCalibur using the FL1 and FL2 channels. 
 
2.5.3 Murine endothelial cell surface lectin binding assay 
A validated panel of lectins was chosen to assess cell surface 
glycosylation patterns on WT and Gal-3-/- MLEC, which were treated and 
then plated as in section 2.7.4.  The cells were incubated with the 
following biotinylated lectins in lectin buffer (dH2O containing 0.26% 
HEPES sodium salt and 0.88% NaCl) for 45 min at room temperature: 
Helix pomatia agglutinin (HPA; 20µg/mL; Sigma), Sambucus nigra lectin 
(SNA; 166ng/mL), Peanut agglutinin (PNA; 20µg/mL), Maackia 
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amurensis lectin II (MAL II; 3.3µg/mL) and Lycopersicon esculentum 
lectin (LEL; 400ng/mL) (all Vector Labs).  The cells were washed twice in 
lectin buffer followed by incubation for 30 min at room temperature with a 
streptavidin PE-conjugated secondary antibody (120ng/mL in PBS-BSA; 
Invitrogen) before a final two washes in PBS-BSA and transfer to flow 
cytometry tubes in 2% PFA for analysis on the FACSCalibur using the 
FL1 channel.   
 
2.6 Flow cytometry using murine whole blood 
2.6.1 Collection of murine blood by cardiac puncture 
Gal-3-/- or WT mice were deeply anaesthetised and up to 900µL of blood 
was collected by cardiac puncture into heparin-coated syringes (100µL of 
100U/mL).  Once complete, the blood was carefully expelled into a 
microcentrifuge tube and inverted twice to mix.  The mice were then 
euthanised by cervical dislocation.  Leukocytes were stained with Turk’s 
solution (0.01% crystal violet in 3% acetic acid) with a dilution factor of 20 
(25µL blood with 475µL Turk’s solution).  Differential counts were 
performed using a Neubauer haemocytometer viewed under a light 
microscope. 
 
2.6.2 Antibody staining of white blood cells 
Murine whole blood was treated for 15min at 37°C with PBS (Sham), 
murine IL-1β (1-100ng/mL) or murine TNF-α (10-200ng/mL; Gibco) 
before centrifuging at 300 g for 5 min and aspiration of the supernatant.  
Cells were resuspended in murine FC Block (0.5µg/mL; eBiosciences) 
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and incubated for 10min on ice.  The following rat anti-mouse primary 
antibodies were added directly to the wells and incubated for 45min on 
ice in the dark: PE-conjugated Gal-3 (clone M3/83, 8µg/mL; 
eBiosciences), PE-conjugated IgG2a isotype control (clone eBR2a, 
8µg/mL; eBiosciences), FITC-conjugated Ly-6G (clone 1A8, 5µg/mL; BD 
Pharmingen), PE-conjugated CD11b (clone M1/70, 2µg/mL; 
eBioscience), PE-conjugated IgG2b k (2µg/mL; eBioscience), APC-
conjugated L-selectin (CD62L) (clone MEL-14, 1µg/mL; eBioscience), 
APC-conjugated IgG2a κ (1µg/mL; eBioscience), Alexa Fluor® 488 Ly-6C 
(clone HK1.4, 2.5µg/mL; BioLegend).  The blood was washed twice in 
PBS-BSA before the addition of lysis buffer.  Multi species 10x red blood 
cell lysis buffer (eBioscience) was brought to room temperature before 
dilution in dH2O and addition of 250µL per well with gentle pipetting to 
mix, followed by incubation for 10 min until the suspension had lost 
turbidity.  The plate was washed twice in PBS-BSA before samples were 
transferred to flow cytometry tubes in 2% PFA and analysed on a 
FACSCalibur using the FL1, FL2 and FL4 channels. 
 
2.6.3 Lectin binding assay on murine leukocytes 
Approximately 1mL murine whole blood was collected as in section 2.8.1 
and immediately underwent red cell lysis in 10mL 1x multi species red 
cell lysis buffer for 10 min.  The cells were centrifuged at 300 g for 5mins 
then resuspended in 1mL lysis buffer for a further 5 min before two 
washes in PBS-BSA and transfer to 96-well plate for staining.  They were 
incubated with 25µL lectin buffer containing FC Block (0.5µg/mL) for 10 
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min before the addition of the following antibodies and biotinylated lectins 
in lectin buffer for 45 min at room temperature: FITC-conjugated Ly-6G 
(clone 1A8, 5µg/mL), Alexa Fluor® 488 Ly-6C (clone HK1.4, 2.5µg/mL), 
HPA (20µg/mL), SNA (166ng/mL), PNA (20µg/mL), MAL II (3.3µg/mL) 
and Phaseolus vulgaris leucoagglutinin (L-PHA; 4µg/mL; Vector 
Laboratories).  The cells were washed twice in lectin buffer followed by 
incubation for 30 min at room temperature with a streptavidin PE-
conjugated secondary antibody (120ng/mL in PBS-BSA; Invitrogen) 
before a final two washes in PBS-BSA.  Following transfer to flow 
cytometry tubes in 2% PFA, the cells were analysed on a FACSCalibur 
using the FL1 and FL2 channels.   
 
2.7  Ex vivo flow chamber assay 
This assay was used to assess leukocyte behaviour under conditions of 
flow, which were generated using an automated syringe pump (Harvard 
Apparatus) connected to small-diameter tubing and chamber slides 
allowing observation of the leukocytes over a monolayer of recombinant 
protein or live cells.  The flow chamber slides were viewed using a Nikon 
Eclipse TE3000 microscope fitted with x10 and x20 phase contrast 
objectives (Nikon).  Six 10s frames were collected for each well using a 
Q-Imaging Retiga EXi Digital Video Camera (Q-Imaging) and videos were 
analysed using Image Pro-Plus software (Media cybernetics).  
 
  
 89 
2.7.1 Murine whole blood flow over E-selectin 
Ibidi µ-Slide VI0.4 cell microscopy chambers were coated with 
recombinant mouse E-selectin Fc Chimera (2µg/mL: R&D Systems) in 
100µL PBS/well for 2h at room temperature.  The wells were blocked 
using 0.5% Tween-20 in PBS for 1h at room temperature.  Murine whole 
blood was collected by cardiac puncture, diluted 1:10 in Hank’s balanced 
salt solution (HBSS; Gibco) and flowed through the chamber at 
1.010mL/min for 3min.  This was followed by HBSS at the same rate for 
1min before image acquisition and subsequent offline analysis.  In some 
experiments the whole blood was pre-treated for 15min at 37°C with 
human recombinant Gal-3 (hrGal-3; 10ng/mL) prior to flow.  In other 
experiments WT and Gal-3-/- whole blood was collected, centrifuged for 8 
min at 200 g to collect the platelet-rich plasma, which was then spun 
again for 5 min at 1000 g.  The remaining platelet-poor plasma was then 
added back to the leukocytes from the opposite genotype donor, for 
example the WT leukocytes received the Gal-3-/- platelet-poor plasma 
and vice versa before they were flowed over E-selectin for 3 min at 
1.010mL/min and leukocyte capture was quantified. 
 
During analysis the number of firmly adherent leukocytes was assessed 
and these were further classified according to their appearance under the 
phase contrast objective.  Those that were phase dark were deemed to 
be leukocytes showing a more activated phenotype.  Experiments were 
repeated at least three times and statistical significance was assessed 
using one-way ANOVA with an appropriate post hoc test. 
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2.8  Enzyme-linked immunosorbent assays (ELISA) for 
Gal-3 
An enzyme-linked immunosorbent assay (ELISA) was used to determine 
the quantity of Gal-3 in murine platelet-poor plasma using the murine Gal-
3 DuoSet® ELISA development Kit (R&D Systems).  Whole blood was 
collected from the animals as described in section 2.6.1, the platelet-poor 
plasma was isolated as described in section 2.7.1  and used directly or 
stored at -80°C until analysis by ELISA assay. 
 
2.8.1 ELISA protocol 
Certified high binding, flat-bottomed clear 96-well plates (Costar) were 
coated overnight at room temperature with capture antibody (2.0µg/mL) 
diluted in PBS without carrier protein.  It was then washed three times by 
submersion in wash buffer (0.05% Tween-20 in PBS, pH7.4; Sigma) and 
then aspirating each well, after the final wash the plate was blotted on 
clean paper towels to ensure complete removal of wash buffer. Blocking 
was carried out for a minimum of 1h at room temperature using reagent 
diluent [1% low endotoxin bovine serum albumin (BSA; Sigma) in PBS, 
0.2µm sterile filtered].  The plate was washed once more before samples 
and standards were added in duplicate, a seven-point standard curve 
with 2-fold serial dilutions in reagent diluent and a high standard of 
1000pg/mL was used.  Samples were added neat or diluted in reagent 
diluent to an appropriate expected concentration range.  The samples 
and standards were incubated for 2h at room temperature before 
undergoing the washing procedure once more.  Detection antibody at a 
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final concentration of 200ng/mL in reagent diluent was added and the 
plate incubated for a further 2h at room temperature.  The wash step was 
once more carried out and the plate incubated for 20min at room 
temperature with streptavidin-horseradish peroxidase diluted 1:200 in 
reagent diluent, avoiding direct light.  The wash step was repeated for a 
final time before substrate solution was added; substrate solution A 
(stabilised H2O2; R&D Systems) was mixed with an equal volume of 
substrate solution B (stabilised tetramethylbenzidine; R&D Systems) and 
delivered to each well.  The plate was observed periodically and once the 
standard curve displayed an appropriate intensity range the reaction was 
stopped using sulphuric acid (2N; Sigma) and the plate gently tapped to 
mix the reagents, typically after 10min. The absorbance values were 
collected by scanning with a Multiskan plate reader (LabSystems) set to 
450nm with wavelength correction set to 540nm.   
 
2.8.2 Determination of unknown Gal-3 concentrations 
GraphPad Prism 4 (GraphPad) software was used.  Absorbance values 
for standards were averaged and plotted against the known logarithmic 
concentration of Gal-3 using a sigmoidal dose-response (variable slope) 
equation for best curve fit.  From this the unknown concentrations of Gal-
3 in each sample could be calculated using their averaged absorbance 
values.  Levels of Gal-3 were plotted and statistical significance was 
assessed using one-way analysis of variance (ANOVA) and an 
appropriate post hoc test. 
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2.9 Assessment of murine tissue mRNA  
2.9.1  Total RNA isolation from murine cremaster muscle samples 
Murine cremaster muscles were dissected and snap frozen in LN2 
following intrascrotal treatment for 4 hours with PBS (sham, 400µL), 
TNFα (300ng) or varying concentrations of rGal-3 (200-1000µg) as 
described in section 2.6.1.  Frozen cremasters were weighed and quickly 
transferred to soft tissue homogenising tubes containing 1.4mm ceramic 
beads (Bertin Technologies) before disruption in 600µL buffer RLT 
(Qiagen) using the Precellys 24 tissue homogeniser set to 5500 g for 20 
sec three times with 20 sec pauses. The tubes were centrifuged at 8000 
g and the supernatant further disrupted by passage through a 27G 
syringe at least ten times before RNA isolation with the RNeasy kit 
(Qiagen) and on-column DNase according to manufacturer guidelines.  
Briefly, 600µL 70% EtOH was added to the supernatants and mixed well 
by pipetting, the sample was transferred in 700µL volumes to a spin 
column and centrifuged at 8000 g for 15 sec to allow adsorption of RNA 
onto the spin column silica membrane.  Flow though was discarded, 
350µL of buffer RW1 was added and the column was centrifuged at 8000 
g for 15 sec before 80µL of DNase I incubation mix was added directly to 
the membrane, which was incubated at room temperature for 15 min.  
350µL buffer RW1 followed by 500µL buffer RPE was added before 
centrifugation at 8000 g for 15 sec after each addition.  An extended 2 
min centrifugation step at 8000 g was carried out after addition of 500µL 
buffer RPE to further dry the membrane.  The column was placed in a 
new collection tube and 40µL dH2O was added directly to the membrane, 
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the tubes were centrifuged for 1 min at 10000 g before the eluate was 
collected and added back to the membrane for a final repeat 
centrifugation followed by storage on ice.   
 
The quality and concentration of RNA was assessed using a Nanodrop 
ND-1000 Spectrophotometer (NanoDrop Technologies) following 
manufacturer guidelines.  The spectral measurement was made with 1µL 
sample, the concentration was measured in ng/µL from the absorbance 
at 260nm.  The ratio of absorbencies at 260/280nm and 230/260nm were 
used to assess protein and salt contamination, where pure samples have 
a ratio of approximately 2. 
 
2.9.2 cDNA synthesis 
RNA was reverse transcribed into cDNA using a thermal cycler (Abgene) 
and a mastermix composed as follows; 2µg RNA in 7µL dH20, 1µL 40mM 
dNTP mix (10mM of each component; dATP, dGTP, dCTP and dTTP; 
Promega), 1µL oligo (dT)15 and 4µL dH20.  The initial mastermix was 
incubated at 65°C for 5 min to denature RNA secondary structure then 
placed on ice for 2 min to allow the oligos to anneal.  A second mastermix 
was prepared; 4µL 5x first strand buffer, 1µL 0.1M dithioreitol (DTT), 1µL 
RNaseOUT and 1µL Superscript™ III reverse transcriptase (200U/µL, all 
Invitrogen) and added to each sample before brief mixing.  Samples were 
incubated at 55°C for 1 h for cDNA extension and then heated at 70°C for 
15 min to halt the reaction.   
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2.9.3  Real-time PCR 
Quantitative real time PCR was performed using a mastermix prepared 
as follows; 1µL gene-specific primer (Qiagen), 5.2µL 2x Power SYBR 
Green Mastermix (Applied Biosystems) and 1.8µL dH20 and dispensed 
into each well of a 384-well plate (Applied Biosystems).  Primers included 
those for Lgals3, Gapdh, Rpl32, Il-1b, tnf, Il-6, Ccl2, Cxcl1, Cxcl12, Ly-
6G, Csf1r, Pecam1, Icam1 and Sele.  Diluted cDNA was added to each 
well to the equivalent of approximately 50ng/2µL of the original RNA that 
was reverse transcribed, each sample was tested in duplicate.  Thermal 
cycling was carried out using the ABI Prism® 7900 Real Time PCR 
system according to manufacturer recommendations; 50°C for 2 min, 
95°C for 15 min, then 40 cycles of 94°C for 15 s, 55°C for 30 s and 72°C 
for 30 s.  SYBR green binds and emits fluorescence upon binding to 
newly synthesised double-stranded DNA thus reflecting the number of 
amplicons generated, the cycle threshold (Ct) value was defined as the 
cycle at which the sample reached a set threshold level of fluorescence.  
The comparative Ct method (Pfaffl, 2001) was used to measure gene 
transcription, where the Ct values were first normalised with an 
endogenous housekeeping gene and then to the control samples, which 
were used as a calibrator and given a value of 1 and the results were 
expressed as relative units based on 2-ΔΔCt. 
 
2.9.4 Genotyping of Gal-3-/- mouse colony 
Standard PCR was carried out to ensure the knockout mouse colony was 
intact using the REDExtract-N-amp™ Tissue PCR kit  (Sigma) which 
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enables genomic DNA extraction from murine tail clippings.  Briefly, tail 
clippings of approximately 0.5cm in length were incubated for 10 min at 
room temperature in 50µL extraction solution containing 12.5µL tissue 
preparation solution before a subsequent incubation at 95°C for 3 min.  
The reaction was halted by the addition of 50µL neutralisation solution 
and vortexing.  Wild type reverse, common and mutant primers for the 
detection of the Lgals3 gene (The Jackson Laboratory) were diluted to 
10µM with dH2O to make one primer mix; the reaction mix was prepared 
in a 384 well plate with 4µL sample, 10µL REDExtract-N-amp™ 2x 
reaction mix and 6µL primer mix to give a final concentration of 0.3µM per 
primer.  Thermal cycling (Abgene) was carried out according to 
manufacturer recommendations; 94°C for 3 min, then 35 cycles of 94°C 
for 30 s, 65°C for 30 s and 72°C for 30 s with a final incubation at 72°C 
for 2 min.  The amplified DNA (15µL) and low molecular weight marker 
(8µL; New England Biolabs) was directly loaded onto a 2% agarose gel 
for separation by electrophoresis, which was prepared using Tris-acetate-
EDTA (TAE) buffer and Gel Red nucleic acid stain (1:10000; Biotium) and 
run at 100V until the lanes approached the end of the gel before product 
size was examined using a UV light box.   
 
2.10  Assessment of murine cremaster protein content 
Murine cremaster muscles were dissected and snap frozen in LN2 
following intrascrotal treatment for 4 hours with PBS (sham, 400µL) or 
rGal-3 (1000µg) as described in section 2.6.1.  Frozen cremasters were 
weighed and quickly transferred to soft tissue homogenising tubes 
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containing 1.4mm ceramic beads (Bertin Technologies) before disruption 
in 600µL PBS containing protease inhibitors Aprotinin, Leupeptin and 
Pepstatin (all 10µg/mL; Sigma) at 600 g for 2 × 30 s cycles with one 30 s 
break.  The supernatant was collected and 1% Triton-X-100 was added 
before the samples were stored at -80°C overnight.  After thawing the 
samples were centrifuged at 10,000 g for 5 min and the protein content 
assed using the Pierce® BCA (Bicinchoninic Acid) assay following 
manufacturer guidelines.  Briefly, 25µL of prepared albumin standard (25-
2000µg/mL) or unknown sample was incubated at 37°C with 200µL 
working reagent and the absorbance at 562nm was measured on a 
Multiskan FC plate reader (Thermo Scientific).  A final protein quantity of 
200µg was then assessed using the mouse cytokine array panel A 
Proteome Profiler™ (R&D Systems) according to manufacturer 
instructions.  Briefly, the membranes were blocked for 1 hour at room 
temperature in a rocking platform while the samples were incubated with 
the biotinylated detection antibody cocktail also for 1 hour at room 
temperature.  The block buffer was aspirated from the well, the 
sample/antibody mix was added and the membranes incubated overnight 
at 4°C.  The membranes were washed thoroughly before addition of 
streptavidin-HRP conjugated secondary antibody for 30 min at room 
temperature and a final wash step was carried out.  The membranes 
were imaged using the supplied chemi-reagent mix and exposure to X-
ray film as well as using the FluorChem E (Protein Simple), which 
increases exposure until the desired intensity is reached, in this case 
approximately 10 min.  Pixel densitometry was carried out using Fiji 
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imaging software (ImageJ) and subtracting an averaged background 
reading from each duplicate antibody spot. 
 
2.11  Statistical analysis 
All data were analysed using GraphPad Prism 4 software.  Data are 
expressed as mean±standard error of the mean (SEM) of n experiments.  
All data were tested for normal distribution.  Statistical significance was 
assessed using unpaired students t-tests, one-way analysis of variance 
(ANOVA) or two-way ANOVA with the appropriate post hoc test, 
commonly Dunnett’s post-test or the Tukey range test.  In all cases a P 
value of ≤0.05 was considered significant. 
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Chapter 3: Examining the role of 
endogenous Gal-3 in leukocyte 
recruitment to the inflamed 
microvasculature 
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3.1 Maintenance of Gal-3-/- colony 
Heterozygote breeding pairs of Gal-3-/- founders and C57BL/6 wild type 
mice were set up and their pups genotyped using tail clippings and the 
primer sequences shown (Figure 3.1A).  Gal-3-/- pups of the F1 
generation, which display only one band at 150 base pairs (Figure 3.1B, 
arrows) were selected and homozygote Gal-3-/- breeding pairs set up.  
The F2 generation were therefore all homozygote Gal-3-/- and could be 
used in further studies.  
. 
 
Figure 3.1 Gal-3-/- breeding pairs were selected from heterozygote 
crosses 
Tail clippings from pups of Gal-3-/-/ C57BL/6 crosses were genotyped as 
described in methods and using the primer sequences shown (A).  
Homozygote Gal-3-/- mice (B, arrows) were then selected and Gal-3-/-/ 
Gal-3-/- breeding pairs set up for further experiments. 
 
 
 
220bp: Wild type 
150bp: Gal-3-/- 
Double band: 
Heterozygote 
B 
A Primer Type 5’!3’ Sequence 
Wild type reverse GAG GAG GGT CAA AGG GAA AG 
Common GAC TGG AAT TGC CCA TGA AC 
Mutant TCG CCT TCT TGA CGA GTT CT 
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3.2 Analysis of the inflamed cremasteric microcirculation 
in wild type mice by intravital microscopy 
The cremasteric microcirculation of C57BL/6 mice was visualised by 
intravital microscopy 2 or 4h after intrascrotal injection with PBS (400µL), 
IL-1β (30ng in 400µL PBS) or TNFα (300ng in 400µL PBS).  Leukocyte 
flux, rolling velocity, adhesion and emigration was investigated in 
segments of 100µm in 3-5 vessels per mouse and results are expressed 
as mean±SEM of 3-4 mice per group.  Statistical significance was 
assessed by one-way ANOVA and Tukey’s multiple comparison post-test.   
 
3.2.1 Response to TNFα treatment 
The microcirculation was found to be strongly inflamed after 4h but not 2h 
treatment with TNFα. The average leukocyte rolling velocity (µm/s) was 
significantly reduced in TNFα-treated animals at 4h when compared to 
sham-treated animals (Figure 3.2B; 4h TNFα 4.8±1.1 vs. sham 31.8±6.3, 
P<0.01, n=4).  The number of rolling leukocytes in 2h or 4h-treated 
animals was not significantly different from sham animals, however there 
was a significant decrease at 4h when compared to the 2h-treated mice 
(Figure 3.2A; 2h TNFα 62.0±18.6 vs. 4h TNFα 11.1±2.7, P<0.05, n=3-4).  
Both the number of adherent cells (per 100µm segment) and those found 
to have emigrated (per 100µm2) either side of the vessel was significantly 
increased in TNFα-treated animals at 4h (Figure 3.2C, D; Adherent 4h 
TNFα 8.4±0.9 vs. sham 3.4±0.5, P<0.01, n=4; Emigration 4h TNFα 
10.4±2.0 vs. sham 3.1±1.0, P<0.05, n=4).   
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Figure 3.2 Fixed-time profile of TNF-α-induced leukocyte 
recruitment in the mouse cremasteric microcirculation 
IVM was performed as detailed in Methods.  Briefly, the cremasteric 
microcirculation in C57BL/6 mice was assessed 2 or 4h after intrascrotal 
injection of PBS (400µL) or murine recombinant TNF-α (300ng in 400µL 
PBS). Leukocyte flux (A), rolling velocity (B), adhesion (C) and emigration 
(D) was investigated in segments of 100µm in 3-5 vessels per mouse and 
results are expressed as mean±SEM of 3-4 mice per group.  Statistical 
significance was assessed by one-way ANOVA and Tukey’s multiple 
comparison post-test; denoted by asterisks *P<0.05 and **P<0.01 
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3.2.2 Response to IL-1β treatment 
The leukocyte recruitment seen after treatment with IL-1β was similar to 
that seen with TNFα, whereby the vessels were strongly inflamed after 4h 
treatment but not after a shorter time of 2h.  Again rolling velocities were 
significantly reduced from those seen in sham-treated animals, though at 
4h they were not reduced to the same extent as seen in TNFα-treated 
animals (Figure 3.3B; 4h IL-1β 12.7±3.8 vs. sham 31.8±6.3, P<0.05, 
n=4).  A significant increase in the number of adherent and emigrated 
cells was observed at 4h (Figure 3.3C, D; Adherent 4h IL-1β 6.6±1.2 vs. 
sham 3.4±0.5, P<0.05, n=4; emigration 4h IL-1β 10.3±2.5 vs. sham 
3.1±1.0, P<0.05, n=4).  The leukocyte rolling flux was unchanged by IL-
1β treatment (Figure 3.3A; sham 34.5±5.7 vs. 4h IL-1β 47.6±5.7, ns, 
n=4).  It was important to characterise these responses to IL-1β and 
TNFα to establish that after 4h treatment the vessels would be 
adequately inflamed in order that we could compare responses in the 
Gal-3-/- mice. 
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Figure 3.3 FIxed-time profile of IL-1β-induced leukocyte recruitment 
in the mouse cremasteric microcirculation 
IVM was performed as detailed in Methods.  Briefly, the cremasteric 
microcirculation in C57BL/6 mice was assessed 2 or 4h after intrascrotal 
injection of PBS (400µL) or murine recombinant IL-1β (30ng in 400µL 
PBS). Leukocyte flux (A), rolling velocity (B), adhesion (C) and emigration 
(D) was investigated in segments of 100µm in 3-5 vessels per mouse and 
results are expressed as mean±SEM of 3-4 mice per group.  Statistical 
significance was assessed by one-way ANOVA and Tukey’s multiple 
comparison post-test; denoted by asterisks *P<0.05. 
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3.3 Analysis of the inflamed cremasteric microcirculation 
in Gal-3-/- mice by intravital microscopy 
The cremasteric microcirculation of Gal-3-/- mice was then assessed after 
4h treatment with inflammogen, reflecting the time taken to see changes 
in leukocyte recruitment in wild type mice. Leukocyte flux, rolling velocity, 
adhesion and emigration was investigated in segments of 100µm in 3-5 
vessels per mouse and results are expressed as mean±SEM of 3-5 mice 
per group.  Statistical significance was assessed by two-way ANOVA and 
with Bonferroni’s multiple comparison post-test. 
 
3.3.1 Response to TNFα treatment 
Leukocyte recruitment was first analysed after treatment with TNFα 
(300ng in 400µL PBS) for 4h.  There were no differences in leukocyte 
flux, rolling velocity, adhesion and emigration in sham-treated Gal-3-/- 
animals compared to their wild type counterparts.  The mice were found 
to display similar levels of leukocyte adhesion after TNFα treatment 
(Figure 3.4C; WT 8.4±0.9 vs. KO 7.8±1.3, not significant) as well as 
leukocyte emigration (Figure 3.4D; WT 10.4±2.0 vs. KO 13.25±4.4, not 
significant).  However, the Gal-3-/- mice lacked the reduction in rolling 
velocity observed in wild type animals in response to TNFα treatment 
(Figure 3.4B; WT 4.8±1.1 vs. KO 34.8±11.1, P<0.05, n=4).  In addition to 
this, Gal-3-/- mice displayed increased leukocyte flux in response to TNFα 
treatment when compared to wild type animals (Figure 3.4A; WT 
11.1±2.7 vs. KO 30.8±7.1, P<0.05, n=4). 
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Figure 3.4 Rolling velocities are not reduced in inflamed post-
capillary venules of Gal-3-/- mice treated with TNFα 
IVM was performed as detailed in Methods.  Briefly, the cremasteric 
microcirculation in C57BL/6 or Gal-3-/- mice was assessed 4h after 
intrascrotal injection of PBS (400µL) or murine recombinant TNFα (300ng 
in 400µL PBS). Leukocyte flux (A), rolling velocity (B), adhesion (C) and 
emigration (D) was investigated in segments of 100µm in 3-5 vessels per 
mouse and results are expressed as mean±SEM of 3-5 mice per group.  
Statistical significance was assessed by two-way ANOVA and with 
Bonferroni’s multiple comparison post-test; denoted by asterisks * 
P<0.05. 
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3.3.2 Response to IL-1β treatment 
Treatment with IL-1β (30ng in 400µL PBS) also induced differing 
responses between wild type and Gal-3-/- mice, which again exhibited a 
lack in reduction of rolling velocities as well as reduced leukocyte 
emigration to the tissue.  Average rolling velocity was reduced after IL-1β 
treatment in wild type mice, though this was not the case in the Gal-3-/- 
mice (Figure 3.5B; WT 12.1±3.0 vs. KO 35.3±10.5, P<0.05, n=4-5).  In 
contrast to the increased emigration recorded after treatment with TNFα 
compared to sham-treated animals, there were significantly fewer 
leukocytes that emigrated in the Gal-3-/- mice after IL-1β treatment (Figure 
3.5D; WT 10.0±1.9 vs. KO 4.5±0.5, P<0.05, n=4-5).  In contrast, the 
number of adherent leukocytes in response to IL-1β treatment was 
comparable in wild type and Gal-3-/- animals (Figure 3.5C; WT 6.7±0.9 vs. 
KO 5.7±1.2, not significant) as were levels of leukocyte flux (Figure 3.5A; 
WT 38.6±8.8 vs. 46.0±16.8, not significant).   
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Figure 3.5 Rolling velocities are not reduced in inflamed post-
capillary venules of Gal-3-/- mice treated with IL-1β in addition to 
reduced leukocyte emigration in these animals 
IVM was performed as detailed in Methods.  Briefly, the cremasteric 
microcirculation in C57BL/6 or Gal-3-/- mice was assessed 4h after 
intrascrotal injection of PBS (400µL) or murine recombinant IL-1β (30ng 
in 400µL PBS). Leukocyte flux (A), rolling velocity (B), adhesion (C) and 
emigration (D) was investigated in segments of 100µm in 3-5 vessels per 
mouse and results are expressed as mean±SEM of 3-5 mice per group.  
Statistical significance was assessed by one-way ANOVA and with 
Bonferroni’s multiple comparison post-test; denoted by asterisks * 
P<0.05. 
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3.4 Analysis of murine Gal-3-/- whole blood under 
conditions of flow 
The parallel plate flow chamber enables the investigation of cells ex vivo 
under conditions that - as closely as possible - mimic those found in 
mammalian blood vessels.  In this case flow chamber slides were coated 
with E-selectin (2µg/mL) and murine whole blood from C57BL/6 or Gal-3-/- 
mice was collected by cardiac puncture using heparin (10U/mL) as an 
anti-coagulant.  The blood was diluted and flown through the E-selectin 
coated chambers at a rate of 1.010mL/min for 3min; this was followed by 
1min of HBSS alone at the same rate before image acquisition.  Results 
are expressed as mean±SEM and significance was assessed using 
unpaired student’s t-tests. 
 
3.4.1 Wild type and Gal-3-/- leukocyte capture to E-selectin in 
parallel flow chambers 
Under conditions of flow, Gal-3-/- leukocytes exhibit a reduced capacity to 
adhere to E-selectin when compared to wild type cells (Figure 3.6A, C; 
total cell count WT 25.7±3.3 vs. KO 12.3±1.1, P=0.0183, n=3).  In 
addition to this the leukocytes that adhere can be classified as phase light 
or phase dark, where phase dark cells are those displaying a more active 
phenotype, which in the presence of a cell monolayer would attempt to 
transmigrate through it.  A much smaller proportion (percentage of total 
cells) of Gal-3-/- cells displayed phase dark morphology when compared 
to wild type cells (Figure 3.6B, C; WT 33.3±6.3 vs. KO 11.7±3.0, 
P=0.0371, n=3).   
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Figure 3.6 Gal-3-/- whole blood displays reduced leukocyte capture 
to E-selectin under conditions of flow 
Ibidi flow chamber µ-slides were coated with recombinant E-selectin 
(2µg/ml) and blocked using 0.5% Tween-20.  C57BL/6 or Gal-3-/- whole 
blood was collected by cardiac puncture using heparin (10U/mL) and 
subsequently diluted 1:10 in HBSS.  Blood was flown for 3mins at 
1.010mL/min, followed by 1min HBSS. Videos of 10s were captured for a 
total of 4-6 frames per mouse and 3 mice per group. A) Captured 
leukocytes in each frame were quantified and classified as phase dark or 
phase light; results are expressed as mean±SEM.  Total cells captured 
for the two genotypes were compared and significance was assessed 
using an unpaired t-test, denoted by asterisk * P<0.05. B) Percentage 
phase dark cells of total leukocytes captured were calculated and results 
are expressed as mean±SEM.  Significance was assessed using an 
unpaired student’s t-test, denoted by asterisks * P<0.05.  C) 
Representative images are stills taken from C57BL/6 (left panel) or Gal-3-
/- (right panel) experiments with higher magnification shown in the insets.  
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3.4.2 Wild type and Gal-3-/- leukocyte capture to E-selectin after 
fluorescent labelling in the same volume 
In addition to investigating the number of adherent leukocytes in separate 
chambers, the whole blood was collected and fluorescently labelled 
before flow over E-selectin in the same chamber.  The wild type blood 
was labelled with carboxyfluorescein succinimidyl ester (CFSE; 20µg/mL) 
and the Gal-3-/- whole blood was labelled with Rhodamine-6G (20µg/mL) 
for 15 minutes at 37°C before mixing the two genotypes and dilution 1:10 
in HBSS directly before flow and image capture.  Results are expressed 
as mean±SEM and significance was assessed using an unpaired 
student’s t-test.  As seen in separate chambers, the Gal-3-/- whole blood 
exhibited significantly fewer adherent cells in comparison to wild type 
whole blood (Figure 3.7A; WT 4.0±0.7 vs. KO 2.1±0.3, P=0.0327, n=7 
frames).  
 
3.4.3 White blood cell counts of wild type and Gal-3-/- mice 
When carrying out these experiments, a small volume of whole blood was 
collected and a white blood cell count carried out using a 
haemocytometer.  There was found to be no significant difference in 
white blood cell count (cells/µL) between wild type and Gal-3-/- mice (WT 
29.92±0.17 vs. KO 28.00±3.41, n.s).   
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Figure 3.7 Fluorescently labelled Gal-3-/- whole blood displays 
reduced leukocyte capture to E-selectin under conditions of flow 
Ibidi flow chamber µ-slides were coated with recombinant E-selectin 
(2µg/ml) and blocked using 0.5% Tween-20.  C57BL/6 or Gal-3-/- whole 
blood was collected by cardiac puncture using heparin (10U/mL) and 
labeled separately with CFSE (20µg/ml, Gal-3-/-) or R-6G (2µg/ml, 
C57BL/6) for 15min at 37°C before mixing and diluting 1:10 in HBSS.  The 
blood was flown through one chamber for 3mins at 1.010mL/min, followed 
by 1min HBSS. Videos of 10s were captured for a total of 7 frames per 
experiment and N=1. A) Captured leukocytes in each frame were 
quantified and classified as CFSE or R-6G positive.  Results are 
expressed as mean±SEM and significance was assessed using an 
unpaired student’s t-test, denoted by asterisks * P<0.05.  B) 
Representative still taken from recordings, red R-6G positive cells are from 
C57BL/6 and green CFSE positive cells are from Gal-3-/- mice.  
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3.5 Analysis of murine Gal-3-/- whole blood by flow 
cytometry 
3.5.1 E-selectin ligand expression on Gal-3-/- neutrophils 
Wild type or Gal-3-/- whole blood was collected by cardiac puncture using 
heparin (10U/mL) and treated for 10min at 37°C with vehicle (PBS), 
TNFα (50ng/mL) or IL-1β (50ng/mL) before cell staining with antibodies 
against CD44 and PSGL-1 (CD162) as well as the neutrophil marker Ly-
6G (Clone 1A8).  Data are shown as mean±SEM and significance was 
assessed by two-way ANOVA and Bonferroni’s multiple comparison post-
test.  Gal-3-/- neutrophils displayed comparative basal expression of both 
CD44 (Figure 3.8A; WT 2137.2±149.6 vs. KO 2394.4±88.1, ns, n=3) and 
PSGL-1 (Figure 3.8A; WT 378.1±36.2 vs. KO 431.2±69.8, ns, n=3).  
Expression after treatment with IL-1β or TNFα was calculated as fold 
change from vehicle.  There were no differences from wild type cells in 
CD44 expression on Gal-3-/- neutrophils after IL-1β (Figure 3.8C; WT 
104.2±14.2 vs. KO 93.6±6.7, not significant) or TNFα (Figure 3.8C; WT 
111.8±10.2 vs. KO 100.4±9.6, not significant) treatment.  In contrast, 
when compared to wild type cells Gal-3-/- neutrophils displayed reduced 
PSGL-1 expression after treatment with TNFα (Figure 3.8C; WT 
115.7±2.2 vs. KO 98.9±2.5, P<0.01, n=3) but not IL-1β (Figure 3.8C; WT 
99.9±3.6 vs. KO 109.7±3.8, not significant). 
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Figure 3.8 Gal-3-/- neutrophils display reduced PSGL-1 after 
treatment with TNFα 
Wild type or Gal-3-/- whole blood was collected by cardiac puncture using 
heparin (10U/mL) and treated for 10min at 37°C with vehicle (PBS), 
TNFα (50ng/mL) or IL-1β (50ng/mL).  Murine Fc Receptors were blocked 
before cell staining with antibodies against CD44 and PSGL-1 (CD162) 
as well as the neutrophil marker Ly-6G (Clone 1A8); analysis was carried 
out with the FACSCalibur Flow cytometer and FlowJo software, as 
detailed in Methods. A) Basal expression of CD44 and PSGL-1 on wild 
type and Gal-3-/- neutrophils.  B) Representative histogram plots showing 
basal CD44 (top) and PSGL-1 (bottom) expression on wild type (filled 
blue) and Gal-3-/- (dark blue line) monocytes, with isotype control (grey). 
C) Ligand expression after IL-1β and TNFα treatment.  MFI values were 
plotted as fold change from vehicle treated; the data are shown as 
mean±SEM of 3-4 mice per group, significance was assessed by two-way 
ANOVA and Bonferroni’s multiple comparison post-test. 
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3.5.2 E-selectin ligand expression on Gal-3-/- monocytes 
Wild type or Gal-3-/- whole blood was collected by cardiac puncture using 
heparin (10U/mL) and treated for 10min at 37°C with vehicle (PBS), 
TNFα (50ng/mL) or IL-1β (50ng/mL) before cell staining with antibodies 
against CD11b and L-selectin as well as the monocyte marker Ly-6C.  
Data are shown as mean±SEM and significance was assessed by two-
way ANOVA and Bonferroni’s multiple comparison post-test.  Gal-3-/- 
monocytes displayed comparative basal expression of both CD44 (Figure 
3.9A; WT 117.9±21.8 vs. KO 111.0±18.3, ns, n=3) and PSGL-1 (Figure 
3.9A; WT 347.3±39.0 vs. KO 310.1±61.4, ns, n=3).  Expression after 
treatment with IL-1β or TNFα was calculated as fold change from vehicle.  
In contrast to those seen on neutrophils, there were no differences from 
wild type cells in PSGL-1 expression on Gal-3-/- monocytes after IL-1β (C; 
WT 85.0±9.0 vs. KO 111.3±11.0, not significant) or TNFα (C; WT 
78.7±8.3 vs. KO 106.3±12.5, not significant) treatment.  However, the 
expression of CD44 on Gal-3-/- monocytes was increased from that seen 
on wild type cells in response to IL-1β (C; WT 84.0±10.6 vs. KO 
126.5±7.7, P<0.01, n=3) but not TNFα (C; WT 95.5±10.7 vs. KO 
95.4±8.4, not significant) treatment.    
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Figure 3.9 Gal-3-/- monocytes display increased CD44 after treatment 
with IL-1β 
Wild type or Gal-3-/- whole blood was collected by cardiac puncture using 
heparin (10U/mL) and treated for 10min at 37°C with vehicle (PBS), 
TNFα (50ng/mL) or IL-1β (50ng/mL).  Murine Fc Receptors were blocked 
before cell staining with antibodies against CD44 and PSGL-1 (CD162) 
as well as the monocyte marker Ly-6C; analysis was carried out with the 
FACSCalibur Flow cytometer and FlowJo software, as detailed in 
Methods. A) Basal expression of CD44 and PSGL-1 on wild type and 
Gal-3-/- monocytes.  B) Representative histogram plots showing basal 
CD44 (top) and PSGL-1 (bottom) expression on wild type (filled blue) and 
Gal-3-/- (dark blue line) monocytes, with isotype control (grey). C) Ligand 
expression after IL-1β and TNFα treatment.  MFI values were plotted as 
fold change from vehicle treated; the data are shown as mean±SEM of 3-
4 mice per group, significance was assessed by two-way ANOVA and 
Bonferroni’s multiple comparison post-test. 
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3.5.3 Lectin binding on Gal-3-/- neutrophils 
Wild type or Gal-3-/- whole blood was collected by cardiac puncture using 
heparin (10U/mL); the cells were stained with antibodies against the 
neutrophil marker Ly-6G (Clone 1A8) as well as a validated panel of 
lectins before analysis by flow cytometry.  Data are shown as mean±SEM 
of MFI and significance was assessed using an unpaired student’s t-test.  
When compared to their wild type counterparts, Gal-3-/- neutrophils were 
found to display comparable binding of the lectins SNA (Figure 3.10C; 
WT 4.4±0.7 vs. KO 4.4±1.0, not significant), L-PHA (Figure 3.10C; WT 
249.3±66.0 vs. KO 248.1±81.7, not significant) and MAL II (Figure 3.10C; 
WT 19.5±3.3 vs. KO 29.9±2.7, not significant).  In contrast, Gal-3-/- 
neutrophils displayed reduced capability to bind the lectins PNA (Figure 
3.10A,C; WT 17.6±2.2 vs. KO 7.0±1.0, P<0.05, n=3) and HPA (Figure 
3.10B,C; WT 32.6±4.5 vs. KO 18.9±3.2, P<0.05, n=6) when compared to 
wild type cells.   
 
3.5.4 Lectin binding on Gal-3-/- monocytes 
Wild type or Gal-3-/- whole blood was collected by cardiac puncture using 
heparin (10U/mL); the cells were stained with antibodies against the 
monocyte marker Ly-6C as well as a validated panel of lectins before 
analysis by flow cytometry.  Data are shown as mean±SEM of MFI and 
significance was assessed using an unpaired student’s t-test.  When 
compared to their wild type counterparts, Gal-3-/- monocytes were found 
to display similar binding of the lectins SNA (Figure 3.11C; WT 12.9±1.5 
vs. KO 11.5±1.4, not significant), L-PHA (Figure 3.11C; WT 64.5±11.8 vs. 
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KO 59.5±16.1, not significant) and MAL II (Figure 3.11C; WT 27.1±3.3 vs. 
KO 33.4±5.4, not significant).  Though not significant, it is possible that 
Gal-3-/- monocytes display reduced binding of the lectins HPA (Figure 
3.11B,C; WT 2.5±0.3 vs. KO 1.7±0.3, P=0.1304, n=5-6) and PNA (Figure 
3.11A,C; WT 15.0±1.6 vs. KO 8.6±0.7, P=0.0606, n=2-3) when compared 
to wild type cells.    
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Figure 3.10 Murine neutrophils display reduced PNA and HPA lectin 
binding sites on their cell surface 
Wild type or Gal-3-/- whole blood was collected by cardiac puncture using 
heparin (10U/mL).  Murine Fc Receptors were blocked before cell 
staining with antibodies against the neutrophil marker Ly-6G (Clone 1A8) 
as well as a validated panel of lectins; analysis was carried out with the 
FACSCalibur Flow cytometer and FlowJo software, as detailed in 
Methods. A) Representative histogram plots showing PNA lectin binding 
on wild type (blue) and Gal-3-/- (green) neutrophils, with isotype control 
(grey). B) Representative histogram plots showing HPA lectin binding on 
wild type (blue) and Gal-3-/- (green) neutrophils, with isotype control 
(grey). C) MFI values were plotted for all the lectins tested and the data 
are shown as mean±SEM of 3-6 mice per group, significance was 
assessed using an unpaired student’s t-test. 
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Figure 3.11 Murine monocytes display a trend for reduced PNA and 
HPA lectin binding sites on their cell surface 
Wild type or Gal-3-/- whole blood was collected by cardiac puncture using 
heparin (10U/mL).  Murine Fc Receptors were blocked before cell 
staining with antibodies against the monocyte marker Ly-6C as well as a 
validated panel of lectins; analysis was carried out with the FACSCalibur 
Flow cytometer and FlowJo software, as detailed in Methods. A) 
Representative histogram plots showing PNA lectin binding on wild type 
(blue) and Gal-3-/- (green) monocytes, with isotype control (grey). B) 
Representative histogram plots showing HPA lectin binding on wild type 
(blue) and Gal-3-/- (green) monocytes, with isotype control (grey). C) MFI 
values were plotted for all the lectins tested and the data are shown as 
mean±SEM of 3-6 mice per group, significance was assessed using an 
unpaired student’s t-test. 
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3.5.6 CD11b and L-selectin expression on Gal-3-/- neutrophils 
Wild type or Gal-3-/- whole blood was collected by cardiac puncture using 
heparin (10U/mL) and treated for 10min at 37°C with vehicle (PBS), 
TNFα (50ng/mL) or IL-1β (50ng/mL) before cell staining with antibodies 
against CD11b and L-selectin as well as the neutrophil marker Ly-6G 
(Clone 1A8).  Data are shown as mean±SEM and significance was 
assessed by two-way ANOVA and Bonferroni’s multiple comparison post-
test.  In contrast to treatment with IL-1β, which did not alter expression 
from vehicle treated cell levels; treatment with TNFα increased neutrophil 
expression of CD11b in wild type cells (Figure 3.12C; vehicle 
828.4±226.6, IL-1β 982.8±218.6 vs. TNFα 1616.2±84.4).  Furthermore, 
when compared to their wild type counterparts, Gal-3-/- neutrophils 
exhibited significantly reduced levels of CD11b basally (Figure 3.12C; WT 
828.4±226.6 vs. KO 191.0±28.3, P<0.05, n=3-5) and after treatment with 
IL-1β and TNFα (Figure 3.12C; WT 1616.2±84.4 vs. KO 918.0±34.0, 
P<0.01, n=3-5).   
 
In a similar fashion to CD11b expression patterns in wild type neutrophils, 
treatment with TNFα induced L-selectin shedding though IL-1β did not 
(Figure 3.13C; vehicle 187.6±66.0, IL-1β 198.58±58.2 vs. TNFα 
44.1±7.9).  However, L-selectin shedding was unaltered in the Gal-3-/- 
neutrophils basally (Figure 3.13C; WT 187.6±66.0 vs. KO 137.1±63.3, ns, 
n=5) and after TNFα treatment (Figure 3.13C; WT 44.1±7.9 vs. KO 
43.2±18.3, ns, n=5). 
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Figure 3.12 Gal-3-/- neutrophils display reduced levels of CD11b 
basally and after treatment with TNFα and IL-1β 
Wild type or Gal-3-/- whole blood was collected by cardiac puncture using 
heparin (10U/mL) and treated for 10min at 37°C with vehicle (PBS), 
TNFα (50ng/mL) or IL-1β (50ng/mL).  Murine Fc Receptors were blocked 
before cell staining with antibodies against CD11b as well as the 
neutrophil marker Ly-6G (Clone 1A8); analysis was carried out with the 
FACSCalibur Flow cytometer and FlowJo software, as detailed in 
Methods. A) Representative histogram plots of wild type and Gal-3-/- 
neutrophils stained for isotype control (grey) or CD11b after treatment 
with vehicle (blue), IL-1β (red line) or TNFα (dark red).  B) Tables show 
matching MFI values for the representative histogram plots, wild type on 
the left and Gal-3-/- cells on the right.  C) MFI values were plotted and the 
data are shown as mean±SEM of 3-4 mice per group, significance was 
assessed by two-way ANOVA and Bonferroni’s multiple comparison post-
test, denoted by asterisks * P<0.05 and ** P<0.01.  
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Figure 3.13 Gal-3-/- neutrophils display normal levels of L-selectin 
basally and after treatment with TNFα and IL-1β 
Wild type or Gal-3-/- whole blood was collected by cardiac puncture using 
heparin (10U/mL) and treated for 10min at 37°C with vehicle (PBS), 
TNFα (50ng/mL) or IL-1β (50ng/mL).  Murine Fc Receptors were blocked 
before cell staining with antibodies against L-selectin as well as the 
neutrophil marker Ly-6G (Clone 1A8); analysis was carried out with the 
FACSCalibur Flow cytometer and FlowJo software, as detailed in 
Methods. A) Representative histogram plots of wild type and Gal-3-/- 
neutrophils stained for isotype control (grey) or L-selectin after treatment 
with vehicle (blue), IL-1β (red line) or TNFα (dark red).  B) Tables show 
matching MFI values for the representative histogram plots, wild type on 
the left and Gal-3-/- cells on the right.  C) MFI values were plotted and the 
data are shown as mean±SEM of 3-4 mice per group, significance was 
assessed by two-way ANOVA and Bonferroni’s multiple comparison post-
test.  
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3.5.7 CD11b and L-selectin expression on Gal-3-/- monocytes 
Wild type or Gal-3-/- whole blood was collected by cardiac puncture using 
heparin (10U/mL) and treated for 10min at 37°C with vehicle (PBS), 
TNFα (50ng/mL) or IL-1β (50ng/mL) before cell staining with antibodies 
against CD11b and L-selectin as well as the monocyte marker Ly-6C.  
Data are shown as mean±SEM and significance was assessed by two-
way ANOVA and Bonferroni’s multiple comparison post-test.  The 
variation in the monocyte populations was much greater than in the 
neutrophil population.  In a similar fashion to the neutrophil expression 
pattern, treatment with TNFα but not IL-1β increased monocyte 
expression of CD11b (Figure 3.14C; vehicle 310.4±107.8, IL-1β 
418.2±149.5 vs. TNFα 562.8±144.8) and induced L-selectin shedding 
(Figure 3.15C; vehicle 195.5±42.6, IL-1β 193.4±48.2 vs. TNFα 
92.0±28.3).   
 
In contrast to expression on neutrophils, CD11b expression on Gal-3-/- 
monocytes was comparable to wild type cells, both in vehicle (Figure 
3.14C; WT 310.4±107.8 vs. KO 325.2±153.8) and TNFα treated cells 
(Figure 3.14C; WT 562.8±144.8 vs. KO 523.4±159.6).  L-selectin 
shedding was also unchanged in the Gal-3-/- monocytes after TNFα 
treatment (Figure 3.15C; WT 92.0±28.3 vs. KO 62.7±23.7), though its 
possible that their basal expression of the selectin showed a trend to be 
reduced when compared to their wild type counterparts (Figure 3.15C; 
WT 197.5±42.6 vs. KO 116.6±50.3). 
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Figure 3.14 Gal-3-/- monocytes display normal levels of CD11b 
basally and after treatment with TNFα and IL-1β 
Wild type or Gal-3-/- whole blood was collected by cardiac puncture using 
heparin (10U/mL) and treated for 10min at 37°C with vehicle (PBS), 
TNFα (50ng/mL) or IL-1β (50ng/mL).  Murine Fc Receptors were blocked 
before cell staining with antibodies against CD11b as well as the 
monocyte marker Ly-6C; analysis was carried out with the FACSCalibur 
Flow cytometer and FlowJo software, as detailed in Methods. A) 
Representative histogram plots of wild type and Gal-3-/- neutrophils 
stained for isotype control (grey) or L-selectin after treatment with vehicle 
(blue), IL-1β (red line) or TNFα (dark red).  B) Tables show matching MFI 
values for the representative histogram plots, wild type on the left and 
Gal-3-/- cells on the right.  C) MFI values were plotted and the data are 
shown as mean±SEM of 3-4 mice per group, significance was assessed 
by two-way ANOVA and Bonferroni’s multiple comparison post-test.  
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Figure 3.15 Gal-3-/- monocytes display normal levels of L-selectin 
basally and after treatment with TNFα and IL-1β 
Wild type or Gal-3-/- whole blood was collected by cardiac puncture using 
heparin (10U/mL) and treated for 10min at 37°C with vehicle (PBS), 
TNFα (50ng/mL) or IL-1β (50ng/mL).  Murine Fc Receptors were blocked 
before cell staining with antibodies against L-selectin as well as the 
monocyte marker Ly-6C; analysis was carried out with the FACSCalibur 
Flow cytometer and FlowJo software, as detailed in Methods. A) 
Representative histogram plots of wild type and Gal-3-/- neutrophils 
stained for isotype control (grey) or L-selectin after treatment with vehicle 
(blue), IL-1β (red line) or TNFα (dark red).  B) Tables show matching MFI 
values for the representative histogram plots, wild type on the left and 
Gal-3-/- cells on the right.  C) MFI values were plotted and the data are 
shown as mean±SEM of 3-4 mice per group, significance was assessed 
by two-way ANOVA and Bonferroni’s multiple comparison post-test.  
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3.6 Characterisation of isolated murine lung endothelial 
cells from Gal-3-/- mice 
Murine lung endothelial cells were isolated from C57BL/6 or Gal-3-/- mice 
and first characterised by flow cytometric analysis of cell surface 
expression of Gal-3 and the endothelial cell marker, ICAM-2.  There were 
no morphological differences between the wild type and Gal-3-/- MLEC 
(Figure 3.16B,C) when viewing by bright field microscopy in addition to by 
forward-side scatter flow cytometry plots (Figure 3.16A).  The gated 
cellular events were plotted on a histogram for MFI of Gal-3 (blue) or its 
isotype control IgG2a (grey), the wild type cells were found to moderately 
express Gal-3 on their surface under basal conditions and the Gal-3-/- cell 
were found to have no Gal-3 expression (Figure 3.16A, middle panel).  
Over 90% of the total events in both C57BL/6 and Gal-3-/- mice 
expressed cell surface ICAM-2 (green), confirming that the isolated cell 
populations were of high purity for endothelial cells (Figure 3.16A, right 
panel).   
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Figure 3.16 Characterisation of wild type and Gal-3-/- murine primary 
endothelial cells 
Confluent MLEC were collected and stained on ice for cell surface 
antigens before analysis with the FACSCalibur Flow cytometer and 
FlowJo software, as detailed in Methods.  A) Representative forward/side 
scatter plot for the MLEC populations, gated for >80% of the total events.  
B) Histogram showing mean fluorescent intensity of gated MLEC 
population for IgG2a isotype control (grey) or Gal-3 (blue) stained wild 
type (top) and Gal-3-/- (bottom) cells.  C) Histogram showing mean 
fluorescent intensity of gated MLEC population for unlabelled control 
(grey) or ICAM-2 (green) stained wild type (top) and Gal-3-/- (bottom) 
cells.   
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3.6.1 Basal surface expression of E-selectin and ICAM-1 on wild 
type and Gal-3-/- MLEC 
Confluent wild type and Gal-3-/- MLEC were collected and murine Fc 
receptors were blocked before cell staining for surface ICAM-1 and E-
selectin and their isotype controls before analysis by flow cytometry.  MFI 
was expressed as mean±SEM of 3 mice sets and statistical significance 
was assessed using an unpaired student’s t-test.  When compared to 
their wild type counterparts, Gal-3-/- MLEC express significantly reduced 
basal ICAM-1 (Figure 3.17 lower panel; WT 623.7±110.0 vs. KO 
121.6±106.2, P<0.05, n=3).  Though slightly reduced, the levels of 
surface E-selectin on Gal-3-/- MLEC were comparable to wild type (Figure 
3.17 upper panel; WT 8.7±2.8 vs. KO 5.3±0.6, not significant). 
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Figure 3.17 Basal surface expression of E-selectin and ICAM-1 on 
wild type and Gal-3-/- MLEC 
Confluent wild type and Gal-3-/- MLEC were collected and murine Fc 
receptors were blocked before cell staining for surface ICAM-1 and E-
selectin and their isotype controls before analysis with the FACSCalibur 
Flow cytometer and FlowJo software, as detailed in Methods.  A) MFI 
was expressed as mean±SEM of 3 mice sets for E-selectin (upper panel) 
and ICAM-1 (lower panel). Statistical significance was assessed using an 
unpaired student’s t-test and is denoted by asterisks * P<0.05.  B) 
Representative histogram plots showing isotype control (grey tinted), wild 
type cells (blue) and Gal-3-/- cells (red line) stained for E-selectin (upper 
panel) and ICAM-1 (lower panel). 
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3.6.2 Surface expression of E-selectin and ICAM-1 on wild type and 
Gal-3-/- MLEC after TNFα treatment 
Confluent wild type and Gal-3-/- MLEC were treated for 4h with vehicle 
(PBS) or TNFα in varying concentrations (10, 100, 200ng/mL).  The 
MLEC were collected and murine Fc receptors were blocked before cell 
staining for surface ICAM-1 and E-selectin and their isotype controls and 
analysis by flow cytometry. MFI was expressed as mean±SEM of 3 mice 
sets and statistical significance was assessed using two-way ANOVA 
followed by Bonferroni’s multiple comparison post-test.  There were no 
significant differences in the levels of E-selectin expression on wild type 
and Gal-3-/- MLEC in response to treatment with TNFα though the 
variation within mice sets was extremely large (Figure 3.18A, upper 
panel,). In contrast, the Gal-3-/- MLEC expressed much-reduced ICAM-1 
on their surface after treatment with 100ng/mL TNFα (Figure 3.18A, lower 
panel; WT 1070.3±245.0 vs. KO 280.3±262.9, P<0.05, n=3).  Additionally, 
though the interaction of gene and treatment did not cause significant 
variation in the results, the effect of gene overall was considered 
significant (Figure 3.18A, lower panel, P=0.0002, n=3) 
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Figure 3.18 Surface expression of E-selectin and ICAM-1 on wild 
type and Gal-3-/- MLEC after TNFα treatment 
Confluent wild type and Gal-3-/- MLEC were treated for 4h with vehicle 
(PBS) or TNFα in varying concentrations (10, 100, 200ng/mL).  The 
MLEC were collected and murine Fc receptors were blocked before cell 
staining for surface ICAM-1 and E-selectin and their isotype controls 
before analysis with the FACSCalibur Flow cytometer and FlowJo 
software, as detailed in Methods.  A) MFI was expressed as mean±SEM 
of 3 mice sets for E-selectin (upper panel) and ICAM-1 (lower panel). 
Statistical significance was assessed using two-way ANOVA followed by 
Bonferroni’s multiple comparison post-test and is denoted by asterisks * 
P<0.05.  B) Representative histogram plots showing isotype control (grey 
tinted), vehicle (PBS) treated wild type cells (filled pale blue), TNFα 
(100ng/mL)-treated wild type cells (blue line), vehicle (PBS) treated Gal-3-
/- cells (filled pale red) and TNFα (100ng/mL)-treated Gal-3-/- cells (red 
line) stained for E-selectin (upper panel) and ICAM-1 (lower panel). 
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3.6.3 Surface expression of E-selectin and ICAM-1 on wild type and 
Gal-3-/- MLEC after IL-1β treatment 
Confluent wild type and Gal-3-/- MLEC were treated for 4h with vehicle 
(PBS) or IL-1β in varying concentrations (1, 50, 100ng/mL).  The MLEC 
were collected and murine Fc receptors were blocked before cell staining 
for surface ICAM-1 and E-selectin and their isotype controls and analysis 
by flow cytometry. MFI was expressed as mean±SEM of 3 mice sets and 
statistical significance was assessed using two-way ANOVA followed by 
Bonferroni’s multiple comparison post-test.   When compared to their wild 
type counterparts, the Gal-3-/- MLEC expressed much reduced E-selectin 
on their surface after treatment with both 50ng/mL (Figure 3.19A,B, upper 
panel; WT 58.5±4.7 vs. KO 37.0±21.8, P<0.01, n=3) and 100ng/ml 
(Figure 3.19 A, B, upper panel; WT 37.0±21.8 vs. KO ±, P<0.05, n=3) IL-
1β.  Furthermore, ordinary two-way ANOVA found that the interaction of 
both gene and treatment caused significant variation in the results at all 
concentrations (Figure 3.19 A, B, upper panel, interaction P=0.0441, n=3) 
and the Gal-3-/- MLEC were found to have significantly reduced E-selectin 
expression overall (Figure 3.19 A, B, upper panel, P=0.0006, n=3). 
 
The Gal-3-/- MLEC expressed much-reduced ICAM-1 on their surface 
after treatment with 50ng/mL IL-1β (Figure 3.19A A, B, lower panel; WT 
1055.7±228.8 vs. KO 276.5±257.3, P<0.05, n=3).  Additionally, though 
the interaction of gene and treatment did not cause significant variation in 
the results, the effect of gene overall was considered significant (Figure 
3.19 A, B, lower panel, P=0.0002, n=3).  
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Figure 3.19 Surface expression of E-selectin and ICAM-1 on wild 
type and Gal-3-/- MLEC after IL-1β treatment 
Confluent wild type and Gal-3-/- MLEC were treated for 4h with vehicle 
(PBS) or IL-1β in varying concentrations (1, 50, 100ng/mL).  The MLEC 
were collected and murine Fc receptors were blocked before cell staining 
for surface ICAM-1 and E-selectin and their isotype controls before 
analysis with the FACSCalibur Flow cytometer and FlowJo software, as 
detailed in Methods.  A) MFI was expressed as mean±SEM of 2-3 mice 
sets for E-selectin (upper panel) and ICAM-1 (lower panel). Statistical 
significance was assessed using two-way ANOVA followed by 
Bonferroni’s multiple comparison post-test and is denoted by asterisks * 
P<0.05 and ** P<0.01.  B) Representative histogram plots showing 
isotype control (grey tinted), vehicle (PBS) treated wild type cells (filled 
pale blue), IL-1β (50ng/mL)-treated wild type cells (blue line), vehicle 
(PBS) treated Gal-3-/- cells (filled pale red) and IL-1β (50ng/mL)-treated 
Gal-3-/- cells (red line) stained for E-selectin (upper panel) and ICAM-1 
(lower panel). 
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3.7 Discussion 
The role of endogenous Gal-3 in leukocyte recruitment was examined; 
Gal-3-/- mice and Gal-3-/- leukocytes were studied in models of 
inflammation using techniques such as IVM and flow chamber assays, 
which enable the analysis of aspects of the cascade in isolation.  Firstly, 
the wild type response to fixed-time treatment with TNFα and IL-1β 
locally was characterised; these cytokines were chosen for a number of 
reasons.  It is well established that these two stimuli are important pro-
inflammatory modulators of both the acute inflammatory response 
(Dinarello, 2011, Dinarello, 2000) and long-term disease pathogeneses 
where inflammation has become chronic in nature, for example in 
rheumatoid arthritis (Schiff, 2000, Kollias et al., 1999).  Initial studies on 
the effects of these cytokines on endothelial cell function found that in 
vitro they induce increased expression of E-selectin (Bevilacqua et al., 
1989), VCAM-1 (Osborn et al., 1989) and ICAM-1 (Pober et al., 1986), 
thus initiating their state of ‘adhesiveness’ for leukocytes.  Furthermore, 
the administration of these cytokines in vivo results in leukocyte 
recruitment that may differ in mode; for example, an early study 
examining responses to both cytokines intradermally in the rabbit found 
that IL-1β-induced neutrophil extravasation peaked at 3-4h whereas 
TNFα-induced neutrophil extravasation was much quicker and also 
associated with protein synthesis-independent oedema formation 
(Rampart et al., 1989).  More recently, Thompson et al. reported that 
neutrophil recruitment in cremasteric venules of PECAM-1-/- mice was 
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reduced when compared to wild type mice treated with IL-1β but not 
TNFα (Thompson et al., 2001).   
 
In this study IVM showed that after 4 - but not 2h - treatment with these 
cytokines the cremasteric microcirculation was shown to be inflamed and 
exhibited increased levels of leukocyte adhesion and emigration as well 
as reduced leukocyte rolling velocity, which is in line with the literature 
(Young et al., 2002, Thompson et al., 2001).  In terms of endogenous 
Gal-3, Gal-3-/- mice displayed similar leukocyte recruitment profiles to 
their wild type counterparts, with the exception of slow rolling in response 
to both stimuli and emigration after IL-1β, but not TNFα treatment.  
Though the vessels were inflamed, the leukocyte rolling velocity in 
response to both TNFα and IL-1β 4h treatment was not reduced in Gal-3-
/- animals, suggesting that Gal-3 is a requirement for slow rolling in this 
experimental system.  
 
Early intravital studies using the cremaster model to investigate leukocyte 
rolling established that expression of P-selectin at the endothelial cell 
surface and P-selectin-dependent leukocyte rolling (20-50µm/s) occur 
within 10 min of surgical trauma and that this is upregulated after 2 h 
treatment with TNFα.  In contrast, baseline E-selectin expression is 
barely detectable but significantly upregulated after 2 h treatment with 
TNFα (Jung and Ley, 1997).  At 2 hours after TNFα treatment leukocytes 
in wild type, P- or L-selectin-/- mice were travelling at rolling velocities of 
3-7µm/s; however, in E-selectin-/- mice the leukocyte rolling velocity 
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remained at 12-20µm/s (Kunkel and Ley, 1996).  Thus, since leukocyte 
rolling is carried out by Selectin binding and slow rolling predominantly by 
E-selectin, it was important to look at Gal-3 roles in E-selectin-dependent 
rolling in greater depth.   
 
The parallel chamber flow assay was used as this enabled the 
investigation of both wild type and Gal-3-/- leukocytes in tandem; murine 
whole blood from wild type or Gal-3-/- mice was flown over E-selectin-
coated plates and the number of leukocytes captured was quantified. It 
was found that the absence of Gal-3 did not affect white blood cell counts 
and so any differences observed can be attributed to changes in the 
leukocytes themselves.  This is in line with full haematological reports 
published on the Consortium for Functional Genomics, which find no 
differences in Gal-3-/- blood components and leukocyte cell counts when 
compared to wild type mice, excepting a slight but significant reduction in 
blood glucose concentration (CFG, 2013).  Heparin was used to prevent 
clotting as studies have shown that increasing concentrations of this anti-
coagulant does not affect neutrophil-selectin interactions (Reinhardt and 
Kubes, 1998).  Strikingly, Gal-3-/- leukocytes were not captured to the E-
selectin and those few that did displayed an inability to enter a more 
activated phenotype, which was seen in wild type cells when they 
became phase-dark.  This reduced capture of Gal-3-/- cells was replicated 
even when the cells were flown together in the same chamber, with the 
use of fluorescent dyes to distinguish the two genotypes.  These results 
suggest that in absence of Gal-3, leukocytes have undergone inherent 
 137 
changes that cannot be fully rescued by extracellular factors, for example 
those found in the plasma of wild-type mice.  Taken together, the cells 
lack the machinery needed to bind E-selectin and facilitate the 
downstream signalling pathways that are initiated once bound; thus, E-
selectin and its ligands were studied in greater depth. 
 
All selectins have structurally homologous extracellular domains with 
amino acid lectin domains, epidermal growth factor domains and 
complement regulatory repeats; however, they have distinct cytoplasmic 
domains, resulting in their differing roles (Hu et al., 2000).  Early selectin 
studies found that leukocyte adhesion to IL-1β-activated endothelial cells 
induced clustering of E-selectin near the binding sites and that cross-
linking of E-selectin led to its transmembrane linkage to the actin 
cytoskeleton via its cytoplasmic domain (Yoshida et al., 1996).  
Subsequent serine phosphorylation of this domain suggests that it can 
transduce signals and thus is highly important in downstream signalling 
from the receptor (Yoshida et al., 1998).  Upon E-selectin binding by 
leukocytes or antibody cross-linking MAPK is activated; specifically, a 
Ras/Raf/phospho-MEK complex is formed, which is associated with 
increased expression of an early transcription factor for many pro-
inflammatory genes, c-fos (Hu et al., 2000).  These effects were E-
selectin-mediated, as adhesion of JY cells, a human leukocyte cell line 
that binds predominantly via ICAM-1/LFA-1 interactions, to IL-1β-
activated endothelia did not induce MAPK activation (Hu et al., 2000).  
Furthermore, it is now known that rolling on E-selectin leads to LFA-1 
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activation via syk-dependent pathways, whereby the β2-integrin enters 
the extended but not high affinity state to facilitate leukocyte slow rolling 
on ICAM-1 (Kuwano et al., 2010).  Zanardo et al. found that in C57BL/6 
mice treated locally with TNFα for 3h before surgical preparation all 
rolling was E- and P-selectin- dependent; it was mediated predominantly 
by PSGL-1 but another ligand was also present, which was down-
regulated during systemic, but not local TNFα administration (Zanardo et 
al., 2004).  It was unclear whether the ligand was shed or internalised and 
the authors proposed that it was not L-selectin, CD43, β2-integrin or 
CD66-nonspecific cross-reacting antigen, suggesting that there are more 
E-selectin ligands to be identified (Zanardo et al., 2004).  In slight 
contrast, Yang et al. found that E-selectin-mediated slow rolling following 
TNFα treatment was unaffected in PSGL-1-/- mice, confirming that other 
E-selectin ligands are functionally important and this was in addition to 
observing low levels of E-selectin-independent rolling (Yang et al., 1999). 
 
Since there have been no reports of direct interactions between galectins 
and selectins, we hypothesised that lack of endogenous Gal-3 may affect 
availability of separate ligands.  The levels of ESL-1, PSGL-1 and other 
E-selectin ligand expression in Gal-3-/- mice have yet to be reported; 
however, it has been shown that levels of PSGL-1 are similar in Mgat5-/- 
and wild type neutrophils though the expression pattern at the cell surface 
may differ, resulting in altered neutrophil recruitment in these animals 
(Bahaie et al., 2011).  In order to address this, the expression of CD44 
and PSGL-1 was examined by flow cytometry in wild type and Gal-3-/- 
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leukocytes.  Basally, neutrophils and monocytes express comparable 
levels of both ligands when compared to wild type cells; however, after 
treatment with TNFα but not IL-1β, Gal-3-/- neutrophils express reduced 
PSGL-1 in comparison with wild type counterparts.  This suggests a 
possible mechanism behind reduced slow rolling in response to TNFα in 
vivo though, does not explain the reduced IL-1β-induced slow rolling seen 
in the absence of Gal-3.   
 
All selectin ligands carry sLex, commonly on α1,3-fucosylated and α2,3-
sialylated O-glycans and though they are less well understood, E-selectin 
ligands specifically must be modified by a fucosyltransferase such as 
fucosyltransferase VII or IV to be functional.  Recent work has 
established that the E-selectin ligands ESL-1 and CD44 bind in a similar 
fashion to galectins, via N-linked glycans whereas PSGL-1 uses O-
glycans to bind (Block et al., 2012).  The importance of post-translational 
modification of E-selectin ligands to their functionalilty was recently 
demonstrated using mice lacking the polypeptide GalNAc transferase-1, 
which generates core-type O-glycan structures from GalNAc binding to 
threonine or serine residues in their protein backbone.  Galnt-1-/- mice 
display reduced P- and E-selectin-mediated rolling, which in turn reduces 
adhesion and emigration of leukocytes in these animals; signalling 
through syk and thus integrin activation was unaffected, confirming that it 
is the ability of ligands to bind rather than downstream pathways, which 
are impaired (Block et al., 2012).  Of particular importance, Saravanan et 
al. (2009) found that some glycogenes were differentially expressed in 
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Gal-3-/- mice undergoing a corneal model of wound-healing; these 
included glycosyltransferases and glycosidases that were down- or 
upregulated in order to produce less N-glycans and more O-glycans.  For 
example, an enzyme involved in Gal-3 ligand synthesis, β3-
galactotransferase 5 (β3GalT5), was downregulated whereas N-
acetylgalactosaminyltransferases-3 and -7 (ppGalNAcTs-3 and -7) which 
initiate O-glycosylation, were upregulated (Saravanan et al., 2009a).  
Hence the glycosylation pattern of Gal-3-/- leukocytes was assessed, as 
any inherent changes would greatly affect the ability of E-selectin ligands 
such as ESL-1, PSGL-1 and CD44 to bind.  This was carried out using a 
validated panel of biotinylated lectins, which each bind glycans of 
different structures.  As untreated Gal-3-/- leukocytes exhibited reduced 
capture to E-selectin under conditions of flow, basal levels of lectin 
binding by neutrophils and monocytes was analysed by flow cytometry.  
When compared to wild type cells, Gal-3-/- neutrophils exhibited reduced 
levels of PNA and HPA lectin binding, yet comparable levels of SNA, L-
PHA and MAL II binding.  This was also apparent for the Gal-3-/- 
monocytes, though the levels were not quite significant.   
 
HPA selectively binds to α-N-acetylgalactosamine residues and has been 
extensively studied as a marker of cancer cell metastasis; one study 
found that HPA recognises integrin-α6 in breast and colorectal cancer 
cells (Rambaruth et al., 2012). Another study hypothesised that as it is 
similar in structure to sLex, they may have similar but not identical 
glycotopes (Kohler et al., 2010); supporting the idea put forward here that 
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reduced HPA binding indicates reduced selectin ligand binding.  PNA 
lectin has specificity for terminal β-galactose residues, it is inhibited by 
lactose and displays enhanced binding of sialidase-treated glycoproteins, 
which have no terminal sialic acid structures.  The so-called PNA receptor 
in keratinocytes is CD44, an E-selectin ligand; suggesting that though 
CD44 levels are not reduced in Gal-3-/- leukocytes, they may display 
reduced binding capacity due to altered glycosylation (Hudson et al., 
1995).  In fact Gal-3-/- monocytes displayed slightly increased CD44 in 
response to IL-1β perhaps as result of a compensatory mechanism due 
to reduced binding, which warrants further investigation.  Of the 
unchanged lectins, both SNA and MAL II bind sialic acid, though SNA 
prefers to bind to terminal residues in an α2,6 linkage and MAL II prefers 
those in an α2,3 linkage; L-PHA binds β1,8-branches on complex N-
glycans and thus may indicate the presence of galectin and specifically 
Gal-3 ligands.  It is interesting to note that these were not changed, 
especially as Saravanan et al. (2009) found that N-glycans in general 
were reduced in Gal-3-/- mice; however, this study was carried out in 
corneal cells and so there may be cell type-specific differences in 
differential gene expression of the Gal-3-/- animals, which should be 
further investigated.   
 
The two classical stimuli TNFα and IL-1β were used throughout this study 
since they are known to have differing roles on both the leukocytes and 
endothelial cells.  For example, IL-1β activates the endothelia directly 
whereas wild type neutrophils respond to TNFα by increasing their 
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expression of β2-integrin (CD18) and initiating L-selectin shedding, this is 
in contrast to cells treated with IL-1β which do not (Young et al., 2002).  It 
was therefore interesting to examine whether endogenous Gal-3 affected 
this response and to do so flow cytometry using wild type and Gal-3-/- 
whole blood was carried out.  Since Gal-3 is not thought to affect β2-
integrin-dependent leukocyte recruitment (Nieminen et al., 2008), CD11b, 
also known as αM-integrin, which forms Mac-1 with the β2-integrin CD18, 
was investigated.  L-selectin is involved in the initial fast rolling stage of 
leukocyte recruitment, though is important for secondary leukocyte 
capture whereby leukocytes bind L-selectin before strengthening 
interactions on P-and E-selectin (Ley et al., 2007).  It was found that Gal-
3-/- neutrophils exhibited reduced CD11b expression basally and a 
reduced capacity to increase expression of this integrin in response to 
TNFα though the monocytes did not.  Additionally, L-selectin expression 
in the Gal-3-/- neutrophils and monocytes were unchanged from wild type 
cells, both basally and after stimulation, suggesting that their ability to 
initiate the rolling stages of leukocyte recruitment might be unimpaired.   
 
The predominant role of CD11b is during the intravascular crawling stage 
of leukocyte recruitment where Mac-1 binds to its ligand ICAM-1 (Green 
et al., 2004, Phillipson et al., 2006).  To investigate CD11b biology, 
studies often compare Mac-1-/- mice to LFA-1-/- mice, which lack the 
integrin CD18/CD11a.  Mac-1-/- neutrophils adhere to post-capillary 
venules in similar numbers to LFA-1-/- neutrophils, however they fail to 
crawl towards areas of preferential transmigration and though they 
 143 
eventually transmigrate in similar numbers to wild type neutrophils, this 
process requires a much longer length of time compared to their wild type 
counterparts (Petri et al., 2008).  Of particular importance to our finding 
that Gal-3-/- leukocytes express reduced CD11b basally and fail to reduce 
their rolling velocity in response to TNFα treatment of the cremaster, are 
studies which report that Mac-1 binding to ICAM-1 is involved in slow 
leukocyte rolling in response to this cytokine (Dunne et al., 2003).  
 
To complement these studies carried out on the leukocytes, murine lung 
endothelial cells (MLECs) were isolated from wild type and Gal-3-/- mice 
and analysed by flow cytometry.  Firstly, basal levels of E-selectin and 
ICAM-1 were examined, as these CAMs both have roles in leukocyte 
slow rolling and their expression is upregulated by IL-1β and TNFα 
stimulation (Pober et al., 1986, Bevilacqua et al., 1989).  Levels of E-
selectin in the two MLEC genotypes were comparable; however, Gal-3-/- 
MLEC exhibited much-reduced ICAM-1 under basal conditions.  
Furthermore, the effect of gene was considered to significantly reduce 
ICAM-1 expression on endothelial cells after treatment with TNFα and IL-
1β.  Similarly, after IL-1β but not TNFα treatment, Gal-3-/- MLECs also 
expressed reduced E-selectin overall; a finding that would have direct 
consequences for IL-1β-induced slow rolling and possibly subsequent 
transmigration.  Furthermore, if Gal-3-/- neutrophils are unable to increase 
CD11b expression upon incubation with these classical stimuli and Gal-3-
/- endothelial cells express reduced ICAM-1, this may explain why Gal-3-/- 
leukocytes do not reduce their rolling velocity in vivo.  It is worth noting 
 144 
here that despite this altered endothelial cell surface cell adhesion 
molecule expression, levels of adhesion were unchanged in the Gal-3-/- 
mice, both basally and after stimulation.  However, Kubes et al. 
demonstrated that rolling needs to be reduced by approximately 90% to 
affect levels of leukocyte adhesion; these authors used a high dose of 
fucoidin, a sulphated homopolymer of fucose, to attain this level of 
reduction and determined the ensuing attenuation of reperfusion-induced 
leukocyte adhesion (Kubes et al., 1995).  Furthermore, in wild type mice 
treated with TNFα approximately 90% of rolling leukocytes progress to 
become adherent and in E-selectin-/- mice where rolling velocities remain 
high, 50% of the rolling leukocytes are still able to adhere (Kunkel et al., 
2000).  These studies and data presented here highlight the complex yet 
distinct nature of each step in the leukocyte recruitment cascade.   
 
In addition to its role in slow rolling, Gal-3-/- mice examined using intravital 
microscopy exhibited a significantly reduced level of emigrated 
leukocytes in response to 4h IL-1β treatment when compared to the wild 
type response.  This effect was absent in TNFα-treated mice and thus it 
is particularly interesting to note that there may be stimulus-specific roles 
for Gal-3.  Furthermore, since IL-1β activates the endothelia directly 
(Young et al., 2002) the differences in leukocyte emigration observed 
between TNFα and IL-1β-treated Gal-3-/- mice suggest that endothelial 
function may be compromised in these mice, possibly in terms of their 
expression of CAMs and junctional adhesion molecules involved in 
transmigration.  More recently, it was found that neutrophil transmigration 
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elicited by IL-1β but not TNFα is protein-synthesis dependent and 
requires ICAM-2, JAM-A then PECAM-1 in distinct but sequential steps 
(Woodfin et al., 2009, Young et al., 2002).  In future the expression of 
these molecules in Gal-3-/- endothelial cells should be assessed as well 
as their glycosylation pattern, since all three contain N-glycosylation sites 
(Koenen et al., 2009, Feduska et al., 2013, Newton et al., 1999).  Also of 
interest to this study, IL-1β but not TNFα-induced neutrophil 
transmigration is dependent on α6-integrin (Dangerfield et al., 2005), 
which is recognised by HPA lectin, one of those found to exhibit reduced 
binding in Gal-3-/- cells.  In future, expression of α6-integrin in the IL-1β-
treated Gal-3-/- cremasters should be assessed as this would account for 
the stimulus specific roles.  Another possibility is that similar to 
observations in Mac-1-/- mice, Gal-3-/- cells take longer to emigrate in 
response to IL-1β and that, given the IVM time course used here this 
translates as an overall reduction.  In future, different fixed time protocols 
should be used, such as recruitment to the murine air-pouch in response 
to these classical stimuli to establish whether transmigration is impaired 
in the long-term.   
 
Gal-3 roles in leukocyte recruitment have been studied in in vivo models 
of inflammation, albeit using different tissues and inflammatory stimuli; 
the findings presented here are in keeping with published results, which 
are summarised in Table 1.1.  Many investigations report reduced 
leukocyte infiltration of the affected tissue in Gal-3-/- mice; lower numbers 
of lymphocytes and eosinophils were recruited to OVA-challenged 
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airways (Ge et al., 2010), there was reduced monocyte, macrophage and 
neutrophil recruitment to the CNS in a model of EAE (Jiang et al., 2009) 
and despite slightly conflicting reports using a thioglycollate broth model 
of peritonitis, two studies found reduced infiltration of neutrophils at either 
day 1 or 4 after insult (Hsu et al., 2000, Colnot et al., 1998).  Farnworth et 
al. found that Gal-3-/- mice exhibited more severe lung injury associated 
with reduced neutrophil recruitment at 15 h after S. pneumoniae infection, 
which is β2-integrin-independent (Farnworth et al., 2008).  This reduction 
in extravasated neutrophils at 12-24 h was also reported by Nieminen et 
al., who found that recruitment was unaffected in β2-integrin-dependent E. 
Coli-driven lung infection in Gal-3-/- animals (Nieminen et al., 2008).  This 
is in slight contrast to the reduction in rolling velocity in Gal-3-/- mice 
presented here as slow rolling in TNFα-treated cremaster venules is 
dependent on β2-integrins; since leukocyte velocities in CD18-/- mice 
treated with TNFα were approximately 3-fold higher than those in wild 
type mice (Jung et al., 1998).  However, as these findings have been 
reported when investigating different vascular beds and responses to 
varied stimuli, they would involve different phenotypes such as adhesion 
molecule profiles and ultimately, distinct outcomes (Rao et al., 2007a).  
Indeed, taken together these investigations further suggest that Gal-3 is a 
multi-faceted molecule capable of interacting with and acting via different 
receptors in different cells and tissues.    
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Chapter 4: Examining the effect of 
exogenous Gal-3 on leukocyte 
recruitment to the inflamed 
microvasculature 
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4.1 Analysis of the murine cremasteric microcirculation in 
response to treatment with exogenous Gal-3  
4.1.1 Local Gal-3 treatment results in increased leukocyte 
recruitment in a time-dependent manner 
In order to establish whether exogenous Gal-3 was capable of initiating 
leukocyte recruitment to the cremasteric microcirculation in the absence 
of a classical inflammogen, a time-course using rGal-3 was carried out.  
Intravital microscopy was first performed using wild type C57BL/6 mice, 
which were injected i.s. with rGal-3 (500ng in 400µL PBS) 2 or 4h before 
subsequent analysis.  Leukocyte flux, rolling velocity, adhesion and 
emigration was investigated in segments of 100µm in 3-5 vessels per 
mouse and results are expressed as mean±SEM of 3-4 mice per group.  
Statistical significance was assessed by one-way ANOVA and Dunnett’s 
multiple comparison post-test.  Leukocyte recruitment overall was 
increased at the 4h but not the 2h time-point with no significant 
differences observed between sham-treated animals and those treated 
with Gal-3 for 2h (Figure 4.1C,D).  In comparison, at 4h the 
microcirculation displayed significantly reduced leukocyte rolling velocities 
(Figure 4.1B; Sham 25.2±7.2 vs. 4h 8.8±0.5, P<0.05, n=3-4) as well as 
significant increases in both adhesion (Figure 4.1C; sham 3.7±0.9 vs. 4h 
6.5±0.5, P<0.05, n=3-4) and emigration (Figure 4.1D; sham 3.4±1.3 vs. 
4h 8.3±1.2, P<0.05, n=3-4).  In contrast, the levels of leukocyte flux were 
comparable between all treatments (Figure 4.1A).  
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Figure 4.1 Treatment of the mouse cremasteric microcirculation with 
recombinant Gal-3 results in increased leukocyte recruitment in a 
time-dependent manner  
IVM was performed as detailed in Methods.  Briefly, the cremasteric 
microcirculation of C57BL/6 mice was assessed 2 or 4h after intrascrotal 
injection of PBS (sham, 400µL) or recombinant rGal-3 (500ng in 400µL 
PBS).  Leukocyte flux (A), rolling velocity (B), adhesion (C) and 
emigration (D) was investigated in segments of 100µm in 3-5 vessels per 
mouse and results are expressed as mean±SEM of 3-5 mice per group.  
Statistical significance was assessed by one-way ANOVA and Tukey’s 
multiple comparison post-test; denoted by asterisks *P<0.05. 
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4.1.2 Validation of the use of anti-Ly-6G to label murine neutrophils 
In addition to assessing total leukocyte recruitment, the extravasation of 
neutrophils specifically can be visualised using fluorescently labelled 
antibodies against murine Ly-6G, which are administered via the tail vein 
(10µg in 200µL saline) immediately prior to administration of a local 
stimulus to the cremaster by i.s. injection.  Firstly, it was important to 
establish whether the antibody itself would affect the leukocyte 
recruitment recorded in this system, in particular the ability of the 
neutrophils to emigrate into the tissue.  In order to do this leukocyte 
recruitment was assessed in C57BL/6 mice that had been administered 
anti-Ly-6G, IgG2a (isotype control, 10µg in 200µL saline) or vehicle 
(200µL saline) i.v. as well as TNFα (300ng in 400µL PBS) i.s. in all cases.  
The average total (Ly-6G positive plus negative cells) leukocyte flux, 
rolling velocity, adhesion and emigration in each group was analysed and 
assessed for significance using two-way ANOVA and Tukey’s multiple 
comparison post-test.   
 
When compared to vehicle treated mice, administration of anti-Ly-6G or 
its isotype control did not cause significant differences in the responses to 
i.s. TNFα with respect to leukocyte flux (Figure 4.2A; Veh 45.9±7.9, 
IgG2a 15.8±2.0 vs. Ly-6G 26.9±9.7, not significant), rolling velocity 
(Figure 4.2B; Veh 12.8±4.6, IgG2a 22.7±4.8 vs. Ly-6G 7.1±2.1, not 
significant), adhesion (Figure 4.2C; Veh 5.5±0.6, IgG2a 5.7±0.8 vs. Ly-6G 
9.3±1.3, not significant) or emigration (Figure 4.2D; Veh 16.3±1.1, IgG2a 
16.4±1.0 vs. Ly-6G 23.6±2.5, not significant). 
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In addition to assess leukocyte recruitment, it was also important to 
confirm that the antibody was specifically labelling neutrophils.  After 
vessel recording, whole blood was collected by cardiac puncture and 
analysed by flow cytometry after red cell lysis.  The leukocyte cell 
populations could be distinguished by forward side scatter (Figure 4.2E, 
upper panel) and showed that the neutrophil population was 90.9% 
positive for Ly-6G, with no staining of lymphocytes or monocytes (Figure 
4.2E, lower panel).    
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Figure 4.2 Validation of the anti-mouse Ly-6G antibody used to label 
neutrophils in the murine cremasteric microcirculation 
IVM was performed as detailed in Methods.  Briefly, the cremasteric 
microcirculation in C57BL/6 mice was assessed 4h after intrascrotal 
injection of murine recombinant TNFα (300ng in 400µL PBS) and i.v. 
administration of saline (200µL), anti-mouse Ly-6G (2µg in 200µL saline) 
or anti-mouse IgG2a (2µg in 200µL saline).  Leukocyte flux (A), rolling 
velocity (B), adhesion (C) and emigration (D) was investigated in 
segments of 100µm in 2-3 vessels per mouse and results are expressed 
as mean±SEM of 2-3 mice per group.  Ly-6G positive cells are shown in 
the filled (grey) columns and Ly-6G negative cells in the empty columns.  
Statistical significance was assessed by two-way ANOVA and Tukey’s 
multiple comparison post-test.  E) After vessel recording, whole blood 
was collected by cardiac puncture and analysed by flow cytometry after 
red cell lysis.  Upper panel shows the forward-side scatter plot of a 
representative sample and lower panel shows the fluorescence intensity 
of the gated cell populations.  
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4.1.3 Investigating neutrophil recruitment to the cremasteric 
microcirculation in response to rGal-3 
Following validation, the anti-Ly-6G antibody was used to label 
neutrophils recruited to the cremaster after C57BL/6 mice were-treated 
i.s. with vehicle (PBS, 400uL) or rGal-3 (200ng-1000ng in 400uL PBS).  
Vessels were recorded using the brightfield and PE channels before 
offline analysis and image stills are shown (Figure 4.3) from 
representative sham-treated (top panel) or rGal-3-treateted mice 
(1000ng; lower panel).   
 
In contrast to the vessels of sham animals shown in the upper panel, it is 
clear that many Ly-6G positive neutrophils as well as unlabelled 
leukocytes are present in and closely surrounding the vessels of the rGal-
3-treated animals.  A dose-response was therefore performed in C57BL/6 
mice at the 4h time-point with varying doses of rGal-3 (200ng, 500ng, 
1000ng in 400µL PBS).   
 
The average Ly-6G positive and negative leukocyte flux, rolling velocity, 
adhesion and emigration in each group was analysed in segments of 
100µm in 3-5 vessels per mouse and results are expressed as 
mean±SEM of 3-4 mice per group.  Significance was assessed using two-
way ANOVA and Tukey’s multiple comparison post-test.   
 
Though there may be a slight trend for reduced flux in 1000ng-treated 
mice, levels of leukocyte flux remained comparable between all treatment 
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groups for both Ly-6G -ve (Figure 4.4A; sham 18.9±5.0 vs. 1000ng 
11.8±4.7, not significant) and Ly-6G +ve (Figure 4.4A; sham 47.5±3.7 vs. 
1000ng 23.1±11.6, not significant) cell populations.  However, rolling 
velocities were significantly reduced from sham levels in both 500ng and 
1000ng-treated mice and this reduction was similar for Ly-6G -ve 
(Figure 4.4B; Sham 69.8±24.2 vs. 500ng 14.0±5.1, 1000ng 5.1±1.1, 
P<0.01, n=3-4) and Ly-6G +ve (Figure 4.4B; Sham 55.0±18.1 vs. 500ng 
13.6±4.7, 1000ng 5.2±1.2, P<0.05, n=3-4) cells.   
 
The numbers of adherent cells recorded after treatment with lower does 
of rGal-3 were not increased from numbers seen in sham-treated animals 
and were comparable between Ly-6G -ve (Figure 4.4C; Sham 1.3±0.4, 
200ng 1.9±0.9, 500ng 2.4±0.1, not significant) and Ly-6G +ve (Figure 
4.4C; Sham 0.6±0.4, 200ng 1.4±0.9, 500ng 2.0±0.5, not significant) cells 
at all treatment groups.  However, at the highest treatment of 1000ng, 
adhesion was significantly increased from sham for both Ly-6G -ve 
(Figure 4.4C; sham 1.3±0.4 vs. 1000ng 4.8±0.3, P<0.05, n=3) and Ly-6G 
+ve (Figure 4.4C; sham 0.6±0.4 vs. 1000ng 5.5±1.8, P<0.01, n=3) cells, 
which accounted for approximately half of the total cells seen.   
 
In a similar pattern to that seen with the adherent cells, the numbers of 
emigrated cells recorded after treatment with lower does of rGal-3 were 
also not increased from numbers seen in sham-treated animals and were 
comparable between Ly-6G -ve (Figure 4.4D; Sham 4.4±1.1, 200ng 
2.9±0.8, 500ng 3.743±0.8, not significant) and Ly-6G +ve (Figure 4.4D; 
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Sham 2.5±0.5, 200ng 2.7±1.8, 500ng 3.738±0.8, not significant) cells at 
all treatment groups.  Once again, at the highest treatment of 1000ng, 
emigration was significantly increased from sham for both Ly-6G -ve 
(Figure 4.4D; sham 4.4±1.1 vs. 1000ng 12.1±1.3, P<0.05, n=3) and Ly-
6G +ve (Figure 4.4D; sham 2.5±0.5 vs. 1000ng 12.3±4.4, P<0.01, n=3) 
cells, which accounted for approximately half of the total cells in the 
tissue.  
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Figure 4.4 Treatment of the mouse cremasteric microcirculation with 
rGal-3 results in increased neutrophil recruitment in a dose-
dependent manner 
IVM was performed as detailed in Methods.  Briefly, the cremasteric 
microcirculation in C57BL/6 mice was assessed 4h after intrascrotal 
injection of PBS (sham, 400µL) or recombinant rGal-3 (200-1000ng in 
400µL PBS) and i.v. administration of anti-mouse Ly-6G (2µg in 200µL 
saline) to label murine neutrophils.  Leukocyte flux (A), rolling velocity (B), 
adhesion (C) and emigration (D) was investigated in segments of 100µm 
in 3-5 vessels per mouse and results are expressed as mean±SEM of 3-4 
mice per group.  Ly-6G positive cells are shown in the filled (grey) 
columns and Ly-6G negative cells in the empty columns.  Statistical 
significance was assessed by two-way ANOVA and Tukey’s multiple 
comparison post-test; denoted by asterisks * P<0.05 and ** P<0.01 
between Ly-6G-ve bars and # P<0.05 and ## P<0.01 between Ly-6G+ve 
bars. 
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4.1.4 Investigating monocyte recruitment to the cremasteric 
microcirculation in response to rGal-3 using IVM 
IVM was performed as detailed in Methods.  Briefly, the cremasteric 
microcirculation in CX3CR1gfp/+ mice was assessed 4h after intrascrotal 
injection of PBS (sham) or recombinant rGal-3 (1000ng). GFP positive 
and negative leukocyte rolling velocity, adhesion and emigration was 
investigated in segments of 100µm in 3-5 vessels per mouse and results 
are expressed as mean±SEM of 3 mice per group.  Statistical 
significance was assessed using an unpaired students t-test.   
 
In response to rGal-3 treatment, there was no difference in the leukocyte 
rolling velocity of GFP +ve and GFP -ve cells (Figure 4.5A; +ve 27.6±11.1 
vs. –ve 43.3±11.2, not significant).  This was also the case for levels of 
adhesion (Figure 4.5B; +ve 1.3±0.3 vs. –ve 2.0±0.6, not significant) and 
emigration (Figure 4.5C; +ve 2.6±0.6 vs. –ve 7.6±2.6, not significant), 
where GFP positive cells accounted for approximately half of the total 
cells recruited.  When comparing levels of GFP positive monocytes alone, 
rGal-3 treatment significantly increased recruitment of these cells when 
compared to sham-treated animals.  Monocyte rolling velocity was 
significantly reduced after rGal-3 treatment (Figure 4.6A; sham 62.7±9.2 
vs. rGal-3 27.6±6.4, P<0.05, n=3).  This was in addition to increased 
adhesion (Figure 4.6A; sham 0.4±0.03 vs. rGal-3 1.3±0.2, P<0.01, n=3) 
and (Figure 4.6A; sham 0.8±0.06 vs. rGal-3 2.6±0.4, P<0.01, n=3) 
emigration of monocytes to the inflamed rGal-3-treated area. 
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Figure 4.5 Local treatment with rGal-3 induces leukocyte recruitment 
to the area, including monocytes 
IVM was performed as detailed in Methods.  Briefly, the cremasteric 
microcirculation in mice bearing GFP under their CX3CR1 promoter was 
assessed 4h after intrascrotal injection of PBS (400µL) or recombinant 
rGal-3 (1000ng in 400µL PBS).  Leukocyte rolling velocity (A), adhesion 
(B) and emigration (C) was investigated in segments of 100µm in 3-5 
vessels per mouse and results are expressed as mean±SEM of 3 mice 
per group.  GFP positive cells are shown in the filled (grey) columns and 
GFP negative cells in the empty columns.   
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Figure 4.6 Local rGal-3 treatment results in reduced monocyte 
rolling velocity as well as increased monocyte adhesion and 
emigration  
IVM was performed as detailed in Methods.  Briefly, the cremasteric 
microcirculation in mice bearing GFP under their CX3CR1 promoter was 
assessed 4h after intrascrotal injection of PBS (400µL) or recombinant 
rGal-3 (1000ng in 400µL PBS).  A) GFP positive leukocyte rolling 
velocity, adhesion and emigration was investigated in segments of 
100µm in 3-5 vessels per mouse and results are expressed as 
mean±SEM of 3 mice per group. Statistical significance was assessed 
using an unpaired students t-test, denoted by asterisks * P<0.05 and ** 
P<0.01.  B) Representative still taken from recording of a sham-treated 
mouse, GFP positive cells are shown in green.  C) Representative still 
taken from recording of a rGal-3-treated mouse, GFP positive cells are 
shown in green.   
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4.1.5 Investigating monocyte recruitment to the cremasteric 
microcirculation in response to rGal-3 using confocal 
microscopy 
Cremasters from sham or rGal-3-treated (1000ng) CX3CR1gfp/+ mice were 
exteriorised and stained as detailed in section 2.6.  Emigrated neutrophils 
and monocytes per frame were quantified and results are expressed as 
mean±SEM of 4-5 vessels per mouse and 4 mice per group.  Significance 
was assessed using an unpaired students t-test.  Similarly to the vessels 
analysed by IVM, mice treated with rGal-3 exhibited increased emigration 
of neutrophils when compared to sham-treated animals (Figure 4.7A; 
sham 1.4±0.7 vs. rGal-3 9.7±4.5).  Furthermore, monocytes were present 
in the rGal-3-treated cremasters in similar numbers to neutrophils (Figure 
4.7A; Neutrophils 9.7±4.5 vs. monocytes 5.2±1.3).  Finally, the number of 
emigrated monocytes was significantly increased in rGal-3-treated 
vessels when compared to their PBS-treated counterparts (Figure 4.7A; 
sham 1.2±0.7 vs. rGal-3 5.2±1.3, P<0.05, n=4).   
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4.1.6 Analysis of murine cremaster mRNA content after treatment 
with rGal-3 
In order to further examine the effects of rGal-3 on the tissue after i.s. 
injection, the cremasters were collected and immediately snap frozen in 
liquid nitrogen, before subsequent RNA isolation, cDNA synthesis and 
real-time PCR analysis of expression of various inflammatory genes was 
carried out.  The cremasters from C57BL/6 mice-treated i.s. with vehicle 
control (PBS) or rGal-3 (1000ng) were analysed.  Results were 
expressed as 2-ΔΔCT where gene expression was normalised to an 
internal housekeeping gene (GAPDH) and then normalised against the 
sham cremasters, which were set at one.   
 
When compared to their sham-treated counterparts, cremaster muscle 
treated with rGal-3 displayed significantly increased mRNA for IL-1β 
(Figure 4.8; sham 3.0±2.7 vs. rGal-3 123.2±46.3, P<0.05, n=3), 
Keratinocyte-derived chemokine (KC, Figure 4.8; sham 4.7±4.0 vs. rGal-3 
74.7±5.0, P<0.001, n=3), monocyte chemoattractant protein-1 (MCP-1, 
Figure 4.8; sham 0.3±0.1 vs. rGal-3 63.1±19.4, P<0.05, n=2-3) and IL-6 
(Figure 4.8; sham 4.8±3.5 vs. rGal-3 169.7±36.2, P<0.01, n=3) and there 
was a trend for increased TNFα (Figure 4.8; sham 3.0±2.7 vs. rGal-3 
18.0±9.1, not significant, n=3).  In contrast, the expression of SDF-1 was 
not changed in rGal-3-treated cremaster muscle when compared to sham 
preparations (Figure 4.8; sham 1.0±0.1 vs. rGal-3 0.8±0.2, not 
significant). 
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Figure 4.8 Intrascrotal rGal-3 increases levels of local cytokines and 
chemokines found in the cremaster 
The cremasteric microcirculation in C57BL/6 mice was assessed 4h after 
intrascrotal injection of PBS (400µL) or recombinant rGal-3 (1000ng in 
400µL PBS) by IVM. Directly following the vessel recordings, the mice 
were culled by cervical dislocation and the cremaster muscle collected for 
immediate snap freezing in liquid Nitrogen and longer storage at -80°C.  
Tissues were homogenised from frozen and RNA extraction, cDNA 
synthesis and real-time PCR was then performed for IL-1β, TNFα, KC, 
SDF-1, MCP-1 and IL-6.  Results are expressed as 2-ΔΔCT where gene 
expression is normalised to an internal housekeeping gene (GAPDH) and 
then normalised once more to the sham cremasters, which were set at 
one.  They are displayed as mean±SEM of 2-3 mice per group. .  
Significance was assessed using an unpaired student’s t-test and is 
denoted by asterisks * P<0.05, ** P<0.01 and *** P<0.001. 
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4.1.7 Analysis by proteome array of murine cremaster protein 
content after treatment with rGal-3 
Murine cremaster muscles were dissected and snap frozen following 
intrascrotal treatment for 4 hours with PBS or rGal-3 (1000ng).  Frozen 
cremasters were homogenised and the protein content assessed before a 
final protein quantity of 200µg was then assessed using the mouse 
cytokine array panel A Proteome Profiler™ (R&D Systems) according to 
manufacturer instructions. The membranes were imaged using the 
FluorChem E, which increases exposure until the desired intensity is 
reached, in this case approximately 10 min.  Pixel densitometry was 
carried out using Fiji imaging software (ImageJ) and subtracting an 
averaged background reading from each duplicate antibody spot.   
 
The proteome array of rGal-3-treated cremaster samples displayed 
increased binding of many cytokines and chemokines, when compared to 
sham cremaster arrays (Figure 4.9A).  This was semi-quantified for two 
separate arrays of different cremaster samples using pixel densitometry; 
however, the variation between these two sets was high.   
 
Cytokines increased after rGal-3 treatment included IFNγ (Figure 4.10; 
Sham 100% vs. 233.1±79), MCP-1 (Figure 4.10; Sham 100% vs. 
448±171), IL-6 (Figure 4.10; Sham 100% vs. 181±45), KC (Figure 4.10; 
Sham 100% vs. 266±80), MIP-1α (Figure 4.10; Sham 100% vs. 195±75), 
MIP-2 (CXCL2) (Figure 4.10; Sham 100% vs. 235±137) and TNFα 
(Figure 4.10; Sham 100% vs. 163±33).  Crucially, the levels of some 
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proteins in rGal-3 arrays were comparable to sham arrays, for example 
MIP-1β (Figure 4.10; Sham 100% vs. 96±14) or were reduced after 
stimulation with the lectin, for example BCA-1 (Figure 4.10; Sham 100% 
vs. 74±0.4).  
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Figure 4.10 Densitometric analysis of cremaster proteome after 
treatment with rGal-3 
Murine cremaster muscles were dissected and snap frozen following 
intrascrotal treatment for 4 hours with PBS (400µL) or rGal-3 (1000µg).  
Frozen cremasters were homogenised and the protein content assessed 
before a final protein quantity of 200µg was then assessed using the 
mouse cytokine array panel A Proteome Profiler™, as described in 
Methods.  The membranes were imaged using the FluorChem E, which 
increases exposure until the desired intensity is reached, in this case 
approximately 10 min.  Pixel densitometry was carried out using Fiji 
imaging software (ImageJ) and subtracting an averaged background 
reading from each duplicate antibody spot. Results are expressed as 
mean±SEM of the duplicates, as a percentage of the sham-treated 
cremaster blot, for two separate arrays. 
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4.2 Analysis of exogenous Gal-3 under conditions of flow 
4.2.1 Treatment with rGal-3 does not increase Gal-3-/- leukocyte 
capture to E-selectin 
The Gal-3 content of wild type platelet-poor plasma was evaluated by 
ELISA against a known standard curve (Figure 4.11).  The plasma was 
found to contain 9.29ng/mL Gal-3, which was comparable to levels 
described in the literature.  Subsequently, Gal-3-/- whole blood was 
collected and treated for 15 minutes at 37°C with PBS or rGal-3 
(10ng/mL) before dilution 1:10 in HBSS and flow through the chamber. 
Captured leukocytes in each frame were quantified and classified as 
phase light or dark and results are expressed as mean±SEM of 6 frames 
per mouse and 6 mice per group.  Significance between total capture was 
assessed using an unpaired students t-test.  However, it was found that 
the rGal-3 was not able to rescue the phenotype as the cells did not 
adhere in significantly greater numbers to E-selectin when compared to 
vehicle treatment (Figure 4.12A; Vehicle 5.9±1.0 vs. rGal-3 7.3±1.3, not 
significant , n=6). 
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Figure 4.11 Wild type murine plasma contains Gal-3 
Wild type C57BL/6 or Gal-3-/- whole blood was collected by cardiac 
puncture using heparin (10U/mL) and immediately centrifuged at 200 g 
for 8min to pellet the white and red blood cells.  The platelet-rich plasma 
was collected and centrifuged again at 1000 g for 5min; the platelet-poor 
plasma was then collected for analysis by ELISA.  The plasma was 
diluted 1:100 in reagent diluent (supplied) and plated in duplicate for 
comparison to known concentrations of Gal-3 (standard curve shown in 
the top panel).  Gal-3 content in each well was calculated using 
absorbance at 450nm with wavelength correction set to 540nm.  Results 
are expressed as mean±SEM of 3 mice per group.  
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Figure 4.12 rGal-3 is unable to rescue Gal-3-/- leukocyte capture to E-
selectin under conditions of flow 
Ibidi flow chamber µ-slides were coated with recombinant E-selectin 
(2µg/ml) and blocked using 0.5% Tween-20. Gal-3-/- whole blood was 
collected by cardiac puncture using heparin (10U/mL) and treated for 
10min at 37°C with vehicle (PBS) or recombinant Gal-3 (10µg/ml).  The 
blood was diluted 1:10 in HBSS and flown for 3mins at 1.010mL/min, 
followed by 1min HBSS. Videos of 10s were captured for a total of 6 
frames per mouse and 6 mice per group. A) Captured leukocytes in each 
frame were quantified and classified as phase light or dark.  Results are 
expressed as mean±SEM and significance was assessed using an 
unpaired students t-test.  B) Representative images are stills taken from 
recordings, the top panel shows Gal-3-/- whole blood treated with vehicle 
(PBS) and the lower panel shows Gal-3-/- whole blood treated with rGal-3.  
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4.2.2 Examining the role of Gal-3 in the plasma compartment 
To determine whether exogenous Gal-3 in the plasma may account for 
the differences observed in binding to E-selectin, the effect of the plasma 
compartment was examined.  C57BL/6 or Gal-3-/- whole blood was 
collected by cardiac puncture and the platelet-poor plasma from both 
genotypes was then isolated and delivered back to the cells. The 
C57BL/6 cells were gently mixed with the Gal-3-/- plasma and vice versa, 
before immediate flow over E-selectin.  Videos of 10s were captured for a 
total of 6 frames per mouse and 3-4 mice per group; captured leukocytes 
in each frame were quantified and classified as phase light or dark.  
Results are expressed as mean±SEM and significance was assessed by 
two-way ANOVA followed by Bonferroni’s multiple comparison post-test.   
 
In the absence of both wild type plasma and wild type leukocytes, there 
was significantly reduced capture of phase light and phase dark cells to 
the E-selectin.  When compared to the control well containing wild type 
cells flown with wild type platelet-poor plasma, wild type cells flown with 
Gal-3-/- platelet-poor plasma exhibited reduced phase light (Figure 3.9A; 
WT/WT 15.9±2.2 vs. WT/KO 4.2±0.5, P<0.001, n=3-4) and phase dark 
leukocyte capture (Figure 3.9A; WT/WT 9.9±2.7 vs. WT/KO1.0±0.3, 
P<0.001, n=3-4).  Similarly, Gal-3-/- cells flown with wild type platelet-poor 
plasma also exhibited significantly reduced capture of phase dark (Figure 
3.9A; WT/WT 9.9±2.7 vs. KO/WT 1.3±0.3, P<0.001, n=3-4) and phase 
light (Figure 3.9A; WT/WT 15.9±2.2 vs. KO/WT 9.5±1.6, P<0.01, n=3-4) 
cells when compared to wild type cells flown with wild type plasma.   
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Figure 4.13 Exogenous Gal-3 in the plasma compartment is required 
for wild type though can not rescue Gal-3-/- leukocyte capture to E-
selectin under conditions of flow 
Ibidi flow chamber µ-slides were coated with recombinant E-selectin 
(2µg/ml) and blocked using 0.5% Tween-20.  C57BL/6 or Gal-3-/- whole 
blood was collected by cardiac puncture using heparin (10U/mL) and 
immediately centrifuged at 200 g for 8min to pellet the white and red 
blood cells.  The platelet-rich plasma was collected and centrifuged again 
at 1000 g for 5min; the platelet-poor plasma was then collected and 
delivered back to the cells. The C57BL/6 cells were gently mixed with the 
Gal-3-/- plasma and vice versa.  The blood was diluted 1:10 in HBSS and 
flown for 3mins at 1.010mL/min, followed by 1min HBSS. Videos of 10s 
were captured for a total of 6 frames per mouse and 3-4 mice per group. 
A) Captured leukocytes in each frame were quantified and classified as 
phase light or dark.  Results are expressed as mean±SEM and 
significance was assessed by two-way ANOVA followed by Bonferroni’s 
multiple comparison post-test between selected groups, denoted by 
asterisks * P<0.05 and ** P<0.01 and *** P<0.001 when comparing phase 
light cells to phase light cells in the control WT/WT group and # P<0.05 
and ## P<0.01 and ### P<0.001 when comparing phase dark cells to 
phase dark cells in the control WT/WT group.  B) Representative images 
are stills taken from recordings; the top panel shows C57BL/6 cells 
treated with Gal-3-/- plasma and the lower panel shows Gal-3-/-cells 
treated with C57BL/6 plasma.  
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4.3 Intravenous administration of rGal-3 to C57BL/6 mice 
4.3.1 Analysis by intravital microscopy 
Mice were anaesthetized and their jugular vein cannulated before IVM 
was performed, as detailed in Methods.  Briefly, the cremasteric 
microcirculation in C57BL/6 mice was assessed following intravenous 
administration of vehicle (saline, 200µL) or recombinant rGal-3 (150ng).  
Leukocyte flux, rolling velocity, adhesion and emigration was investigated 
in segments of 100µm in 3-5 vessels per mouse and results are 
expressed as mean±SEM of 2-3 mice per group.  Statistical significance 
was assessed by two-way ANOVA and Bonferroni’s multiple comparison 
post-test.   
 
Administration of rGal-3 i.v. did not affect leukocyte recruitment over the 
60 min time-course.  Leukocyte flux remained the same immediately after 
rGal-3 administration at 15 min (Figure 4.14A; Vehicle 65.0±13.5 vs. rGal-
3 60.0±17.2, not significant) and also at the 60 min time-point (Figure 
4.14A; Vehicle 73.5±4.0 vs. rGal-3 39.5±12.2, not significant).   
 
In addition, leukocyte rolling velocities were calculated as percentage of 
baseline and remained steady over the time-course in both treatment 
groups, where at 60 min rGal-3 treated animals did not display different 
rolling velocities when compared to the vehicle-treated group (Figure 
4.14B; Vehicle 92.2±41.2 vs. rGal-3 126.5±33.4, not significant).  
Furthermore, Adhesion was unchanged by the addition of rGal-3 i.v., 
even at the longest 60 min post-administration analysis (Figure 4.14C; 
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Vehicle 1.0±0.5 vs. rGal-3 1.7±0.3, not significant).  Finally, administration 
of rGal-3 i.v. did not increase leukocyte emigration, which remained 
unchanged from vehicle-treated animals at the 60min time-point (Figure 
4.14D; Vehicle 3.3±0.3 vs. rGal-3 2.7±0.2, not significant). 
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Figure 4.14 Administration of rGal-3 intravenously does not affect 
leukocyte recruitment in the short-term 
Mice were anaesthetized and their jugular vein cannulated before IVM 
was performed, as detailed in Methods.  Briefly, the cremasteric 
microcirculation in C57BL/6 mice was assessed following intravenous 
administration of vehicle saline (200µL) or recombinant rGal-3 (150ng in 
200µL saline).  Leukocyte flux (A), rolling velocity (B), adhesion (C) and 
emigration (D) was investigated in segments of 100µm in 3-5 vessels per 
mouse and results are expressed as mean±SEM of 2-3 mice per group.  
Statistical significance was assessed by two-way ANOVA and 
Bonferroni’s multiple comparison post-test. 
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4.3.2 Analysis of leukocyte adhesion molecule expression by flow 
cytometry 
Wild type C57BL/6 mice were treated intravenously for 4h with vehicle 
(200µL saline) or rGal-3 (150ng in 200µL saline)- before blood was 
collected by cardiac puncture using heparin (10U/mL).  Murine Fc 
Receptors were blocked before cell staining with antibodies against 
PSGL-1, CD11a, CD11b, CD11c, CD44 or CD62L (L-selectin) and 
analysis by flow cytometry.  MFI values were plotted and the data are 
shown as mean±SEM of 3 mice per group, significance was assessed 
using an unpaired student’s t-test.   
 
When compared to the expression on vehicle-treated counterparts, rGal-
3-treated mice displayed unchanged expression of PSGL-1 (Figure 
4.15A; Vehicle 11.8±4.4 vs. rGal-3 19.6±7.1, not significant), CD11a 
(Figure 4.15A; Vehicle 100.5±16.2 vs. rGal-3 134.0±17.8, not significant), 
CD11b (Figure 4.15A; Vehicle 0.4±0.08 vs. rGal-3 0.8±0.2, not 
significant), CD11c (Figure 4.15A; Vehicle 1.0±0.6 vs. rGal-3 1.1±0.3, not 
significant), CD44 (Figure 4.15A; Vehicle 33.5±2.8 vs. rGal-3 51.0±6.4, 
not significant) or L-selectin (Figure 4.15A; Vehicle 164.5±33.0 vs. rGal-3 
177.3±7.1, not significant).  
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Figure 4.15 Intravenous administration of rGal-3 does not affect 
leukocyte adhesion molecule expression in the short term 
Wild type C57BL/6 mice were treated intravenously for 4h with vehicle 
(200µL saline) or rGal-3 (150ng in 200µL saline)- before whole blood was 
collected by cardiac puncture using heparin (10U/mL).  Murine Fc 
Receptors were blocked before cell staining with antibodies against 
PSGL-1, CD11a, CD11b, CD11c, CD44 or CD62L (L-selectin); analysis 
was carried out with the FACSCalibur Flow cytometer and FlowJo 
software, as detailed in Methods. A) MFI values were plotted and the 
data are shown as mean±SEM of 3 mice per group, significance was 
assessed using an unpaired student’s t-test. B) Representative histogram 
plots showing leukocytes stained for isotype control (grey) or cell 
adhesion molecule after treatment with vehicle (blue) or rGal-3 (red line). 
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4.4 Analysis of cell adhesion molecule expression after 
treatment with rGal-3 
4.4.1 Surface expression of E-selectin and ICAM-1 on MLEC after 
rGal-3 treatment  
Confluent wild type and Gal-3-/- MLEC were treated overnight with vehicle 
(PBS) or rGal-3 (10 or 100ng/mL).  The MLEC were collected and murine 
Fc receptors were blocked before cell staining for surface ICAM-1 and E-
selectin and their isotype controls and analysis by flow cytometry. MFI 
was expressed as mean±SEM of 3 mice sets and statistical significance 
was assessed using two-way ANOVA followed by Bonferroni’s multiple 
comparison post-test.   Similarly to the expression pattern seen after 
treatment with IL-1β and TNFα, when compared to their wild type 
counterparts the Gal-3-/- cells displayed reduced E-selectin (Figure 4.16A, 
upper panel; P=0.0187, n=3) and ICAM-1 (Figure 4.16A, lower panel; 
P=0.0001, n=3) expression overall.  However, in wild type cells rGal-3 
treatment itself did not alter expression of E-selectin (Figure 4.16, upper 
panel; Vehicle 8.7±2.8, 100ng/mL 8.6±0.7, not significant) or ICAM-1 
(Figure 4.16, lower panel; Vehicle 623.7±110.0, 100ng/mL 586.0±115.7, 
not significant).  This was also the case in Gal-3-/- cells for both E-selectin 
(Figure 4.16, upper panel; Vehicle 5.3±0.6, 100ng/mL 6.1±0.9, not 
significant) and ICAM-1 (Figure 4.16, lower panel; Vehicle 121.6±106.2, 
100ng/mL 124.6±109.2, not significant).   
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Figure 4.16 Surface expression of E-selectin and ICAM-1 on wild 
type and Gal-3-/- MLEC after rGal-3 treatment 
Confluent wild type and Gal-3-/- MLEC were treated overnight with vehicle 
(PBS) or rGal-3 (10 or 100ng/mL).  The MLEC were collected and murine 
Fc receptors were blocked before cell staining for surface ICAM-1 and E-
selectin and their isotype controls before analysis with the FACSCalibur 
Flow cytometer and FlowJo software, as detailed in Methods.  A) MFI 
was expressed as mean±SEM of 2-3 mice sets for E-selectin (upper 
panel) and ICAM-1 (lower panel). Statistical significance was assessed 
using two-way ANOVA followed by Bonferroni’s multiple comparison 
post-test and is denoted by asterisks * P<0.05 and ** P<0.01.  B) 
Representative histogram plots showing isotype control (grey tinted), 
vehicle (PBS) treated wild type cells (filled pale blue), rGal-3 (10ng/mL)-
treated wild type cells (blue line), vehicle (PBS) treated Gal-3-/- cells (filled 
pale red) and rGal-3 (100ng/mL)-treated Gal-3-/- cells (red line) stained for 
E-selectin (upper panel) and ICAM-1 (lower panel). 
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4.4.2 Analysis by confocal microscopy of murine cremaster cell 
adhesion molecule expression after in vivo treatment with 
rGal-3 
Cremasters from wild type C57BL/6 mice treated intrascrotally for 4h with 
PBS, rGal-3, rGal-3 plus lactose or rTNFα were exteriorised and stained 
as detailed in section 2.6; images are representative of 3 mice per group.  
Local treatment with TNFα increased expression of ICAM-1 and PECAM-
1 in the cremasteric microcirculation (Figure 4.17; 2nd column) when 
compared to sham-treated vessels.  In addition, treatment with rGal-3 
also increases PECAM-1 expression above basal levels, though did not 
affect expression of ICAM-1 (Figure 4.17; 3rd column).  Again, local 
treatment with TNFα increased expression of VCAM-1 and E-selectin in 
the cremasteric microcirculation compared to sham-treated animals 
(Figure 4.18; 1st and 2nd columns).  Furthermore, these increases in 
VCAM-1 and E-selectin expression were also seen in rGal-3-treated 
animals (Figure 4.18; 3rd column).  However, local treatment with rGal-3 
plus Lactose also increased expression of these two cell adhesion 
molecules (Figure 4.18; 4th column).  
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Figure 4.17 Treatment with rGal-3 may increase expression of 
PECAM-1 in the cremasteric microcirculation 
Cremasters from wild type C57BL/6 mice treated intrascrotally for 4h with 
sham PBS (400µL), rGal-3 (1000ng) or rTNFα (300ng) were exteriorised 
and fixed flat on wax sheets in 4% PFA before permeabilisation and 
blocking for 2h at room temperature, as detailed in Methods.  Cremasters 
were stained with antibodies against PECAM-1 (Alexa Fluor® 488 
secondary-conjugated) and ICAM-1 (PE-conjugated) and their relevant 
isotype controls, then washed before mounting in DAPI-containing 
medium and imaging by confocal microscopy, as detailed in Methods.  
Merged antibody staining is shown in the top row, ICAM-1 in red in the 
middle row and PECAM-1 in green in the lower row, with different 
cremaster treatments in columns, labelled along the top. 
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4.5 Discussion 
In addition to its intracellular localisation, Gal-3 is secreted and thus found 
extracellularly, where it exerts its effects predominantly by interacting with 
glycans on the cell surface and associated with the extracellular matrix.  
In order to investigate the effects of exogenous Gal-3 intravital 
microscopy was again used, in this case to examine the leukocyte 
response to local treatment with the recombinant protein.  A time-course 
was first carried out and it was found that the vessels were highly 
inflamed after 4h intrascrotal treatment with the lectin, when the leukocyte 
flux and rolling velocities were significantly reduced and the numbers of 
adherent and emigrated cells were significantly increased. Once we had 
established that Gal-3 could elicit an inflammatory response, we were 
interested to see whether the lectin would act dose-dependently and 
exhibit cell-type specific responses.  
 
In order to examine the effects of Gal-3 on neutrophils specifically, the 
recombinant protein was administered i.s. following injection with anti-Ly-
6G i.v. and neutrophil recruitment was recorded by intravital microscopy.  
However, it was first important to establish that the anti-Ly-6G did not 
affect leukocyte recruitment in this system.  The use of anti-Ly-6G 
antibodies has been shown to impair murine bone marrow neutrophil 
migration to LTB4 in transwell assays in addition to being routinely used 
in vivo to deplete circulating neutrophils via a complement-dependent 
mechanism (Abbitt et al., 2009).  The same study also reported anti-Ly-
6G to be lethal when combined with a local i.s. injection of TNFα; 
 182 
however, these in vivo studies use a 5-fold higher dose of anti-Ly-6G 
given after the local area had been primed for 4h with a higher 
concentration of TNFα.  In addition to this, even the higher dose of anti-
Ly-6G did not affect expression of activation markers CD11b and L-
selectin or release of ROS from murine neutrophils (Abbitt et al., 2009).  
Furthermore the use of the anti-Ly-6G clone 1A8 rather than clone RB6-
8C5, which binds both Ly-6G and Ly-6C, a marker found not only on 
neutrophils but on dendritic cells, monocytes and lymphocytes increases 
neutrophil-specificity of the antibody (Daley et al., 2008). 
 
Consequently, the use of anti-Ly-6G antibody to label neutrophils was 
validated in our system.  Anti-Ly-6G administration did not alter the 
number of recruited leukocytes, as levels of flux, velocity, adhesion and 
emigration were unchanged from vehicle and isotype-treated animals.  
The isotype control antibody was used to measure the levels of non-
specific binding of the Ly-6G antibody and indeed no vascular 
components were stained by isotype control IgG2a, confirming that the 
binding seen in anti-Ly-6G-treated animals was specific to this neutrophil 
antigen. In addition, analysis of whole blood taken after IVM was carried 
out by flow cytometry confirmed that there was no staining of either the 
monocytes or lymphocytes, while over 90% of the neutrophils were 
labelled.   
 
A dose response was then carried out where animals were treated 
intrascrotally with increasing doses of recombinant Gal-3 in addition to 
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receiving anti-Ly6G to label the neutrophils.  Whilst leukocyte flux was 
unaffected, there was a dose-dependent increase in the number of 
adherent or emigrated neutrophils, as well as a reduction in rolling 
velocity of the neutrophils to a similar extent as the non-labelled 
leukocytes.  This confirms that in this system exogenous Gal-3 can act 
specifically to increase neutrophil trafficking to the inflamed area in vivo, 
however, approximately half of the recruited cells remained unidentified.  
 
In order to examine the monocyte response to exogenous Gal-3 in 
isolation, mice containing GFP under their CX3CR1 promoter were used.  
The mice were treated with the highest dose of rGal-3 to elicit an 
inflammatory response, and then monocyte recruitment was examined 
using IVM.  Once more, the mice exhibited increased recruitment of all 
leukocytes in response to rGal-3.  Furthermore, it was apparent that the 
monocytes exhibited reduced rolling velocities to similar levels as the 
remaining leukocytes, as well as making up approximately half of the total 
cells recruited.  This was confirmed using confocal microscopy and 
staining for MRP14 (to label neutrophils), which again showed that rGal-3 
elicited increased levels of neutrophil and monocyte recruitment 
compared to sham-treated animals, as well as almost equal numbers of 
the two cell types emigrating in to the tissue.  These in vivo results are in 
line with papers reporting Gal-3 action as a chemoattractant for 
neutrophils as well as monocytes and macrophages in static assays 
(Sano et al., 2000).    
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The recruitment of neutrophils and monocytes in response to local 
treatment with exogenous Gal-3 was further examined, the cremasters 
were collected and analysed by real-time PCR to give a snapshot of the 
cytokines and chemokines present after 4h treatment with the lectin.  
Expression of IL-1β, TNFα, KC, MCP-1 and IL-6 was significantly 
increased in response to Gal-3 whereas SDF-1 levels were unchanged.  
This data suggests that Gal-3 is able to activate cells present in the local 
area, such as the stromal and endothelial cells to induce release of 
cytokines and chemokines, which would initiate and potentiate a local 
inflammatory response, which is consistent with reports in the literature.  
Since levels of Gal-3 are increased at sites of joint destruction in RA, Filer 
et al. investigated the effect of exogenous Gal-3 treatment of human 
synovial fibroblasts, which increased their production of IL-6, GM-CSF, 
TNFα and MMP-3 as well as the neutrophil chemoattractant IL-8 and the 
monocyte chemoattractants MCP-1, MIP-1α and RANTES.  The authors 
established that autocrine TNFα stimulation was not the cause of this 
release; in fact ERK MAPK activation occurred within 5 min and JNK, p38 
MAPK and Akt phosphorylation was evident at 15 min as well as 
activation of NFκB (Filer et al., 2009).  The activation of PI3K by Gal-3 
has also been demonstrated in macrophages, which is often associated 
with chemokine production by stromal cells (MacKinnon et al., 2008) as 
well as E-selectin-dependent neutrophil rolling and trafficking (Puri et al., 
2005), both cell types that are abundant in the cremaster muscle.  To 
investigate this further, cremasters treated intrascrotally for 4h with rGal-3 
were analysed by proteome profile array, which evaluates expression of 
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many cytokines and chemokines present in the sample.  When compared 
to sham, rGal-3-treated cremaster samples exhibited increased binding of 
the array, thus many more of these inflammatory mediators were present 
in higher quantities in these tissues.  Among these were TNFα, IFNγ, the 
neutrophil chemoattractants KC and MIP-2 (CXCL2) and the monocyte 
chemoattractants MCP-1 and MIP-1α.  These arrays provide semi 
quantitative data, but are useful to show a snapshot of the local tissue 
microenvironment after treatment with the lectin and support the 
presence of pro-inflammatory mediators.   
 
Despite treating locally with rGal-3, we wanted to ensure that the lectin 
was not entering the systemic circulation and acting on neutrophils and 
monocytes directly. Of note here are previous papers suggesting that 
Gal-3 may act as a soluble adhesion molecule for neutrophils in vitro, 
where it increased their binding to endothelial monolayers, this effect was 
dependent on its ability to oligomerise at the cell surface (Kuwabara and 
Liu, 1996, Sato et al., 2002).  Furthermore, when the two cell types are 
incubated together in vitro, Gal-3 forms clusters between the endothelial 
cell surface and adherent neutrophils, these are concentrated at tricellular 
corners of the endothelium where these cells preferentially transmigrate 
(Nieminen et al., 2007).  In addition, Melo et al. found that treatment with 
Gal-3 of sarcoma cells null for endogenous Gal-3 increased migration on 
laminin suggesting that any defects in the cells could be rescued by a 
direct effect of the recombinant protein.  This was CRD-dependent and 
associated with SHP-2 tyrosine phosphatase-dependent increased 
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FAK/paxillin turnover at focal adhesion complexes as well as increased 
Akt phosphorylation and PI3K-dependence (Melo et al., 2011).  In order 
to investigate whether extracellular Gal-3 has a direct effect in ex vivo 
flow chamber assays the quantity of Gal-3 in the plasma was analysed 
and found to be approximately 10ng/mL.  However, treating Gal-3-/- 
leukocytes with plasma levels of rGal-3 was unable to rescue their 
phenotype and did not increase their capture to E-selectin under 
conditions of flow.  Secondly, the plasma compartment of wild type mice 
was compared to that from Gal-3-/- blood.  It was found that plasma from 
wild type mice did not increase capture of Gal-3-/- leukocytes to E-
selectin, as well as Gal-3-/- plasma reducing the levels of capture of wild 
type cells.  These results suggest further that, in our systems, the lack of 
both intracellular and extracellular Gal-3 results in impaired leukocyte 
function.   
 
The flow chamber is useful to investigate interactions with E-selectin in 
isolation, however it was also interesting to determine if these results 
would be confirmed in vivo; rGal-3 was administered intravenously during 
analysis by IVM and the leukocyte recruitment followed over a time-
course.  It was found that rGal-3 had no effect on leukocyte recruitment to 
the area over a 60 min period, suggesting that exogenous Gal-3 does not 
act on leukocytes or vascular endothelial cells directly, at least within 60 
min.  Furthermore, after rGal-3 treatment in vivo in the short term, 
leukocytes were analysed by flow cytometry, however, their expression of 
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CAMs such as PSGL-1, L-selectin, CD44 or CD11a, b and c were 
unchanged in response to this lectin.   
 
Endothelial cell function and particularly the upregulation of CAM 
expression, is vital to the leukocyte recruitment cascade; consequently, 
exogenous Gal-3 effects on this cell type were investigated.  Isolated 
MLECs were treated with increasing concentrations of rGal-3 and 
analysed by flow cytometry; however, they did not alter their expression 
of ICAM-1 or E-selectin.  As this simplified in vitro analysis may not 
support Gal-3 effects and since we know the recombinant protein initiates 
an inflammatory response in vivo, CAM expression in the cremaster after 
rGal-3 treatment was then investigated by confocal microscopy, using 
TNFα as a positive control.  Using this method to view protein 
expression, it is possible that rGal-3 treatment results in increased 
expression of PECAM-1, VCAM-1 and E-selectin.  The pan-Galectin 
inhibitor lactose also resulted in a robust increase in VCAM-1 and E-
selectin expression, however, this could be acting via many mechanisms 
and pathways that do not involve Gal-3 as it would bind all galectins and 
many unrelated cell surface molecules.  These data are interesting and 
may indicate that exogenous Gal-3 can stimulate endothelial cells directly 
to upregulate CAM expression or it could be acting on another cell type in 
vivo and causing that cell to bring about endothelial cell activation.  
However, the images provide qualitative information only and do not give 
any idea as to the mechanism of action of the lectin, which in future 
should be dissected further in the context of most recent literature. 
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Galectins that bind to cell surface glycoproteins are known to form lattices 
and transduce signals by crosslinking these glycotopes; due to its 
chimeric structure, Gal-3 forms large heterogeneous and disorganised 
lattices.  Instances of exogenous Gal-3 forming lattices and interacting 
with integrins at the cell surface have been investigated in the context of 
various processes and disease states, resulting in the hypothesis of 
outside-in signalling pathways by which Gal-3 modulates integrin 
function.  This was studied in cancer cells where the lectin binding to 
Mgat5-modified glycans and subsequent lattice-formation activated 
integrins leading to fibronectin remodelling and cell migration.  Further 
investigation found that epidermal growth factor binding triggered Gal-3 
lattice and ILK-dependent integrin signalling with subsequent 
src/pCav1/RhoA/ROCK-dependent production of focal actin structures, 
fibronectin remodelling and cell migration (Boscher and Nabi, 2013).  
More recently, Gal-3 was found to form a complex with β1-6 N-glycans on 
CD147 and β1-integrin, resulting in their redistribution and clustering on 
the surface of retinal pigment epithelial cells.  The exact functional 
implications of this association are still unclear, though it contributes to 
the pathogenesis of proliferative vitreoretinopathy (Priglinger et al., 2013).  
Similar associations have been found with the integrins αvβ3, which lead 
to endothelial cell migration and angiogenesis (Markowska et al., 2010, 
Ochieng et al., 1998); α5β1, which affected carcinoma cell motility 
(Lagana et al., 2006); and α3β1, where Gal-3 cross-linking led to 
lamellipodia development in a model of corneal injury (Saravanan et al., 
2009b).  In addition, Gal-3 binding to VEGF-R2 results in its retention at 
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the cell membrane and subsequent interaction with αvβ3-integrin leads to 
ILK-dependent increases in endothelial cell migration and proliferation 
(Markowska et al., 2011).  There is also an epigenetic link between Gal-3 
and members of the integrin family; a functional feedback loop occurs 
with β-integrins whereby Gal-3 expression in GE11 epithelial cells is 
increased in cells also expressing β1-integrins due to demethylation of the 
Lgals3 promoter.  Gal-3 then promotes β1-integrin-mediated cell adhesion 
to laminin and fibronectin as well as cell migration (Margadant et al., 
2012).  In future, Gal-3 interactions with remaining members of the 
integrin family should be studied in the context of neutrophil and 
monocyte recruitment in vivo with the use of blocking antibodies. 
 
Gal-3 effects on monocyte migration have been studied in vitro; Polli et al. 
investigated whether exogenous Gal-3 acts as a haptotactic agent – one 
that is immobilised on extracellular matrix components of endothelial 
cells, the basement membrane or connective tissue to facilitate cellular 
migration.  This is particularly interesting since Gal-3 interacts with the 
extracellular matrix and promotes adhesion of neutrophils to laminin and 
fibronectin (Kuwabara and Liu, 1996).  They found that Gal-3 binds to 
monocyte cell surface glycoproteins in a CRD-dependent manner and 
that while soluble Gal-3 induced monocyte migration in transwell assays, 
this was increased when the lectin itself was immobilised or present with 
laminin or fibronectin but not vitronectin.  Furthermore, this was replicated 
for human macrophages, though only in the presence of laminin, 
suggesting extracellular matrix components can also control leukocyte 
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trafficking and that Gal-3 interacts selectively with them in the presence of 
different cell types.  In addition and in concert with findings presented 
here, the authors found no difference in levels of CD11b, CD11c or L-
selectin in monocytes stimulated with exogenous Gal-3 (Danella Polli et 
al., 2013).  Taken together, these studies further suggest that Gal-3 
lattice formation has pleiotropic effects on cell migration and specifically 
on the initiation and continuation of leukocyte adhesion by interacting with 
carbohydrate counterparts such as those exposed on integrins and the 
extracellular matrix.  
 
Despite this, it is important to note that though extracellular Gal-3 effects 
are predominantly mediated by glycan interactions and thus are usually 
dependent on the CRD of the lectin, there may be CRD-independent and 
thus protein-protein interaction effects of the molecule at play here.  One 
study describes exogenous Gal-3 effects on the JAK-STAT gene 
expression pathway in microglial cells where treatment with the lectin 
increased phosphorylation of JAK2 and STAT 1, 3 and 5, which regulate 
expression of pro-inflammatory genes; though CRD-independent, this 
required the presence of the IFNγR1.  Furthermore, Gal-3 treatment 
increased levels of TNFα, IL-6, IL-1β, IP-10, IL-12p40 and IFNγ mRNA, 
while TGFβ, IL-10 and IL-13 remained the same; this was in addition to 
increasing expression of ICAM-1, MCP-1 and IL-8 in microglia (Jeon et 
al., 2010).  Though this study was carried out to investigate traumatic 
brain injury, it is interesting that in other inflammatory models Gal-3 can 
affect expression of chemokines and cell adhesion molecules 
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independent of its CRD and highlights that N-terminus-dependent 
mechanisms of Gal-3 action may operate.  In future, in vivo effects of 
rGal-3 should be dissected with respect to CRD or N-terminus 
dependency, using lactose or fragments of the Gal-3 N-terminus.   
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Chapter 5: Concluding remarks 
and future directions 
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This study has used in vivo imaging to explore the hypothesis that Gal-3 
acts as a positive regulator of leukocyte recruitment to the inflamed 
microcirculation and unveils novel biology for exogenous and 
endogenous Gal-3 in controlling vascular inflammation.  The results 
obtained throughout this PhD studentship are summarised in Error! 
Reference source not found.. 
 
The data presented in Chapter 3 show that endogenous Gal-3 is required 
for slow rolling of leukocytes in response to local treatment with IL-1β and 
TNFα as well as for the emigration of leukocytes in response to IL-1β.  
These stimulus-specific effects can be attributed to further inherent 
changes in the cells such as their gene expression profile and 
glycosylation pattern.  This is demonstrated by reduced levels of HPA 
and PNA lectin binding and CD11b expression basally on neutrophils, 
which when stimulated with TNFα also express reduced PSGL-1 and 
CD11b.  Finally, Gal-3-/- endothelial cells express reduced ICAM-1 basally 
and after TNFα or IL-1β treatment, in addition to expressing reduced E-
selectin after IL-1β treatment only.  
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These findings have raised many points of interest that could be 
addressed and though some may be broader in scope than others, they 
include:  
1. Assessing the glycosylation profile of Gal-3-/- endothelial cells; it 
has long been established that endothelial cells upregulate cell 
adhesion molecules to facilitate leukocyte recruitment, but it is 
important that these molecules also present the correct 
glycosylation profile to the leukocyte.  For example, differential 
glycan expression is associated with inflammatory diseases that 
have a vascular component, such as psoriasis, myocarditis, 
ulcerative colitis and vasculitis; furthermore, the glycosylation 
profile has been postulated to act as a zip code, targeting cells to 
different organs and sites of inflammation (Renkonen et al., 2002).  
Studies investigating primary human monocyte adhesion found 
that TNFα stimulation of HUVEC increases N-glycan expression at 
cell junctions, possibly by affecting gene expression of the 
enzymes required for their production (Chacko et al., 2011).  
Further highlighting the importance of appropriate N-glycosylation 
are studies that found that ICAM-1 protein folding, trafficking and 
binding to CD11b are affected otherwise (Jimenez et al., 2005, 
Diamond et al., 1991). 
2. To characterise further endogenous Gal-3 roles on emigration in 
response to IL-1β; for example with the use of more powerful IVM 
technology to assess leukocyte crawling and the proportion of 
para- versus transcellular emigration in Gal-3-/- animals.  In 
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addition to using longer fixed-time models of leukocyte recruitment 
such as recruitment to the murine air pouch. 
3. Characterise further the Gal-3-/- response to additional 
inflammatory stimuli, with the use of tri-colour IVM using antibodies 
to identify leukocyte subsets affected. 
4. Quantify expression of molecules involved in emigration, 
particularly PECAM-1, ICAM-2, JAM-A and integrin-α6 in Gal-3-/- 
mice after treatment in vivo.  
5. The use of blocking antibodies against E-selectin, ICAM-1, CD11b 
and integrin family members in vivo and in vitro to assess which 
molecules are involved in Gal-3-dependent slow rolling and 
emigration. 
6. Whether signalling pathways and cellular activation are 
compromised in Gal-3-/- cells after treatment with classical stimuli, 
particularly the MAPK system after binding to E-selectin. 
 
Concurrently, the data presented in Chapter 4 indicate that exogenous 
Gal-3 elicits an inflammatory response alone and induced both neutrophil 
and monocyte recruitment to the area.  After 4 h treatment with the lectin 
the cremaster contained increased mRNA for IL-1β, TNFα, KC, MCP-1 
and IL-6; increased protein expression of these mediators with the 
exception of IL-1β, was confirmed by proteome profile array alongside 
IFNγ, MIP-2 and MIP-1α.  The recombinant lectin does not act directly on 
the leukocytes, which was confirmed using various techniques including 
intravenous administration of the lectin during intravital microscopy.  
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Finally, endothelial cells treated in vitro with Gal-3 did not increase ICAM-
1 or E-selectin expression however, treatment in vivo followed by 
confocal analysis showed possible increases in PECAM-1, VCAM-1 and 
E-selectin expression.   
 
In the context of work presented here, exogenous Gal-3 may have 
multiple effects on the local tissue microenvironment – firstly, to stimulate 
the production of classical neutrophil and monocyte chemoattractants by 
stromal cells and secondly, it may interact with glycoproteins to provide a 
‘pro-recruitment’ status at the endothelial cell surface.  Furthermore by 
acting as a haptotactic agent, the lectin may use selective interactions 
with the extracellular matrix to modulate trafficking of leukocyte subsets 
differentially.  Addressing the following aims would elucidate the 
mechanism of exogenous Gal-3 action further: 
1. To identify which cells are secreting the chemokine and cytokine 
panel observed in response to Gal-3 treatment; for example by 
analysing supernatants of fibroblast and endothelial cells cultured 
with the lectin. 
2. To then examine which signalling pathways Gal-3 acts on; by 
using inhibitors of kinases known to be associated with various 
Gal-3 functions: PI3K, MAPK systems such as ERK1/2, JNK and 
p38 MAPK, and Akt. 
3. To establish the localisation of Gal-3 itself after in vivo treatment; 
for example imaging by confocal microscopy to confirm which cells 
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Gal-3 acts on, whether it forms clusters at the cell surface and if it 
is interacting with integrins or members of the extracellular matrix. 
4. To use Gal-3 CRD inhibitors such as lactose or the N-terminus 
fragment of the lectin to determine which portion of the molecule 
elicits an inflammatory response in vivo. 
 
Finally, to highlight the clinical relevance of this study, Gal-3 is a multi-
faceted carbohydrate binding protein that exhibits modulatory properties 
on many aspects of the immune response to disease; it has been 
implicated in RA, atherosclerosis, S. pneumoniae infection, metastatic 
cancers, stroke and bacterial sepsis.  Recently, a genome wide 
association study was carried out on circulating Gal-3 and two loci were 
found; the gene itself Lgals3 was found, indeed this is the only study so 
far to do so.  The second is the ABO gene locus though the study 
concludes that it is still unknown how the ABO gene variants may affect 
circulating Gal-3 levels (de Boer et al., 2012).  However, the ABO gene 
variant is associated with many inflammatory markers, haematological 
parameters, cancers and cardiovascular diseases, which are all 
pathophysiologies that Gal-3 itself has roles in.  In future, elucidating the 
cellular mechanisms behind Gal-3 action might provide therapeutic 
benefit to many patients suffering from these inflammatory disorders.  
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